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ABSTRACT
Three aspects of the production and applications of monoclonal antibodies (mabs) were investigated. 
Two new cell lines (C23/11 and HET-37) were produced for use as potential fusion partners in human 
mab production. C23/11 was established from a blood sample obtained from a patient with myeloma. 
It was shown to have many of the cellular and antigenic properties associated with a lymphoblastoid 
cell line. HET-37 is a human/murine heteromyeloma cell line which was established after C23/11 cells 
were fused with murine NSO cells. Both C23/11 and HET-37 were characterised using electron- 
microscopy, histology, immunophenotyping, isoenzyme analysis and DNA fingerprinting. In the second 
experimental section, three mab (HMFG-1, AUA-1 and H17E2) were labelled with the radioactive 
isotope, Indium-III. They were used for localisation of tumour in 21 patients with suspected ovarian 
carcinoma. IDIn-mab immunoscintigraphy was found to be a more sensitive technique for evaluation 
ovarian cancer than X-ray, CAT scan and ultrasound. Inln-mab immunoscintigraphy was particularly 
useful in localising tumours in patients with serum CA-125 levels greater than 100 IU/ml. F(ab’)2 
fragments of HMFG-1 were labelled with technetium and were used to determine the distribution of 
ovarian tumour in a patient with minimal residual disease. In the final experimental section, HMFG-1 
was chemically conjugated to the photosensitiser hematoporphyrin, Hp. HMFG-l-Hp was shown to kill 
antigen-bearing MCF-7 cells in vitro after irradiation. The HMFG-l-Hp conjugate had no effect on EJ- 
138 cells under identical conditions. The EJ-138 cell line does not express the antigen to which the 
HMFG-1 antibody binds.
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ABBREVIATIONS
ADCC Antibody-dependent cell-mediated cytolysis
ADEPT Antibody-directed enzyme prodrug therapy
AG Azaguanine
AGENT Antibody-guided enzyme nitrite therapy
AMCA Aminomethyl coumarin acetic acid
AUA-1 Arklie’s unknown antigen-1
B-Cell B lymphocyte cell
(5-Gal P-galactosidase
BCA Bicinchoninic acid
BSA Bovine serum albumen
BSOH Bi-lateral salpingo-oophorectomy
CAT Computerised axial tomography
CD Cluster of differentiation
CDC Complement-dependent cytotoxicity
CDR Complementarity-determining regions
DMF N,N'-dimethylformamide
DMSO Dimethylsulphoxide
DOTA Tetraazacyclododecane-N-N' JV"rN,"-tetraacetic acid
d.t. Doubling time
DTE Dithioerythritol
DTPA Diaminotriethylenepenta-acetic acid
DTT Dithiothrietol
DMEM Dulbecco’s modification of Eagle’s medium
DMEM10 DMEM (supplemented with 10% (v/v) FCS)
EBV Epstein-Barr virus
EDC 1 -ethyl-3-(-3-dimethylaminopropyl) carbodiimide
EDTA Ethylenediaminetetra-acetic acid
ELISA Enzyme-linked immunosorbent assay
F(ab) F(ab) fragment of immunoglobulin
F(ab’)2 F(ab’)z fragment of immunoglobulin
FACS Fluorescence activated cell sorter
FCS Foetal calf serum
FDA Food and Drugs Administration
FIGO International Federation of Gynaecology and Obstetrics
FITC Fluorescein-isolhiocyanate
FN False negative
FP False positive
G-418 Geneticin
GTP Guanine phosphoribosyl transferase
G-6-P Glucose-6-phosphate dehydrogenase
HAMA Human anti-mouse antibody
HAHA Human anti-human antibody
HAT Hypoxanthine aminopterin thymidine
H/E Hematoxylin and Eosin stain
HEPES (N- [2-Hy droxyethy l]piperazine-N’ - [2-ethane sulphonic acid])
HGPRT Hypoxanthine guanine phosphoribosyl transferase
hmab Human monoclonal antibody
HMFG Human milk fat globule
Hp Hematoporphyrin
HpD Hematoporphyrin derivative
HPLC High Pressure Liquid Chromatography
HRP Horse radish peroxidase
HSA Human serum albumen
HT Hypoxanthine thymidine
hu-mab Humanised monoclonal antibody
IC50 50% inhibitory concentration
IFO Ifosfamide
Ig Immunoglobulin
EL-1 Interleukin 1
IL-2 Interleukin 2
mIn Indium-III
i.p. Intra-peritoneal
EPDT Immunophotodynamic therapy
i.v. Intra-venous
LAL Limulus amoebocyte lysate
LAT Landschiitz Ascites Tumour
LCL Lymphoblastoid cell line
LDH Lactate dehydrogenase
Leu-OME L-leucine-O-Methyl ester
mab Monoclonal antibody
2-ME 2-mercaptoethanol
MDH Malate dehydrogenase
MDP Methylene diphosphonate
MPI Mannose phosphate isomerase
n Number of replicates
NaOH Sodium hydroxide
N.D. Not determined
NP Nucleoside phosphorylase
N.S. Non-secretors
OD Optical density
OUA Ouabain
ONPG O-niirophenyl galactopyranoside
P Passage number
PAGE Polyacrylamide gel electrophoresis
PB Peptidase B
PBL Peripheral blood lymphocytes
PBS Phosphate buffered saline (Dulbecco’s A)
PCR Polymerase chain reaction
PDGF Platelet derived growth factor
PEG Polyethylene glycol
PDT Photodynamic therapy
PHA Phytohemagglutinin
PLC Phosopholipase C a-toxin
PWM Pokeweed mitogen
r Immunoreactivity fraction
ren restriction endonucleases
rpm revolutions per minute
RPMI.S10 RPMI (supplemented with 10% v/v FCS)
s.d. Standard deviation
SAC Soyabean agglutinin
SAR Structure activity relationship
SRBC Sheep red blood cells
SCD Soyabean Casein Digest Medium
SCID Severe combined immune deficient
SDS Sodium-dodecyl sulphate
[T] Total radioactivity
Taa Tumour-associated antigens
Tc Cytotoxic T cells
x
T Cell
99MTc
TEMED
6-TG
Tg
T„
TLC
TN
TNF
TRIS
Ts
w.L
T lymphocyte cell 
Technetium-99M
N,NJi1,Nl-tetramethyl-ethylaminediamine
6-Thioguanine
Thioglycolate
Helper T cell
Thin layer chromatography
True negative
Tumour necrosis factor
Tris(hydroxymethyl)methylamine
Suppressor T cell
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UNITS
cpm counts per minute
hr hours
kD kiloDalton
keV kilo-electron Volts
mCi milliCurie
MBq MegaBequerel
MeV Mega-electron Volts
mg milligram
min minute
ml(s) millilitre(s)
M Molar
mM millimolar
raW milliWatt
pF microFaraday
Pg microgram
fiM microMolar
ng nanogram
nm nanometer
v/v Volume per volume
w/v Weight per volume
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SECTION 1 : INTRODUCTION
1.1. THESIS OUTLINE.
If there was a way to direct drugs and other molecules selectively to target cells, many diseases could 
be treated without affecting non-diseased tissues. Such a selective therapy would allow [he drug dosage 
to be reduced, the harmful side-effects to be minimised and thus, the efficacy of the drug could be 
improved. Selective delivery systems would have wide applications, including use against viral 
infections such as AIDS and hepatitis, against autoimmune diseases such as rheumatoid arthritis, and 
they would be especially useful in locating and perhaps treating cancers.
Conventional cancer therapies exploit the fact that neoplastic cells and tissues are more rapidly dividing 
and usually more vascular than normal cells. However, other healthy cells such as liver cells, bone 
marrow and germ cells also divide rapidly and are often killed non-selectively as a side-effect of such 
therapies. An alternative therapeutic approach is to exploit the differences in the proteins and 
carbohydrate antigens which are present on the surface of cancerous and healthy cells. One such 
approach would be to use highly specific monoclonal antibodies (mabs) which would selectively 
recognise these altered protein or carbohydrate antigens on tumour cells and could, therefore, form the 
basis of both selective diagnostic and therapeutic systems. Researchers involved in monoclonal antibody 
technology are currently looking at new ways of generating murine, human and genetically engineered 
(i.e. recombinant) monoclonal antibodies. Research groups are also looking at novel ways of treating 
diseases, such as cancer, with mabs alone and also with mabs which are chemically and genetically 
conjugated to drugs, toxins and isotopes (Figure 1.1.).
In this thesis, three separate aspects of monoclonal technology will be explored:
(a) The establishment of a human myeloma-derived cell line (C23/11) and a human-murine 
heteromyeloma cell line (HET-37) which could be used to immortalise human antibody 
producing B-cell and ultimately produce human mabs (hmabs). This is discussed in detail in 
Section 3.
(b) The use of therapeuuc-grade murine mabs, which are conjugated to radioactive isotopes to 
diagnose ovarian carcinomas in patients with suspected disease (Section 4).
(c) The production of an immunoconjugate for use in immunophotodynamic therapy. A mab was 
conjugated to a photoactive drug (hematoporphyrin) and was used to selectively kill antigen- 
bearing tumour cell lines (Section 5).
These experimental topics are described in separate sections. However, in the remainder of this 
section, the broader aspects of mab technology and the current and future uses of mabs in oncology are 
critically evaluated.
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Figure 1.1: Summary of the major areas of research in the production and application of
monoclonal antibodies for the detection and treatment of cancer. The grey boxes 
indicate areas in which experimental work was undertaken.
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1.2. MURINE ANTIBODY PRODUCTION.
Murine monoclonal antibodies (mabs) are secreted by immortalised antibody producing B-cells called 
hybridomas. Murine hybridomas secreting specific antibodies were first produced by Köhler and 
Milstein in 1975. They discovered that normal immunised murine B-lymphocytes (which do not grow 
in cultures) could be established as continuous cell lines when fused with malignant plasma cells or 
myelomas. Certain drug-resistant myeloma cells, were isolated and used for fusion. Myeloma cells, 
which are resistant to purine-antimetabolites such as 8-azaguanine or 6-thioguanine, are also deficient 
in the enzyme hypoxanthine-guanosine-phosphoyribosyl-transferase (HGPRT) and must, therefore, 
produce purines by the purine salvage pathway. The purine salvage pathway can be blocked by the 
addition of aminopterin to the medium. Therefore, myeloma cells which are grown in medium 
containing aminopterin and which are also lacking the enzyme HGPRT cannot produce purines. This 
can form the basis of a cell selection system. The myeloma cells will die in culture, normal B-cells 
will not grow in vitro, while B-cell-myeloma hybrids, or hybridomas having taken up the genes for 
purine synthesis, can grow in medium containing hypoxanthine, aminopterin and thymidine (HAT 
medium).
Following the selection of hybridomas which secrete the required antigen-specific antibodies, the cells 
were diluted to a density of one cell per well and grown. All resultant cells were of the same parental 
origin and are therefore monoclonal. The ability to grow large numbers of hybridomas in vivo as 
murine ascites tumours as well as in vitro, has led to the production of a wide range of antigen-specific 
murine mabs. Examples of these antigens include lipids, enzymes, hormones, carbohydrates, viruses, 
bacteria and a plethora of antigens which are found in high concentrations on the surface of tumour 
cells called tumour-associated antigens (Taas). Taas are not specific for neoplastic cells (reviewed by 
Thurin, 1990). They are usually normal antigens, such as placental alkaline phosphatase, human milk 
fat globule and chorioembryonic antigen, which are expressed in elevated levels on cells which do not 
normally express this antigen. Using murine, human and recombinant mabs against Taas, which are 
unconjugated or conjugated to drugs, toxins and isotopes to target the appropriate cells, several 
researchers have detected and killed tumours.
However, murine monoclonal antibodies have not been as successful as initially forecasted in detecting 
and treating cancer. Because of the "foreignness" of murine antibodies in humans, patients have been 
found to develop human-anti-mouse antibodies (HAMA). This immune response is quite potent and 
results in the production of both anti-allotypic and anti-idiotypic antibodies (against the variable region 
of the antibody) (Shawler et al., 1985). HAMA reactions may lead to anaphyaxis and immune complex 
formation (Schroff et al., 1985). Anti-idiotypic antibodies (anti-id) mirror the target antigen and these
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anti-id antibodies compete with the antigen for the injected antibodies (i.e. anti-Taa), and reduce the 
amount of anti-Taa antibody bound to the tumour which reduces cell killing and the quality of the the 
diagnostic images which can be obtained (Herlyn et a l ,  1986). Murine mabs fail to recognise some 
human antigens, and mice will raise antibody responses against human antigens which are not conserved 
between the mouse and human species. Taas sometimes differ from normal antigens in only amino acid 
substitutions or in a small number of carbohydrate moieties (Tsuruo and Hamada, 1990) and human- 
derived mabs are likely to be more subtle in recognising these altered antigens than murine antibodies 
(Larrick and Bourla, 1986).
Aside from the reduced immunogenicity, regulatory agencies such as the FDA are more willing to 
licence human-derived rather than non-human derived products (Brown, 1990). These limitations have 
lead to the production of human-derived mabs, bifunctional antibodies and genetically engineered 
antibody fragments such as Fv and F(ab) (Figure 1.2). The production of these new mabs and their use 
in cancer research is a vast and potentially exciting area of research which will be further outlined.
5
F(abf)2 Fragment
Fc Fragment
Figure 1.2: Structure of an antibody. An antibody consists of heavy (H) and light (L) [either
k or >.] chains which are joined together by disulphide linkages. The antibody 
can be further divided into variable (V) and constant (C) regions. Various 
antibody subunits or fragments can be produced, including the Fc fragment 
which does not bind to the antigen F(ab’)2, F(ab) and Fv fragments which can 
bind to the antigen. Individual VH or VL regions are known as single domain 
antibodies or dabs.
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1-3. HUMAN MONOCLONAL ANTIBODIES.
Studies by Croce and his colleagues in 1980 showed that human hybridomas producing monoclonal 
antibodies (hmabs), could be produced by fusing human B-cells which secreted the required antibodies, 
with human myeloma fusion partners. However, hmab technology has taken longer to establish than 
the murine technology described in Section 1.2. Hurdles which have limited the development of hmabs 
include the source of B-lymphocytes, immunisation strategies used, techniques used to immortalise the 
immunised B-cells, screening methods and problems encountered with the large-scale production of 
hmabs. In fact, every aspect of hmab production has presented new challenges to researchers, and, the 
results have added to the general understanding of human immunity and antibody production.
13.1. Sources of B-Lymphocytes.
Human peripheral blood lymphocytes, (PBLs), spleen, tonsils, lymph nodes, and bone marrow cells, are 
the main sources of cells used in hmab production. Researchers have also used lymphocytes from 
pleural effusions and from placental and tumour infiltrations as sources of pre-immunised B-cells 
(Glassy and Dillman, 1988). The advantages and disadvantages of each B-cell type are summarised 
in Table 1.3.1.
Patients who have suffered from a viral disease such as Herpes simplex (Evans et al., 1984), 
cytomegalovirus (Matsumoto et al., 1986), rubella (Van Meel et al., 1985) and hepatitis B have 
immunised B-cells which require no further immunisation. However, PBLs, lymph nodes and tumour- 
infiltrating lymphocytes have been of limited use in generating hmabs against Taas (reviewed by 
Borrebaeck et al., 1990). The major limiting factors are thought to be the T cell to B-cell ratio (T : B), 
and the fact that these cells are mature and, therefore, not in exponential phase of growth for use in 
fusion studies. Where immature or naive lymphocytes from spleen and tonsil cells have been used, a 
significant anti-Taa response was reported. This effect can be attributed to the low levels of cytotoxic 
T cells (Tc) and suppressor T cells (Ts) in these tissues which inhibit the immune response both in vitro 
and in vivo.
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Table 1.3.1: Sources of B-lymphocytes for use in human monoclonal antibody production.
B-cell Source Advantages Disadvantages Reference
Peripheral Blood 
Lymphocytes
Availability. 
Repeated use. 
IgG response.
Ratio T:B cells.
Lack of naive B-cells.
Glassy et a i ,  1988 
Borrebaeck, 1986
Spleen Cells Correct T:B ratio. Availability. 
Pre-treatment with 
Steroids.
IgM response.
Lowe et al, 1984 
Olsson and Kaplan, 
1984
Tonsil Cells Naive B-cells.
Correct T:B cell ratio. 
Availability.
IgM response. Lagace and Brodeur, 
1985
Carroll et a l., 1990
Tumour Infiltrating 
Lymphocytes
Antigen primed. 
IgG response. 
Availability.
Drug effects and 
myelotoxicity.
Sikora et al., 1982; 
1983
Paulie et al., 1984
Lymph Node Primed antigen. 
IgG response.
Availability. 
Incorrect T:B ratio.
Hirohashi et al., 
1983
Bone Marrow Committed B-cells. 
IgG production.
Availability. Seigneurin et al., 
1983
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1-3.2. In Vitro Immunisation.
Ii is both ethically and practically impossible to immunise human beings against most antigens. 
Similarly, it is often desirable but difficult to make human antibodies that react with self-antigens. In 
vitro immunisation has been used to obtain B-cells with the desired specificity, affinity and, in some 
cases, antibody isotype (Table 1.3.1.). Where in vivo immunisation is not possible, the source of B- 
cells used, the cytokines and mitogens used, as well as the T : B ratio, are vital components for 
successful in vitro immunisation (Borrebaeck, 1988). While tonsil and spleen cells provide rich sources 
of naive B-cells which can be activated in vitro, the antibodies produced following short term in vitro 
immunization are usually of an IgM isotype. IgM mabs are generally of lower specificity than IgG 
antibodies and are involved in many multi-specific antibody interactions (Ghosh and Campbell, 1986). 
Moreover, restimulation of more mature B-cells from tumour-infiltrating lymphocytes has been used 
to produce an IgG response in vitro. Gallatin el al. (1986) argued that PBLs are indeed a good source 
of B-cells producing anti-tumour antibodies, provided the T : B ratio is altered and the correct soluble 
factors are supplied before restimulating of the lymphocytes. Borrebaeck et al., (1988 (b)) have 
suggested the inclusion of the lysosomatropic agent L-leucine-methyl-ester (LEU-OME) in the medium 
for in vitro immunisation. LEU-OME has been shown to accumulate in lysosomes in human 
monocytes, macrophages and cytoxic T cells. The LEU-OME is metabolised to free amino acid and 
alcohol and this causes the death of macrophages and natural killer cells and it has also been shown to 
inhibit CD4* and especially CD8* cytotoxic T cells which inhibit immunisation. PBLs can be an 
excellent source of B-cells. The T : B cell ratio varies from 1 : 2 to 1 : 5, depending on the pre­
treatment method used to reduce Ts and Tc cells (Borrebaeck, 1988 (a)). Other methods used to alter 
the T:B ratio are summarised in Table 1.3.2.
Several other factors have been shown to influence in vitro immunisation. T cell growth factors 
contained in thymus-conditioned medium (TCM) are required for in vitro immunisation. Lymphokines 
such as EL-4 (Ho, 1988), IL-2 (Rosen et al., 1988) and IL-6 (Carroll et al., 1990; 1991) and mitogens 
such as pokeweed mitogen (PWM), phytohemagglutinin (PHA), concanavailin A, lipopolysaccharide 
(LPS), and soyabean agglutinin (SAC) have been used to activate various cell types in vitro 
(Borrebaeck, (1988 (a)). Interestingly, PWM has been added to the medium in a time-delayed manner 
to reduce T cell activation and improve B-cell responses (Carroll et al., 1991). Muramyl dipeptide 
(MDP) is known to improve immune responsiveness but it is not a polyclonal mitogen (Watson and 
Whitlock, 1978). The purity, solubility and concentration of the antigens used affects the success of 
immunisation. Matsumoto et al. (1986), showed that high doses of antigen may actually inhibit 
immunisation, while Ho et al. (1985), showed that the solubility and the purity of the antigen used 
influenced the isotype which is secreted from the cell. They showed that insoluble or particulate 
antigens were shown to favour the production of IgG antibodies.
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Table 1.3.2: Techniques used to deplete supressor T-cells (Ts) from lymphoid samples.
Method Reference
Sheep red blood cell (SRBC) resetting Teng et a l., 1985
Separation on nylon wool. Garzelli et al., 1984 
Ho e t al., 1985 
Yamura et al., 1985
L-leucine-methyl ester Borrebaeck et al., 1988(b)
Sephadex G-10 column Hoffman and Hirst, 1985
Lysis by OKT8, (Ts-specific mab) Lagace and Brodeur, 1985
Cimeiidine Ho et al., 1985
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1.3.3. Immortalisation.
A variety of fusion partners including human myeloma cells, human lymphoblastoid cells, murine 
myeloma cells and mouse-human hybrid cells have been used to immortalise human B-cells. 
Continuous B-cell lines have also been established by viral transformation and by cloning of the Ig 
genes into suitable host cell lines. These techniques will be discussed in more detail in Section 3.1.
1 J .4 . Large Scale Production of hmabs.
After identifying immortalised B-cells which secrete the desired antibodies, it is then necessary to grow 
them at large scale level. Considerable difficulties have been reported in producing stable antibody- 
secreting clones by limiting dilution or by soft-agar cloning techniques (Glassy and Dillman, 1988). 
Further difficulties were encountered when these cells were grown by large scale fermentation. A 
number of different systems have been employed such as hollow fibre reactors (Altshuler et al., 1986), 
agarose beads (Scheirer et a l., 1984), stirred tank reactors (Kitano et al., 1986) and in air-lift 
fermenters (Birch e t al., 1985), but have met with limited success. This area of large scale hmab 
culture has recently been reviewed by Glad and Nilsson (1990). Attempts to grow hmabs in vivo as 
ascites in irradiated pristane-primed nude mice (Kozbar et al., 1985; Kosinski and Hämmerling, 1986), 
or when mixed with human skin fibroblasts, have been of very limited use to date. In a recent review 
by Borrebaeck et al. (1990), it was reported that hmab were produced in Severe Combined Immun- 
Deficient (SCID) mice. These mice are deficient in both T and B cells. However, the amounts of 
hmab produced are still much lower than those obtained with murine mabs.
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1.4. RECOMBINANT MONOCLONAL ANTIBODIES.
The difficulties which are encountered in producing stable human hybridomas prompted several 
researchers to ‘by-pass’ hybridoma technology and, in some instances, animal immunisation altogether. 
The use of mouse-human chimaeric monoclonals, humanised mabs (h-mabs) and the production of mabs 
in non-myeloma cells, yeast, bacteria and even plants has renewed interest in monoclonal technology.
1.4.1. Chimaeric Antibodies.
Chimaeric antibodies are part-human and part-mouse mabs. From Figure 1.4.1., it can be seen that 
these chimaeric antibodies are produced by attaching a human antibody constant region to murine 
antibody variable regions (reviewed by Morrison and Oi, 1989). Therefore, chimaeric antibodies retain 
the specificity of the original murine antibody but should be less immunogenic than intact murine 
antibody. The presence of an intact human Fc portion in these antibodies allows their use to treat 
patients by stimulating both complement-mediated cytotoxicity (CMC) and antibody-dependent cell- 
mediated cytotoxicity (ADCC), and will be discussed in Section 1.11.2. However, the intact Fc portion 
reduces the effectiveness of mabs in tumour imaging (Section 4.4.5.). A number of genetic engineering 
techniques have been used to produce chimaeric mabs. Most of the initial studies transferred human 
genes coding for Fc region DNA into murine myeloma cells using plasmids. pSV2 plasmids which 
contained heavy (and/or) light chain genes and drug-resistant markers, such as xanthine-guanine- 
phosphoribosyltransferase (gtp), were constructed. These drug selection genes can then be used to select 
cells that have been successfully transfected with the plasmid. These cells are called transfcctomas. 
Protoplast fusion, using protoplasts from cultures of Escherichria coli which contain a high plasmid 
copy number have been successfully transfected into cells by using polyethylene glycol (Gilles et al., 
1983). In other studies, chimaeric antibodies which were prepared by calcium phosphate co- 
precipitation (Boulianne et al., 1984) have been shown to have low transfection efficiencies (1 x 10'4 
to 1 x 10'5 transfected cells) (reviewed by O’Kennedy and Roben, 1991). Electroporation has resulted 
in the production of more stably-transfected clones, which can be isolated with frequencies of 10'3 
transfected cells (Boulianne et al., 1984; Potter et al., 1984). These transfectomas can be cloned and 
cultured in the same way as murine hybridomas, and, they have been shown to produce a range of 
stable mabs, with good antigen-binding capacities as well as the correct human isotypes for use in 
therapy (Morrison and Oi, 1989).
Rather than constructing transfectomas, Neubergcr (1985) attempted to produce chimaeric antibodies 
in E. coli. However, the VH and VL chains (Figure 1.2) did not recombine properly and they formed 
and insoluble aggregate within the bacterium. These VH and VL fragments were not glycosylated by
12
-(t•  »•X#
Hvlviiloni.i (e l ls
4-
in RN. \
i
cDNA
Vari.lbk lolislanl
Human
Effector Recombinant MABS
Chimaeric Humanised Effector Hybrid Bifunctional
Figure 1.4.1: General structure of recombinant monoclonal antibodies. Messenger RNA
(mRNA) is prepared from murine hybridomas or EBV transformed cells. First- 
stand copy DNA (cDNA) synthesis is performed and primers corresponding to 
the human framework region are used to initiate PCR amplification (O’Kennedy 
and Roben, 1991). Chimaeric antibodies are constructed by grafting the murine 
hypervariable or CDR regions onto human framework regions. Effector hybrid 
mabs are constructed by attaching antibody binding regions to effector molecules 
such as enzymes and toxins (Section 1.4.). Bifunctional antibodies (BFAs) may 
be produced chemically, by cell hybridisation or by genetic manipulation (Section
1.5.) for use as targeting or effector mabs [adapted from Larrick et al., 1990].
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E. coli and chemical recombination of ihe purified VH and VL regions was both complex and inefficient. 
Strategies which have been used to overcome these problems will be explored in Section 1.4.3.
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1.4.2. Humanised Monoclonal Antibodies.
The genes coding for VH and VL regions contains six complementarity-determining regions (CDRs) 
embedded in a framework region (FR1 - FR4), as shown in Figure 1.4.1. Reichmann and his colleagues 
(1988), designed a recombinant 1humanised’ mab (hu-mab) in which murine CDR regions were 
embedded in human-framework regions. Unlike chimaeric antibodies, the Fc portion and most of the 
F(ab’)2 portions of the antibody are human. Hu-mabs are of use in ADCC and CMC but they are less 
immunogenic and have longer circulating half-lives when administered to patients (Section 4.4.5.). 
Certain residues in the original murine framework make key contacts with murine CDRs that help to 
maintain the 3-dimcnsional conformation of the antibody binding site. This 3-D structure determines 
the antibody binding site and, therefore, the specificity of the antibody for a given antigen. When 
murine framework regions are replaced with human sequences, those CDR contacts are altered which 
alters the affinity of the hu-mab for the specified antigen. Co et al. (1991 (a)) have used human V 
regions that are particularly homologous in sequence to the murine V regions. These hu-V regions have 
minimised so-called ‘framework shift affinity changes’. Computer modelling technology was used to 
locate the CDR-FR contacts and to stabilise hu-mabs against the gB and gD glycoprotein herpes simplex 
virus antigens.
Both chimaeric and humanised monoclonal antibodies have been produced to therapeutic grade and used 
in vivo. The results of these clinical applications of mabs will be discussed in more detail in Section
4.4.5.
1.4.3. Second Generation Recombinant Mabs.
Chimaeric and hu-mabs have been termed the first generation recombinant mabs by Clackson, (1991). 
In this review, he also describes second generation recombinant mabs, where the immunoglobulins are 
produced in bacteria.
First-generation recombinant mabs used murine hybridoma DNA as a source of Fv and CDR DNA. 
Instead of producing hybridomas or immunising animals, these recombinant mabs are constructed from 
DNA derived from primary human tissue. In the case of anti-tumour antibodies, mRNA is isolated 
from a cancer patient’s bone marrow, spleen or tumour infiltrating lymphocytes. These patients should 
have mRNA in their plasma cells which gives rise to antibodies against the tumour as well as other 
mRNA. All the mRNA is translated into DNA by use of the reverse transcriptase enzyme. The DNA 
is cut by restriction endonucleases and only those DNA fragments which code for VH (or VL when DNA 
is cut with a separate set of restriction endonucleases) are isolated and amplified using the polymerase 
chain reaction (PCR). VH and VL genes have been cloned into a range of vectors which includes the
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Figure 1.4.2: Schematic view of a technique described by Clackson, (1991), for producing
genetically engineered Fv fragments in E. çoli using the phagemid library 
technique. mRNA is extracted from a patient’s bone marrow and its cDNA 
amplified by PCR. DNA coding for VH (or VL) fragments is isolated by cutting 
with restriction endonucleases (ren’s) and the resulting VH segments can be 
ligated to the phagemid vector (1). This vector (2) is then transfected into E. çoli 
by electroporation and grown to large scale. Following lysis of the bacteria the 
vector is cut with separate rens (which had cut the VL fragments) and these new 
vectors (3) are electroporated into E. çoli. The phagemid vector used in this 
technique is deficient in some of the genes needed to form a phage coat, or 
capsid. Capsid formation (which allows the expression of Fv fragments) can 
proceed if these genes are borrowed from a helper phage. Capsids expressing 
the correct antigen specific Fv fragments can then be isolated. In the next step, 
the phage DNA is cut out from the vector by a further set of rens and the 
plasmid which contains the functional Fv fragment can be transfected into E. çoli 
and grown to large scale. Following lysis of these bacteria, Fv fragments can be 
purified.
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1.5. BIFUNCTIONAL ANTIBODIES.
Bifunctional antibodies (BFAs) are bi-specific, that is they bind to two separate antigens. Each arm or 
F(ab) fragment binds to a different antigen (Figure 1.4.1.). BFAs have been produced chemically, by 
hybridoma technology and, more recently, by genetic engineering techniques.
Chemically produced BFAs are produced by synthesising an interchain disulphide bond between two 
different types of F(ab) fragments (Brennan et al., 1985; Glennie et al., 1987). These BFAs have two 
functional binding sites and are produced with a higher overall yield than biologically produced BFAs.
BFA can be produced by hybrid hybridomas or quadromas or, in some cases, triomas. Quadroma cells 
are formed when two hybridoma cells are fused, while trioma cells are formed when a hybridoma is 
fused to an immunised B-cell. These hybrid cells produce 16 different random combinations of heavy 
and light chains. Only one of these functional Igs contains the correct heavy and light chain 
recombination to produce a bispecific or bifunctional antibody (Martinis el al., 1982; Milstein and 
Cuello, 1984). This recombination of heavy and light chains is not entirely random. There is a bias 
towards the recombination of homologous (i.e. hybridoma 1 x hybridoma 1) rather than heterologous 
(i.e. hybridoma 1 x hybridoma 2) antibodies. Milstein and Cuello (1984), have estimated that there is 
an overall ratio of 1 heterologous to 12 homologous antibodies formed following cell fusion. The vast 
array of functional immunoglobulins which are produced do not react with correct combination of 
antigens and this neccessitates screening of the large number of clones, which creates both screening 
and purification problems. Techniques such as Protein A-Sepharose and hypoxyapatite column - HPLC 
have simplified this selection process (Nolan and O’Kennedy, 1990).
Genetically engineered recombinant BFA fragments have also been produced. Constructs in which two 
single chain Fv fragments with anti-CD3 and anti-DNP specificities were linked and expressed in 
bacteria. However, further work is needed to obtain an active refolded single-chain BFA (Fanger et 
al., 1991).
Human BFA production has been hindered by the limited success of human hybridoma technology to 
dale. It appears that the developments in genetic engineering will be the most practical method of 
obtaining human BFAs for clinical use (Section 4.4.5.).
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1.6. CATALYTIC ANTIBODIES.
The specificity and speed of antibody-antigen interactions are very similar to those observed in enzyme- 
substrate reactions. Affinity constants of up to 10'12 M 1 which were observed for some antibody- 
antigen reactions, led some researchers to suggest that they may have some enzyme-like catalytic 
activity. The discovery that antibodies can catalyse a range of reactions such as acyl-transfer and 
peptide-bond formations has lead to renewed interest in catalytic antibody or ‘abzyme’ technology 
(reviewed by Green and Tawfik, 1989; Harris, 1991).
Green and Tawfin (1989) outlined several roles for catalytic antibodies. They can act as catalysts in 
organic synthesic and in sterospecific synthesis. Catalytic antibodies may also be used as biosensors 
and as cleavage systems in protein engineering. In addition, catalytic antibodies have several potential 
clinical applications. These applications include:
(a) Catalysis of the breakdown of bacteria and toxins. It was suggested that catalytic antibodies 
with proteolytic activity would act more speedily and with lower overall dose than 
unconjugated antibodies (Section 1.11.).
(b) Similarly, catalytic antibody ‘vaccines’ may passively immunise against toxins, bacteria, virus 
and potentially cancer cells.
(c) Catalytic antibodies may be used to replace enzymes which are deficient in a patient.
(d) These antibodies may replace mab-enzyme conjugates in prodrug activation (reviewed in more 
detail in Section 1.10.2.).
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1.7. CLINICAL APPLICATIONS OF MONOCLONAL ANTIBODIES.
Soon after the discovery of monoclonal antibodies, it became apparent that the exquisite sensitivity and 
selectivity of these molecules would be of medical importance. Mabs have been used to diagnose and 
treat a variety of diseases. Mabs have been used to treat autoimmune disorders such as rheumatoid 
arthritis (Sany, 1990), they have been used as vaccines to treat malaria (reviewed by Coppel, 1986) and 
they have also been used as anti-viral agents (Co et al., 1991 (b)). Mîbs have also been used to 
diagnose non-specific infections and myocardial necrosis (Strauss et a i., 1991). However, particular 
interest has been expressed in the application of mab technology to the detection and treatment of 
cancer.
Several factors influence the type of mab or mab-conjugate which can be used in a particular clinical 
application (Table 1.7.1.). These factors include the intended usage of the antibody (i.e. for detection 
or therapy), the antibody unit used (i.e. IgG, F(ab’)2 or Fv fragment), the antigen target and the 
distribution and pharmokinetics of the mab when administered to patients.
While tumour detection (Section 4) and a novel method of tumour immunotherapy (Section 5.5.5.) will 
be discussed in some depth in later sections the aim of this review is to outline the clinical applications 
of mab technology to date. By summarising the results of studies already conducted and examining the 
problems they have encountered and overcome, it may be possible to find new applications for 
recombinant mabs, to develop more effective immunoconjugates and to make mab therapy more 
accurate and disease-specific in the 1990s.
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Table 1.7.1: Factors affecting the choice of monoclonal antibody for use in vivo.
Factor Choices and Limitations
Intended usage delivery system vs effector molecule
Molecular Species used whole antibody, F(ab’)2, F(ab), Fv 
murine, human, humanised or recombinant 
monospecific, bifunctional
Specificity monospecific vs multispecific mabs
extracellular vs intracellular antigens
minimal cross-reactivity with non-specific antigens
Affinity immunoreactivity (kq > 1010 L/M)
Antigen antigen density (> 106 sites per cell) 
internalisation of antibody, capping 
metabolism/excretion of radiolabeled antibody 
presence of antigen in blood/tumour
Biodistribution route of administration (iv, ip, etc.) 
pharmacokinetics, vascularity of target area, size of target, 
rate of blood clearance and non-specific mab uptake by liver, 
spleen etc.
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1.8. IMMUNOCONJUGATES.
Drugs, toxins, biological response modifiers and radioisotopes have been conjugated to mabs. These 
toxic or localising immunoconjugates have been used to target particular cells which express antigens.
The most stable immunoconjugates have been produced following the covalent linkage of the compound 
to the mab. The most accessible sites for covalent attachment to mab polypeptide chains are the e- 
amino groups of the lysine residues (approximately 90 lysines in a mab). Both drugs and toxins have 
been conjugated to intact mab and mab fragments by stable amide Linkages (Pieters, 1990).
Regardless of the covalent binding technique which is used, the following points are of importance:
(a) The attachment of the drug (or toxin or isotope) must not alter the specificity or 
immunoreactivity of the antibody.
(b) The chemical linkage system must not interfere with the toxicity of the drug.
(c) The drug should be covalently attached to the antibody. Non-specific absorption of the drug
to antibody, which may be reversible, should be minimised.
(d) The conjugate should be prepared under conditions that will minimise the formation of large 
molecular weight complexes which would increase the immunogenicity of the conjugate.
(e) The conjugate protocol should be capable of scale-up to production level. This production
must be carried out under sterile and pyrogen-free conditions, especially if the products are for 
administration to immunocompromised patients.
These general guidelines refer to all immunoconjugates. In the next sections, the production and 
applications of specific immunoconjugates, such as chemoimmunoconjugates, immunotoxins, 
immunocytokines and radio-labelled mabs will be discussed in more detail.
1.8.1. Chemoimmunoconjugates.
Most of the drugs currently used in cancer treatment (Table 1.8.2.) kill all growing cells non- 
specifically. The side effects of these drugs are also well characterised. However, these cytotoxic drugs 
are not ideal agents for use in immunotherapy. Firstly, many of these drugs do not have a chemical
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Table 1.8.1: Summary of Main Im mu noconjugates.
A. CHEMOIMMUNOCONJUGATES 
DNA binding and intercalating agents
Daunomycin, Adriamycin, Bleomycin and Macromycin 
Alkylating agents
Chlorambucil, Melphalan, Mitomycin C, Trenomin, 
cis-Platinum, Phenylenediamine Mustard 
Microtubule inhibitors 
Vindesine, Deacetyl colchicine 
Anti-metabolites
Fluorouracil, Methotrexate, Cytosine arabinoside
Reviewed bv:
Pietersz, (1990)
Reisfeld and Schrappe, (1990) 
Bagshawe, (1989)
Pietersz et al., (1987)
B. IMMUNOTOXINS
Ribosomal protein synthesis inhibitors
Ricin, Gelonin, Abrin, Modeccin, Saporin, Purothionine, 
a-Amanitin, Pokeweed anti-viral protein 
Elongation factor 2 inhibitor 
Diphtheria toxin. Pseudomonas endotoxin
Reviewed bv:
Spooner and Lord, (1990) 
Bjom and Villemez, (1988) 
Vitetta et al., (1987)
C. IMMUNOCYTOKINES 
Local response
Interleukin (IL-2, IL-1), Interferon
Complement activation
C3b, Cobra venom factor (C3/C5 convertase)
Inflammatory response
TNF
Reviewed by:
Ferrini el al., (1990) 
Figlin, (1989)
Foon, (1989) 
Cavagnaro, (1987)
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group which is suitable for conjugation well separated from the active site. The presence of such 
binding groups will allow covalent linkage of the drug lo the antibody without affecting the drug 
potency or toxicity. Several researchers have overcome this problem by introducing new active groups 
and by using carrier molecules such as dextran, polyaminoacids or human serum albumen (Pietersz, 
1990) to minimise reduction in drug potency.
In order to deliver a potent dose of drug to the selected cell, each mab usually has several drug 
molecules attached to it. Even when very active drug immunoconjugates are targeted to the most drug- 
sensitive tumour cells, between 10® to 107 drug molecules must be accumulated in a tumour area to 
mediate tumour killing (Reisfeld and Schrappe, 1990). Johnson et al. (1987) showed that many of the 
commonly used drugs (Table 1.8.1.) lose much of their activity following binding to proteins. This loss 
in activity has been attributed to steric hindrance, altered mechanisms of cellular uptake and reduction 
in the drug half-life following linkage.
Many researchers have abandoned the use of conventional drugs and are beginning to produce new 
drugs specifically designed for mab-conjugation. These drugs have been termed structure-activity- 
relationship (SAR) compounds, and have been designed with both the potency of the drug and the 
immunoreactivity of the antibody in mind. The developments of new SAR drugs such as KS1/4 - 
DA VLB [a vinblastine derivative] (Koppel, 1991), and LY203625 (Laguzza et al., 1989) a new 
synthetic drug mark the beginning of SAR immunoconjugates. Further developments in prodrug 
chemistry (Section 1.10.2.), the use of chemoimmunoconjugates to by-pass multidrug resistance in cell 
lines (Tsuruo and Hamada (1990), and lysosome-sensitive linkages, which allow the release of free-drug 
on internalisation of the complex (Trouet el al., 1982), will maximise tumour cell killing by 
chemoimmunoconjugates.
1.8.2. Immunotoxins.
Toxins were proposed as suitable agents for immunotherapy because of their extreme cytotoxicity. The 
main plant and bacterial toxins which have been conjugated to mabs are summarised in Table 1.8.1. 
Toxins are protein molecules which are found in plants and bacteria and they can be easily conjugated 
to mabs by using heterobifunctional reagents (reviewed by Spooner and Lord, 1990). Toxins may act 
enzymatically on the cell membrane. (Bjom and Villemez, 1988). Ricin and other lectin toxins contain 
an A chain which is non-specifically toxic, and a second sugar-binding B chain. Most immunotoxins 
consist of the toxin A chain conjugated to the mab. This immunotoxin is able to bind to antigen 
bearing cells in a selective manner. The toxin portion of the immunotoxin is activated after the mab 
binds to the cell. Because immunotoxins are often much more cytotoxic than drug-antibody conjugates, 
non-specific uptake by liver, bone marrow and other cells must be avoided. The use of F(ab’)2, Fv and
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smaller single domain antibodies, may reduce non-specific uptake in the liver, spleen and other organs. 
Recombinant anti-Tac effector mabs, with genes coding for toxin fused in frame with the antibody 
DNA, have been produced (Section 1.4.4.), but may not be of practical use in vivo until these problems 
of toxin uptake by non-antigen-bearing cells have been overcome.
1.8.3. Immunocjtokines.
Several researchers have looked at the body’s natural mechanisms for fighting disease and have tried 
to redirect these natural cellular molecules called biological reponse modifiers (BRMs) to kill cancer 
cells.
BRMs such as interferons (Weiner et al., 1988), interleukins (IL-1, IL-2), .colony-stimulating factors, 
erythropoietin, human granulocyte colony-stimulating factor and tumour necrosis factor (TNF) (Reisfeld 
and Schrappe, 1990) have all been conjugated to mabs and used in cancer treatment.
Foon and Fanning (1990) reported that antibody-IL-2 conjugates were used to activate LAK cells and 
tumour-infiltrating lymphocytes which expressed the CALLA antigen. Similarly, Chovnick et al. (1991) 
used a recombinant anti-Tac-IL-2 fusion protein which bound to the IL-2 receptor of cells bearing the 
CALLA antigen and inhibited protein synthesis.
In a recent article by Ferrini and his colleagues (1990), it was noted that immunologists are only 
beginning to unravel the complex reactions of BRMs, cytokines, lymphokines and growth factors. They 
also noted that many of these molecules have pluripotent effects on many cells of the immune system 
(Section 1.11.2.) and, therefore, the efficacy of mab-BRM conjugates on tumour is more difficult to 
monitor than mab-drug, mab-toxin or mab-isotope conjugates. Research aimed at directing BRMs to 
specific cells may help to elucidate these pluripotent effects.
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1.9. RADIOIMMUNOCONJl GATES.
Isotopes conjugated to mabs have two distinct clinical applications, either in diagnosis by 
immunoscinligraphy or treatment by radioimmunolherapy. Both of these applications will be outlined 
in this section and discussed in more detail in Section 4 and Section 5.
1.9.1. Radioimmunotherapy.
The aim of radioimmunotherapy (RIT) is to irradiate and kill antigen-bearing tumour deposits 
throughout the body with minimal radiation damage to normal tissues. A large variety of p-emmitting 
and a-emmitting isotopes and a smaller number of electron capture systems and fissionable nuclides 
have been used in RIT to date (summarised in Table 1.9.1.). The limited success of RIT in vivo has 
mainly been attributed to the inability to target sufficient doses of isotope to the tumour. In a recent 
review by Britton and colleagues (1991(a)), they reported that one day after the administration of mab- 
isotope, approximately 30% of the administered radioactivity has been excreted. They also reported that 
an average of 1% of the administered activity is actually located to the tumour site, while 69% 
accumulates in normal tissues (liver, kidneys, bone marrow and with Iodine compounds, the thymus). 
This leads to extensive lethal irradiation of non-specific tissues. In many cases less than 1% of the 
administered radiation may reach the tumour site. Table 1.9.2. highlights the factors which govern 
successful radioimmunotherapy. Similar factors govern the success of tumour imaging or 
immunoscintigraphy and these will be discussed in detail in Section 1.9.
(a) Tumour Selection:
The size of a solid tumour is a critical parameter in radioimmunolherapy (and in all other 
immunoconjugale therapy regimes). Since the blood supply to a tumour is from the surface 
of the tumour inwards, cells lining the superficial tumour capillaries which are more permeable 
than normal cells and if these cells express the relevant target antigen they will bind the 
antibody more rapidly than cells in the centre of a tumour mass. Additionally, the core of the 
tumour is often less oxygenated, and therefore, less sensitive to radiotherapy, so that the deeper 
pans of larger tumours not only receive less radiolabelled antibody, but the radiation they 
receive is less effective (Hagan et al., 1986). An antibody which binds to an antigen on the 
surface of a tumour may not bind to necrotic tissue in the centre of an anoxic tumour. These 
necrotic tumour cells often express different non-tumour antigens such as TNF, and the 
inclusion of such a mab-conjugate (i.e. anti-TNF) in a cocktail of mabs may increase access 
to the tumour and bind to the centre of larger tumours (Epstein et a l., 1990).
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Table 1.9.1: Radioisotopes for Use in Radioimmunotherapy.
Radioisotope Half
Life
(days)
Particulate
Energy
(MeV)
Comment Reference
A. (3-Emitters Reviewed by:
Iodine-131
Rhenium-188
8
0.7
0.6
2.1
Readily available, 
cheap
too-long half-life 
thymus uptake
Tc-99m chemistry 
stable in vivo 
too short half-life
Britton et al„ 
1991(a)
DiMaggio et 
a i., 1990
Levy and 
Miller, 1991
Rhenium-186 3.5 1.1 Energy suitable for 
both imaging and 
therapy
Foon and 
Fanning, 1990
Copper-67 2.5 0.4 - 0.6 Suitable energy, very 
expensive
Yttrium-90 2.5 2.3 Indium-III chemistry 
myelotoxicity
Phosphorus-32 14.3 0.695
Pure negatron 
emitter
Scandium ^ 3.4 0.162
High energy [3 
emitter, expensive
B. a-Emitters
Astatine-211
Bismuth-212
0.35 
1 hour
5.9
6.1
Short range, iodine­
like chemistry
High energy 
emission
c. Electron Capture
Iodine-125 2.5 7.5 Dehalogenation
D. Fissionable 
Nuclides
Mafane et al., 
( 1987)
Boron-10 * Requires external 
source of neutrons, 
delivered to tumours
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Table 1.9.2: Comparison of Factors Affecting the Effectiveness of Radioimmunotherapy and
Immunoscintigraphy.
Radioimmunotherapy Immunoscintigraphy
Cell binding Difficulties in targeting to cells 
in the centre of the tumour
only a fraction of cells are 
required to bind to surface of 
tumour
Isotopes used a  and P emitters, electron 
capture, fissionable nuclide
Y emitters, some P emitters
Isotope half-life long life (days) short life (hours)
Access to tumour site large doses required (> 40 mg) 
to increase penetration
small doses required 
(0.5 - 2 mg)
Tumour geometry size-limited (i.e. diffusion 
limited), can kill seedlings
larger tumours imaged more
easily
Administration multiple fractionated doses, 
regional delivery, intravenous
single dose, usually intravenous
Repeated administration HAMA toxicity, myelotoxicity lower immunogenicity
Immunoconjugate
internalisation
not required to kill cells not required to image cell
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(b) Route o f  Administration:
In order to increase the amount of radiolabel which could attach to the tumour and decrease 
non-specific uptake, various researchers have demonstrated that malignancies which recur in 
the peritoneum, pericardium or pleural cavity are more effectively treated by regional therapy 
to these areas. Recent results by Hird et al. (1990) showed at intraperitoneally administered 
90Y-labelled monoclonal antibodies (80 mg/kg/24 hr) were successfully used to treat recurrent 
ovarian carcinoma. The antibody used was 90Y-HMFG-1 and this antibody was also used to 
locate tumours in these patients (the therapeutic and diagnostic potential of this antibody will 
be discussed in Section 4.4.5.). In this study, free EDTA was administered with the 90Y- 
HMFG-1 to help remove non-specifically bound antibody. The results obtained were superior 
to those found with intraveneously administered antibody and gave reduced myelotoxicity.
Various strategies are also being used to minimise HAMA reactions. These reactions are 
particularly useful where up to 500 mg of mab are administered to each patient. The strategies 
which have been developed to minimise HAMA reactions are summarised in Table 1.9.3. 
Radiation protection for both patient and hospital personnel is an important factor in RIT. 
Improvements in catheters and continuous infusion systems to avoid spillages will be necessary 
in order to satisfy many staff and administrators that this type of therapy is suitable for all 
hospitals with basic Nuclear Medicine departments.
It appears that RIT is an effective method of treating locally recurrent regional disease such as 
peritoneal and pleural effusions, especially where the tumours are small in size and the patient can 
tolerate high doses of antibody without developing an immune response against the injected antibody.
1.9.2. Immunoscintigraphy.
Immunoscintigraphy has been the most useful and successful application of immunoconjugates in 
oncology. Immunoscintigraphy aims to detect tumours in vivo rather than to kill these tumours. Table
1.9.2. shows that immunoscintigraphy uses lower levels of radiation (gamma y), low energy isotopes 
such as mIn and WMTc and smaller doses of radio-labelled mab conjugate than in RIT. Typically, 
patients are administered between 0.5 - 2.0 mg of radiolabel for diagnostic purposes, but are 
administered with up to 500 mg of radiolabelled-mab for therapeutic purposes (Britton et al., 1991(b)). 
While radioimmunotherapy is more successful on very small and diffuse tumours, immunoscintigraphy 
has been most effective on large tumours with larger surface areas to bind antibodies. A detailed 
evaluation of techniques currently used in immunoscintigraphy, with particular emphasis on imaging 
ovarian carcinoma using “in and ” MTc fragments, is given in Section 4.
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Table 1.9.3: Strategies to Overcome Human-Anti-Mouse Antibody (HAMA) Reactions
following Immunotherapy.
Approach T reatment Comments
I Immune Supression azathioprine, 
cyclophosphamide, 
cyclosporin A, 
anti-CD3 mab,
HAMA only partially 
suppressed, potential toxicity 
from immune suppression
II Reduce mab 
Immunogenicity
F(ab’)2, Fv,
hmabs,
hu-mabs
Anti-idiotypic responses can 
occur
III Induction of Tolerance anti-T-cell mab,
total lymphoid irradiation,
hyperimmunisation
Anti-idiotypic responses, 
tolerance is still difficult to 
achieve
[Adapted from Dillman, (1987); Di Maggio et al. (1990)].
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1.10. TWO-STEP IMMUNOCONJUGATE SYSTEMS.
Chemoimmunoconjugates, immunotoxins and radioimmunoconjugates have all been of limited success 
in vivo, mainly due to non-specific uptake of conjugate by non-tumour tissues. Several researchers 
have tried to overcome this non-specific uptake by using pre-treatment with EDTA (Goodwin et al.,
1986) and by lactosamination, biotin-avidin and anti-mouse IgG antibodies (reviewed by Klibanov et 
al., 1988). Other researchers use two step systems, administering the conjugate to the patient and 
allowing the clearance of mab from the bloodstream before activation of the drug or isotope . Novel 
therapy systems, including immunophotodynamic therapy, antibody-directed enzyme prodrug therapy 
and radio-avidin-biotin therapy, may be better solutions to the problem of non-specific tumour uptake.
1.10.1. Immunophotodynamic Therapy.
A group of photoactive drugs termed photosensitisers produce singlet oxygen when activated by light 
in the presence of oxygen. These photosensitisers are relatively harmless in the absence of light. By 
administering photosensitisers such as hematoporphyrin, hematoporphyrin derivatives, phthalocyanines, 
chlorines and benzoporphyrins (reviewed by Nelson el al., 1988) and some more unusual compounds 
such as methyene blue (Yu et a l., 1990) and rhodamine-123, to patients, and then irradiating those areas 
of their body with tumour masses using light focused from a Xenon-Arc lamp, a laser or another light 
source, significant reductions in the mass of these tumours have been observed. The use of 
photosensitisers and light to kill tumour cells is known as photodynamic therapy (PDT), and this area 
has been reviewed extensively (Dougherty, 1984; Ash and Brown, 1988). However, PDT is not a 
selective treatment, i.e. when a patient with a bladder tumour is administered with a photosensitiser, 
both the tumour tissue and normal bladder cells surrounding the tumour take up photosensitiser. Wile 
et al. (1984) argued that the increased blood flow to the tumour increases the amount of photosensitiser 
in the tumour and decreases the blood flow to the surrounding tissue but has only partial selectivity. 
By coupling photosensitisers to monoclonal antibodies the immunophotosensitiser should be delivered 
to the target tumour tissue, with minimal uptake by the normal cells.
STEP 1: Administration of immunophotosensitiser to the tumour cell followed by clearance of
conjugate which has not been taken up by antigen-bearing cells.
STEP 2: Irradiation of tumour area by laser or focused light leading to death of tumour cells.
Immunophotodynamic therapy (IPDT) is particularly selective for tumours than many other 
immunotherapies. Areas such as the liver, spleen and bone marrow, which take up antibody non-
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specifically are not damaged, because these areas are not irradiated. In Section 5, initial studies on the 
preparation of an immunophotosensitiser where hematoporphyrin was conjugated to the anti-HMFG 
antibody will be described. The potential of IPDT as a method of overcoming non-specific drug uptake 
will be discussed Section 5.5.4.
1.10.2. Antibody-directed Enzyme Prodrug Therapy, ADEPT.
Antibody - enzyme conjugates (or recombinant antibody-enzyme molecules) can be used to cleave 
inactive precursors or prodrugs into their active form in vivo using two separate administration steps.
STEP 1: The injection, selective localisation and extracellular retention of an antibody-enzyme
conjugate at the tumour site.
STEP 2: Conversion of the prodrug with a low toxicity to a highly toxic drug by enzymatic
conversion takes place after non-specifically bound antibody has been cleaved from 
the blood pool.
ADEPT systems which have been used to date in tumour cell killing include:
1. Anti-hCG-carboxypeptidase B and the prodrug bis-chloro-benzoic acid, which was converted 
to the active agent bis-chloro-mustard (Searle et al., 1986).
2. Mab-P-lactamase converts the prodrug cephalosporin-DAVLBHYD, to an active DAVLBHYD.
3. Anti-CEA-beta-glucuronidase converts prodrugs etoposide or methylumbelliferone to the active 
form (Bosslet et a l., 1991 (a)).
The enzymes used in ADEPT are usually not human in origin. This has been shown to cause some 
problems, especially with increased immunogenicity in vivo (Bagshawe, 1989). Other enzyme systems 
used include alkaline phosphatase, glucouronide oxidase and phospholipase C (reviewed by Di Maggio 
et al., 1990) while ifosfamide (IFO) (Ceny e t a l., 1990) and tetrachloro-(d,l-trans)-l,2- 
diaminocyclohexaneplatium (TV) (tetraplatin) (Chaney et al., 1991) have recently been proposed as 
prodrugs which may be of use in cancer treatment.
1.10.3. Further Two-Stage Techniques.
Paganelli et al. (1991), have recently reviewed a series of two-stage or pretargeting techniques,
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including:
(a) The Avidin-Biotin System:
Avidins are a family of proteins which have both a high affinity (KD ~ 1015 M) and specificity 
for biotin. Each avidin molecule (or streptavidin molecule) can bind 4 biotin residues. This 
reaction is used to amplify mab reactions both in vitro and in vivo (Section 2.4.3.). Various 
combinations of mab-biotin and avidin-labelled drugs, toxins and radiolabels have been 
proposed (Britton et al., 1991(a)). One such two-step immunotherapy procedure has been 
proposed by Paganelli et a l (1991).
STEP 1: Mab-biotin antibodies are administered intravenously.
STEP 2: Radiolabelled avidin or strepavidin is injected into the peritoneal cavity of
the patient after 2 to 3 days and the resulting mab-biotin-avidin-radiolabel 
complexes may be visualised.
The use of mab-avidin-biotin immunotherapy will be discussed in more detail in Section 5.5.5.
(b) Bifunctional Antibodies:
A number of two-stage therapies involving BFAs with affinities for both tumour/long-lived 
radionuclides (Bosslet et al., 1991(b); Britton et al., 1991(a)) and for the iodinated-Bolton- 
Hunter reagent (Bator and Reading, 1990) will be discussed in more detail in Section 4.4.5.
To date, few clinical studies have been carried out using two-stage immunotherapy strategies. The more 
conventional one-stage immunotherapy procedures have resulted in significant toxicity and damage to 
non-tumour cells. These two-stage strategies do not eliminate these non-tumour effects, but they may 
minimise the unfavourable effects of immunotherapy.
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1.11. THE USE OF UNCONJUGATED MONOCLONAL ANTIBODIES IN VIVO.
Unconjugated antibodies are often forgotten in the race to find effective immunoconjugates. These 
mabs can play a vital role in vivo by stimulating and manipulating the immune system by mimicing a 
patient’s own antibodies. Unconjugated mabs can achieve an anti-tumour response by five different 
mechanisms, (reviewed by Mellstedt, 1990). Each mechanism will be described in more detail.
1.11.1 Complement-Dependent Cytotoxicity (CDC).
An activated terminal complement complex can attack a cell membrane and induce lysis and destruction 
of target cells. Mabs have been used to activate the cascade that causes the production of the 
complement complex. In this system, the Fc portion of the mab (Figure 1.2.) which contains the Clq 
binding site of complement cascade mediates the activation of some components of complement. 
Murine mabs have been less effective than human mabs in mediating complement reactions (Dillman,
1987). Human IgM is the most efficient complement-binding antibody, followed by IgGl, IgG3 and 
IgG2a. Intact mabs (including the Fc portion) are needed for CDC. Human IgM antibodies (which are 
of limited use in immunoconjugate production), have been particularly useful in inducing the regression 
of metastatic melanoma, following the administration of a complement-fixing IgG3 mab against the 
GD3 ganglioside antigen (Vadham-Raj et al., 1988).
1.11.2. Antibody-Dependent-Cell-Medicated-Cytotoxicity (ADCC).
A wide range of cells called effector cells have been shown to produce cytotoxic reaction when 
activated by antibodies. These effector cells include killer (K) cells, macrophages, NK cells, neutrophils 
and even non-immune cells such as platelets (reviewed by Di Maggio et al., 1990). Each of these cell 
types expresses a receptor for the Fc portion of the intact mab, (Fc R). In circulating mabs, the Fc 
portion of the mab is not accessible to the Fc R receptors on effector cells, however, when the mab 
binds to the target antigen, the Fc R binds the Fc region and effector cells are brought to the membrane 
of the tumour cell to cause cell lysis. This process has been shown to be stimulated in vivo when 
biological response modifiers such as IL-2, a-interferon and M-CSF are administered to the patient 
(Masucci et al., 1989; Tang et al., 1989). BFAs are particularly useful in replacing the role of the Fc 
regions in bridging different cells and can bind tumour directly to the effector cell. Fanger et al. (1991) 
have recently reviewed this area in more detail. The use of BFA fragments, without the Fc portion may 
also reduce the immunogenicity of current-intact IgG ADCC treatments. Fanger and his colleagues also 
described the production of a CD4 - Fc fusion protein which binds to HIV infected cells expressing the 
gp-120 antigen and thereby mediates ADCC.
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1.11.3 Interaction with Receptors on Malignant Cells.
Receptors such as platelet-derived growth factor (PDGF) receptors, epidermal growth factor receptor 
(EGF), transferrin receptor and several oncogene-related receptors are known to cause the proliferation 
of target cells (reviewed by Thurin, 1990). Antibodies such as anti-TAC (Waldmann et al., 1988), and 
anti-ECF, (Mendelsohn, 1990), have been used to block these receptors and to retard the proliferation 
of their target cells.
1.11.4. Anti-Idiotypic Antibodies.
When antibodies are repeatedly injected into a patient, the patient develops an immune response against
the antibody, and anti-idiotypic (or anti-antibody) antibodies are produced. When this anti-idiotypic 
antibody (anti-id ab) response is against the variable region of the injected antibody, the anti-id ab is 
said to be the mirror-image of the antigen. These anti-id ab can then be used to mount a second anti- 
idiotypic antibody response (anti-id2), against the mirror antigen. These anti-id2 antibodies can cross- 
react with antigen on a patient’s tumour and can act as an anti-idiotypic vaccine. Anti-id2 antibodies 
reacting with the antigens HMFG-2 and HMFG-1 have been used to treat patients with ovarian 
carcinoma by Courtenay-Luck et al., (1988) and they showed that patients with low volume, residual 
cancers were particularly sensitive to treatment by anti-id2 therapy.
1.11.5. Non-Specific-Effector Cell Activation.
Mellstedt (1990) has argued that non-specific activation of effector cells by mabs has a pleiotrophic
effect on cell regulation. Mab immunotherapy has been reported to stimulate apoptosis, or programmed 
cell death, of tumour cells (Trauth et a l., 1989). As more is learned about cytokines/lymphokines and 
apoptosis, the potential role of mabs in this process will become clearer.
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1.12. CONCLUSIONS.
In the 1970s, mabs were produced by Köhler and Milstein, and in the 1980s, chimaeric and humanised 
monoclonal antibodies became available. The 1990s is the era of immuno-genetics. Recombinant 
mabs, BFAs and fusion proteins are becoming readily available. Epitope mapping technology 
(Holsford et al., 1991) will help define better antibodies to more defined targets. The use of two-stage 
immunotherapy, and strategies to overcome HAMA and HAHA reactions will be investigated and may 
have major clinical implications. Above all, it is important to decide which types of tumours are 
suitable for immunotherapy and immunoscintigTaphy and to use the combined advances in immunology, 
genetics and nuclear medicine to find effective routine clinical uses for mabs.
The future of diagnostic and therapeutic monoclonal antibodies has been aptly summarised by Britton 
et al. (1991):
‘Provided the regulatory authorities do not do permanent damage to this approach to cancer therapy, 
the bullet may yet perform its magic’.
36
SECTION 2 MATERIALS AND METHODS
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2.1. MATERIALS
Reagents used in experimental work were of analytical grade and were obtained from Sigma 
Chemical Co., Poole, Dorset, England; BDH Chemicals Ltd., Poole, Dorset, England and 
Riedel de Häen, AG, Seelze, Hannover, Germany. Cell culture media, supplements, sera and 
disposable plastic-ware were supplied by Row Laboratories, Woodcock Hill, Harefield Road, 
Hertz, WD3 1PQ, U.K. Stains used for cytogenetic and histological analysis were obtained 
from BDH Chemicals Ltd., Poole, Dorset, England. A number of specific reagents, which vary 
from supplier to supplier are listed in Table 2.1.1.
Several experimental kits were also used for diagnostic and analytical purposes; these are 
summarised in Table 2.1.2.
The animal cell lines used are summarised in Table 2.1.3, while the antibodies used in 
immunocytochemistry, ELISA and FACS analysis are listed in Table 2.1.4.
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Table 2.1.1. Sources of Reagents
Reagent Source Address
BriClone Dr. Kenneth Carroll BioResearch Ireland,
Coumarin Kodak Eastman Rochester, 
New York, 
U.S.A.
Dimethylsulphoxide 
(Sure Seal)
Aldrich Chemical Co. Gillingham, 
Dorset, U.K.
Hoechst 33258 Calbiochem Behring Diagnostics, 
La Jolla, CA 92037, 
U.S.A.
Isoton II Coulter Electronics Northwell Drive, 
Luton, LU3 3RH, 
U.K.
Indium-Chloride Mallinckrodt 
Diagnostica DV
Petten,
Holland.
Polyethylene 
Glycol 1500
Boehringer Mannheim Hannover,
Germany.
Taab 812 Resin Taab Laboratory 
Equipment Ltd.
3 Minerva House, 
Aldermaston, 
Berks, RG7 4QN, 
U.K.
Technetium Mallinckrodt 
Diagnostics DV
Petten,
Holland.
Water for Injection 
Water for Irrigation 
(Sterile)
Boots Hospital Products Same Rd., 
Nottingham, 
NG2 3AA, 
U.K.
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Table 2.1.2. Summary of Diagnostic Kits Used
Name Source Address
American Medronate II Kit 
(MDP Bone Kit)
Amersham
International
Amersham,
Bucks.,
HP7 9NA, U.K.
Authentikit
(Isoenzyme Dialysis Kit)
Coming
Laboratories
Palo A1 to, 
CA 94306, 
U.S.A.
Bicinchonic Acid 
(BCA Protein Assay Kit)
Coomassie Protein Assay 
Reagent
Pierce
Chemical Co.
Rockford,
Illinois,
61105, U.S.A.
CoATest 
(Endotoxin Kit)
KabiVitrum Ltd. KabiVitrum House, 
Riverside Way, 
Middlesex,
UB8 2YF, U.K.
Vectastain 
(ABC Staining Kit)
Vector
Laboratories
30 Ingold Street, 
Burlingam,
CA 94010, 
U.S.A.
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Table 2.1.3. Animal Cell Cultures used In Vitro and In Vivo
Cell
Line Cell Type
Cat.
Number Supplier
J82
MCF-7
LOVO
A431
NRK
Human, Bladder Carcinoma 
Human, Breast Adenocarcinoma 
Human, Colon Adenocarcinoma 
Human, Epidermal Carcinoma 
Rat, Normal Kidney
HTB 1 
HTB 22 
CCL 229 
CRL 1555 
CRL 6509
ATCC,
12301 Park 
Lawn Drive, 
Rockville, 
Maryland, 
20861, USA.
RT112/84
EJ-138
NSO
RPMI-8226
Human, Bladder Carcinoma 
Human, Bladder Carcinoma 
Mouse, Balb/c Plasmacytoma 
Human, Myeloma
85061106 
8511412 
84112004 
CCL 155
ECACC,
PHLS,
Porton Down,
Salisbury,
Wiltshire,
SP4 0JG,
U.K.
T24 Human, Bladder Dr. J. Tager, 
University of 
Amsterdam, 
1105 AZ, 
Amsterdam, 
Netherlands.
LAT Mouse, Landschiltz ascites 
tumour cells
From DCU 
stocks.
41
Table 2.1.4. Monoclonal Antibodies used in
Immunocytochemistry, ELISA and FACS Analysis
Antigen Label Dilution Code Supplier
Mouse anti-CD-38 1/20 MCA 376 Serotec,
22 Bankside, 
Oxford, UK.
Mouse anti-EBV 1/20 ROE 176 Seralab,
Crawley Down, 
Sussex, RH104FF.
Sheep anti-human Ig K  light 
chain
Sheep anti-human Ig^ light 
chain
1/200 PC015 The Binding Site 
97 Vincent Dr., 
Edgbaston, 
Birmingham,
B15 25Q, UK.
Goat anti-mouse Ig HRP 1/500 083-67 ATAB,
PO Box 60, 
Scarborough,
MG 04074, USA.
Goat anti-mouse Ig M-8642 Sigma Chemical 
Co., Poole, 
Dorset, UK.
Mouse anti-human HLA-DR - - M704 Dakopatts,
Denmark.
Mouse anti-human IgG - - 5140 Becton Dickinson,
Mouse anti-human CD 19 FITC - M0524 2350 Quem Dr.,
Mouse anti-human CD25 - - 7640 San José,
Goat anti-mouse F(ab’)2 FITC 1/50 M0848 CA 95131-1812,
Goat anti-sheep F(ab’)2 FITC 1/50 P1604 USA.
Swine anti-goat F(ab’)2 FITC 1/50 P2170
Sheep anti-mouse IgG 
(F(ab’)i)
(3-gal. 1/1000 NA 8310 Amersham Int., 
Amersham Place, 
Little Chalfont, 
Bucks. UK.
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2.2. EQUIPMENT
A Nikon type 104 microsocpe was used for fluorescence and phase contrast microscopy. Cells 
in culture were examined using a Nikon type ELWD 0.3 inverted phase contrast microscope. 
Photographs were taken with Nikon F-301 and Nikon FX-35WA cameras. A Nikon HFX-IIA 
automatic exposure unit was used to calculate exposure.
Electron microscopy studies were performed using an Hitachi H-600 electron microscope.
A model DN coulter counter was supplied by Coulter Electronics and was used to enumerate 
cells in growth rate studies.
Slides of cells in suspension were prepared using a Shandon Programmable Cytospin Unit, 
with disposable inserts used for each slide prepared.
Fluorescence Activated Cell Sorting was undertaken using Becton Dickinson FacScan, using 
a Consort 10 Software System.
Electroporation of myeloma cell lines was carried out on a ProGenetor Pulse Controller from 
Hoefer Scientific Instruments, which was fitted with a Gene Pulse Cuvette Unit (Bio-Rad).
Ascites tumours, isolated from the peritoneum of Schofield mice, were dried using a High 
Temperature Vacuum Oven, Furkamp, D.V.
A Hereaus Christ Labofuge 600 and Labofuge GC were used to centrifuge universal tubes 
( 1 - 2 0  mis).
A Hereaus Biofuge A was used for smaller volumes (0.5 - 1.5 mis).
A Hetosicc CD-52 freeze drier was used to lyophilise both HPD and HMFG-l-Hp conjugates.
A LKB 2050 Midget Electrophoresis Unit was used in the preparation of SDS-PAGE gels.
Patients were imaged following immunoscintigraphy with a General Electrics GE 400 AC 
Gamma Camera. Low levels of gamma isotopes were detected using a Nuclear Enterprises 
NE Scalar-Ratemeter.
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An Applied Photophysics Xenon Arc Lamp and a Coherent Light Meter were used for 
irradiation in the photoradiation therapy studies reported.
44
2.3. TISSUE CULTURE METHODS
2.3.1. Routine Culture of Cells in Suspension
NSO, C23/11, RPMI-8226, HET-37, Sp2/0 and LAT cells were maintained in RPMI.SI0 
[RPMI-1640 medium (Flow) supplemented with L-glutamine (2mM) Hepes (ImM) and 10% 
(v/v) FCS]. Cultures were initiated at cell densities of 2 x 10s cells/ml using 12 ml of medium 
per 75 cm2 culture flask. Cells were harvested when -75% confluent by flushing them from 
culture surfaces using a sterile pasteur pipette. All animals cells in culture were incubated in 
a humid, 5% C 02 atmosphere at 37“C.
2.3.2. Routine Cell Culture of Adherent Cells
A431, LOVO, EJ-138 and T24 cells were maintained in DMEM-S10 (DMEM medium 
supplemented with L-glutamine (2mM), Hepes (ImM) and FCS 10% (v/v)). Media for the 
MCF-7 breast adenocarcinoma cell line was further supplemented with sodium pyruvate 
(ImM). The A431, LOVO and EJ-138 cell lines are strongly adherent and required 
trypsinization to release them during harvesting and subculturing procedures. All of the culture 
medium was decanted and 4 ml of trypsin:EDTA solution (Flow Laboratories; 0.25% (w/v) 
trypsin with 0.02% (w/v) EDTA in PBS) was added to the flasks. After 1 minute, a further 
3 - 4 ml of trypsin:EDTA solution was added and incubated at 37°C for 10 minutes. The cell 
suspension was decanted into 5 - 10 ml of complete culture medium to inactivate the trypsin 
and centrifuged at 1,200 rpm for 10 minutes in universal tubes. Cells were resuspended in 36 
ml of culture medium and divided into 3 x 75 cm2 sterile flasks. The MCF-7 cell line does 
not adhere to plastic as strongly as the above cell lines and, therefore, requires a more dilute 
trypsin solution (0.05 (w/v) trypsin; 0.02% (w/v) EDTA in PBS) to minimise surface antigen 
loses (Sasaki, et al., 1981).
2 J J . Cell Counts and Viability Staining
Cell counts were performed on an improved Neubauer Hemocytometer slide. Acridine 
orange/ethidium bromide and/or trypan blue were used routinely to determine cell viabilities 
(Mishell et al., 1980). The acridine orange/ethidium bromide stain solution contained 0.1 mg 
acridine orange and 0.1 mg ethidium bromide in 100 mis PBS. One volume of cells was 
added to an equal volume of stain and examined by UV fluorescence microscopy. Live cells 
stain green while dead cells stain orange. For trypan blue staining, one volume of cells was
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added lo an equal volume of slain (0.2% (w/v) [Sigma]), left for one minute and examined 
within five minutes by light microscopy. Longer incubation periods with stains leads to non­
specific uptake of dye and inacurate results. Live cells excluded the dye and remained white 
while dead cells stained blue.
2.3.4. Long Term Storage and Recovery of Animal Cells
Cryopreservation methods described by Reid and Cour (1985) and Price (1985) were used. 
Stocks of cells were maintained in liquid-nitrogen freezers. Washed cells were resuspended 
to the desired concentration (usually 1 x 107ml) in FCS supplemented with 5% (v/v) 
dimethylsulphoxide (DMSO; cryoprotectorant). One ml aliquots were placed in sterile 
cryotubes (Plow) and frozen at a rate of approximately -1°C per minute to -70°C on a freezing 
tray (Union Carbide) before being immersed in liquid nitrogen. Recovery of cells from liquid 
nitrogen was achieved by thawing the cells rapidly to 37°C and then washing them twice in 
medium, or PBS, as appropriate. Cells recovered from liquid nitrogen were approximately 
90% viabile, with the exception of C23/11 cells which retained approximately 80% overall 
viability.
23 .5 .  Mycoplasma Detection - Hoechst 33258 Fluorescence Assay
The DNA-intercalating agent bisbenzimid (Hoechst 33258) was employed to detect the 
presence of mycoplasma in cellular cytoplasm. The detection mechanism used was further 
described by Carroll el al. (1988). Cultures of mycoplasma-free NRK cells were established 
on glass coverslips using 5 x 103 cells in 1 ml of DMEM containing 6% (v/v) FCS and 
cultured overnight. Supernatant from cultures to be tested was then added to the NRK cells, 
which were reincubated for a further 3 to 4 days or until the cells were approximately 70% 
confluent. Duplicate NRK cultures were fed with fresh media and used as a negative control. 
Positive controls, previously prepared and stored at 4°C were included. The coverslips were 
then washed three times in PBS (taking care to keep the cells on the uppermost surface at all 
times) and fixed for six minutes in 1:1 methanol :acetone solution at -2CPC. The coverslip 
preparations were then rinsed three times in PBS and stained for 10 minutes in Hoechst 33258 
(0.05 pg/ml in PBS). The stain was washed from the cells and the coverslips air-dried and 
mounted on clean slides. Slides were stored in the daric until viewed under UV light on a 
Nikon fluorescence microscope at 100 X magnification with a B2 combination filter (Nikon). 
The membranes of contaminated NRK cells had areas of fluorescence DNA which could be 
associated with mycoplasma, while no such fluorescence was found in the negative and 
control slides.
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2.3.6. Cloning of Suspension Cells by Limited Dilution
Suspension cultures in exponential growth phase were cloned out by limiting dilution in 96 
well plates in order to ensure monoclonality of cells. Prior to cell cloning, % well plates were 
seeded with 100 pi of culture medium supplemented with 10% (v/v) FCS and 5% (v/v) 
BriClone. Cells were removed from culture flasks, 24 well plates or 6 well plates and adjusted 
to a concentration of 4 x 103 cells/ml. Using an octapipette (Costar), lOOpl of cell suspension 
(approximately 400 cells) was added to each of the 8 wells in Row A of the 96 well plate. 
The contents of each well of Row A were mixed thoroughly and 100 fjl transferred to each 
well of Row B (approximately 200 cells). This dilution procedure was continued across the 
microtitre plate until eventually a row of wells existed containing approximately one cell/well. 
The 96 well plates were incubated for 5-6 days and then examined microscopically for clone 
formation. Wells containing one clone per well were allowed to grow to confluence, 
expanded, and the cloning procedure was repeated to ensure monoclonality. Eventually, 
following sequential cloning by limited dilution the cells were expanded into 25 cm2 flasks and 
frozen in liquid nitrogen (Section 2.3.4.).
2.3.7. Determination of the Growth Rate of Cells Grown in Suspension
Cells were subcultured (Section 2.3.1.) the day prior to growth rate determination to ensure 
exponential growth. Four mis of RPMI-S10 was placed in each well of a 6 well plate to which 
1 ml of a 1 x 105 cell/ml suspension was added.
Following a 24 hour incubation period, the contents of duplicate wells were harvested, 
resuspended in 0.5 mis of tissue culture medium and added to 19.5 ml of Isoton II (Coulter 
Electronics). Cells were subsequently counted in a coulter counter (Model DN, Coulter Elec.). 
This procedure was repeated at 24 hour intervals, over a period of 5-7 days and the doubling 
time was determined. All determinations were carried out in duplicate.
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2.4. ESTABLISHMENT AND CHARACTERISATION OF C23/11 & HET-37
2.4.1. Primary Cell Culture of Myeloma Cell Lines.
White blood cells were isolated from human peripheral whole blood by differential 
centrifugation as described by Alley and MacDermott, (1980). Heparinized whole blood and 
bone marrow aspirates were collected from patients with myeloma. The heparinized blood was 
diluted 1:1 with PBS while the bone marrow aspirates were diluted in RPMI-1640 containing 
10% (v/v) FCS (RPMI-S10). Two parts of the cell rich sample were then layered over one part 
of Iymphoprep (Ficoll-Metrizoate; p = 1.077 g/ml) in a sterile universal tube and centrifuged 
at 1,000 rpm for 30 minutes at room temperature in a swinging bucket rotor (Heraeus Christ 
Labofuge 600). The blood cells separated into two distinct fractions: (a) red blood cells, which 
form a pellet; and (b) the white cells which form a "buffy layer" between the Iymphoprep and 
the plasma The while cells were carefully withdrawn using a sterile pasteur pipette, avoiding 
the unnecessary uptake of Ficoll-Metrizoate. Cells were washed three times in RPMI-S10 and 
subsequently resuspended in 6 mis of RPMI-S10. Cells were fed at three day intervals 
according to the method described in Section 2.1.1. with the exception that these cells were 
resuspended in 3 mis of fresh RPMI-1640 and 3 mis of supernatant from the previous passage. 
In this way, growth factors and metabolic intermediates were conserved in the medium. 
Primary myeloma samples were maintained for 6-8 weeks and were then discarded if cell 
growth was not observed.
2.4.2. Histological Staining of Myeloma Cells
Haematoxylin and Eosin (H/E) and Giemsa stains were used to examine the cellular and 
nuclear morphology of myeloma cells. Slides of C23/11, NSO and HET-37 cells in suspension 
were prepared using a Shandon Programmable Cytospin. Slides were then stored at -20°C and 
thawed for 30 minutes prior to staining. Cytospin preparations were fixed in 95% (v/v) alcohol 
for one minute and then washed thoroughly with tap water. When using the H/E stain, cell 
nuclei were stained blue with hematoxylin (0.15% (w/v); Gurr, BDH) for one minute, washed 
in tap water, and the cytoplasm was counterstained with eosin (0.1% (w/v) [in distilled water], 
BDH). The stained cells were subsequently dehydrated in 95% (v/v) alcohol followed by 
100% alcohol and finally cleared in xylene (BDH) before mounting in DPX (BDH). 
Alternatively, cells were stained with Giemsa (5% (v/v)), washed in tap water and then 
dehydrated and mounted as outlined above.
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2.4.3. Immunocytochemical Analysis of Myeloma Cells
Air-dried cytospin preparations of C23/11, NSO and HET 37 were prepared using a Shandon 
Programmable Cyiospin. Cells were tested for the presence of human kappa (k) and lambda 
(X) light chains using the avidin-biotin, ABC Vectastain Kit System (Vector Laboratories). All 
blocking sera, Avidin DH, biotinylated Horseradish peroxidase and the biotinylated goat anti­
mouse antibody were supplied in kit form. Slides were blocked with 100 pi diluted goat serum 
for 20 minutes and the excess was removed. Slides were then stained with primary antibody 
(anti-human kappa chain antibody or anti-human lambda chain antibody) for 30 minutes at 
room temperature and then washed for 10 minutes in PBS. Slides were then incubated with 
the biotinylated anti-mouse antibody (lOOpl) for 30 minutes, washed again in PBS and 
incubated with Avidin-DHO; biotinylated Horseradish peroxidase, (HRP solution) which 
contained excess avidin for 30 minutes. This allowed binding between the antibody containing 
biotin and the unreacted biotin sites on the avidin. Following a 10 minute wash period the 
bound HRP was visualised by a 5 minute incubation with substrate (1:1 solution of 0.02% 
H20 2 : 0.1% diaminobenzidine tetrahydrochloride (DAB) in 0.1 M Tris buffer, pH 7.2). The 
reaction was stopped by washing the slide in water and the cells were counterstained with 
0.3% (w/v) methyl green (BDH) for one minute. Cells were then washed in PBS, dehydrated 
in 95% and 100% alcohol, cleared in xylene and mounted in DPX.
2.4.4. Electron Microscopy of Cell Lines in Cell Culture
Pelleted cells (Section 2.3.1.) were preserved according to the method of McDowell and Trump 
(1976). Cells were then washed three times in 0.1 M phosphate buffer (pH 7.2) post-fixed in 
1 % (v/v) osmium tetroxide (BDH) for two hours and stained in 2% aqueous uranyl acetate for 
one hour. Dehydration was completed by serial incubations of 30 minutes in 50%, 70%, 95%, 
100% alcohol and 100% ethanol. The dehydration process was continued, by incubation in 
propylene oxide (BDH) for 20 minutes and propylene oxide/Taab 812 resin (50:50) for 60
minutes at room temperature. The cell pellet was then incubated in 100% resin for 24 hours
at 60°C. Ultra-thin sections were then examined with an Hitachi H-600 Electron microscope.
2.4.5. Isoenzyme Analysis of Cell Lines
The electrophoretic isoenzyme profiles of a cell line have been used to establish the species 
of origin of lines and have been used for comparison of inter and intraspecies variations which 
exist between different cell lines (Halton e t a l 1983). Isoenzyme analysis was carried out 
using an "Authentikit" (Coming) system; all buffers, agarose gels, substrates, stain and
49
electrophoresis apparatus were supplied in kit form. Cell lysates were prepared from cultures 
containing > 3 x 106 cells/ml in PBS. Samples of 1.2 mis of this suspension were centrifuged 
at 3,000 rpm for 5 minutes and the resulting pellet was resuspended in 300 pi PBS. Cells were 
further disrupted by three freeze-lhaw cycles of -20“C to room temperature, followed by 
centrifugation (Hereaus Labofuge) at 5,000 rpm for 5 minutes. The cell lysate was stored at 
-20°C. The lysate was separated by agarose gel electrophoresis. This was carried out by 
loading 1.0 pi of control lysate or sample lysate specimens into the appropriate pre-cut sample 
well. The loaded agarose film was placed in the cassette base with Universal barbital buffer 
(pH 8.6). Separation was achieved using 90 V for 35 minutes from a LKB power supply unit. 
The resulting isoenzyme profiles were stained using the appropriate substrate linked to a 
formazine dye and migration distances were calculated. The kit contains formazine dyes for 
the detection of seven different isoenzymes; purine Nucleoside Phosphorylase, (NP), Glucose - 
6-phosphate dehydrogenase (G-6-P), Malate dehydrogenase (MDH), Mannose phosphate 
isomerase (MPI), Peptidase B (PB), Aspartate aminotransferase (AST) and Lactate 
dehydrogenase (LDH).
2.4.6. Determination of Surface Antigens on Cell Lines using FACS Analysis
The presence of antigens on the surface of myeloma and heteromyeloma cell lines and the 
effect of conjugation procedures on the immunoreactivity of monoclonal antibodies was 
determined by fluorescence activated cell sorting. A 5 x 10* cell/ml suspension was prepared 
in PBS containing 1% (w/v) BSA and 0.1 %( w/v) sodium azide and placed at 4°C. Cell 
suspension (200 pi) was pipetted into each Falcon FACS analysis tube to which 5 pi undiluted 
antibody (or an appropriate volume of dilute antibody) was added Antibody binding took 
place over 10 minutes at 4°C to prevent internalisation of the antibody. The cells were then 
washed twice in cold PBS containing BSA and sodium azide (as above). While some of the 
antibodies used in FACS were pre-labelled with FITC (Table 2.1.4.) , other antibodies 
required a second FITC-linked antibody to visualise the non-FTTC labelled primary antibody. 
Fluorescein-conjugated F(ab’)2 fragment of rabbit immunoglobulin was pipetted into sample 
and control tubes, incubated at 4°C for 30 minutes, washed twice, resuspended in 500 pi of 
filtered 1% (v/v) paraformaldehyde and stored at 4°C for up to seven days. Analysis was 
performed using a Becton Dickenson FACScan, with Consort 10 software.
2.4.7. Generation of G-418 Resistant Cell Lines
A subclone of the myeloma cell line which was resistant to the antibiotic geneticin (G-418), 
was generated by insertion of the pSV2 neo plasmid containing the gene for G-418 resistance
50
into the cell line by electroporation. C23/11 cells were electroporated using a variation on the 
protocol outlined by Winterboume et al. (1988). C23/11 cells (100 pi) at a concentration of
1 x 106 cells/ml were placed in a gene pulser cuvette (Bio-Rad) to which 200 pi of ImM Tris, 
O.lmM EDTA, pH 8.0, was added. Plasmid DNA, pSV2 neo was (20 pg/ml) was added and 
the suspension was incubated at 4 ^  for 10 minutes. Electroporation was achieved using a 
capacitance of 25 pFD and a constant voltage (0.75 V) in a ProGenetor pulse controller 
(Hoefer Scientific Instruments). Cells which had successfully acquired the G-418 resistance 
gene were selected by their ability to grow in medium supplemented wiih 200 - 1000 pg/ml 
geneticin (Sigma). Continued resistance to G-418 was maintained by the subsequent culturing 
in selective media containing 200 pg/ml geneticin.
2.4.8. Heteromyeloma Cell Production by PEG Mediated Cell Fusion
NSO and C23/11 cells were maintained in mid-log phase of growth by frequent subculturing 
for seven days prior to fusion. The NSO cell line was pre-tested for HAT sensitivity by 
proving their inability to grow in RPMI-S10 containing HAT (100 pM hypoxanthane, lpM 
aminopterin and 60 pM thymidine). Similarly, C23/11 cells were pretested for their inability 
to grow in RPMI-S10 containing 1 x 10 5M ouabain. Both NSO and C23/11 were tested for 
the presence of mycoplasma (Section 2.3.5.). Before fusion C23/11 cells were pretreated with 
neuraminidase (Sigma) at a concentration of 1 unit/ml in RPMI-S10 for 45 minutes at 37°C and 
washed three times in RPM1 before use (Igarashi and Bando, 1990). The pretreated C23/11 
cells were combined with the harvested NSO cells in sterile universal containers. This cell 
mixture was then washed twice in RPMI medium without FCS. Cells were centrifuged at 
4,000 rpm for 10 minutes and the supernatant was fully decanted. The cells were fused in 
PEG-1500 (Boehringer Mannheim). One ml of the PEG solution was added to the pelleted 
cells over one minute with gentle mixing. This suspension was left for a further minute while 
the container was rotated with a continual gentle swirling motion. The PEG was then slowly 
diluted by the dropwise addition of 3 mis of RPMI (serum-free) over three minutes, followed 
by 8 mis of medium over a further 10 minutes. The cells were pelleted and finally 
resuspended at a concentration of 2 x 10s cells/ml o f RPMI-S10 supplemented with 5% (v/v) 
BriClone. One ml of this suspension was added to each well of a 24 well plate and incubated 
at 37°C in 5% C 02. After 24 hours, one ml of RPMI-S10 (supplemented with 5% BriClone,
2 x HAT (Flow) and 2 x lO^M ouabain) was added to each well. Cells were then left 
undisturbed for seven days and subsequently fed in RPMI-S10 containing HAT and 1 x 10'3M 
ouabain. Clones developed after 3-4 weeks. The HAT medium was replaced by HT medium 
after 4 weeks. After 6 weeks the cells were cultured and expanded in RPMI-S10 without HAT, 
HT or ouabain.
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2.4.9. Chromosome Analysis Studies
Several methods have been investigated to differentiate between human and mouse 
chromosomes (Schroder, 1985). G -ll banding and Hoechst 33258 procedures were used. 
The Hoechst 33258 procedure gave the most reproducible stains and an adaption of the 
procedure developed by Kozak et al, (1977) was used. On the day prior to chromosome 
spreading cells were subcultured with 8-10 mis of fresh medium in order to promote maximum 
growth. Metaphase was induced by the addition of 0.5 ml of colcemid (0.1 pg/ml) overnight 
at 37°C. Following cell harvesting and centrifugation, cells were incubated for 15 minutes in 
a hypotonic solution of 0.075 M KCL at 37°C. The enlarged cells were fixed by the gentle 
addition of fresh fixative (methanol glacial: acetic acid, 3:1, at 4°C) for incubation periods of 
one hour, 5 minutes and one minute. The final pelleted cells were prepared for light 
microscopy by staining in 5% (v/v) Giemsa (BDH) or Hoechst 33258 staining. The fluorescent 
intensity of the chromosomes was assessed by staining spreads in a freshly prepared solution 
of 0.04 pg/ml of Hoechst 33258 stain in saline for 10 minutes. Following rinsing in distilled 
water and mounting in glycerol, slides were examined using a Nikon Type 104 fluorescence 
microscope with a UV combination filter system.
2.4.10. In Vivo Growth of Tumour in Nude Mice
In vivo growth of C23/11 myeloma cell line was investigated using the MFl-nu/nu/old/Hsd 
mouse strain. 10 week old female mice were maintained under ‘near sterile’ conditions in an 
Bio-Breed isolator unit. All food, water and bedding were sterilized at 121°C for 15 minutes 
prior to use. Tumours were established in vivo following injection of 1 x 107 cells in 0.5 mis 
PBS. Animals were injected in either the interclavical or intraperitoneal regions. Animals were 
checked daily and maintained for 8 weeks or until the appearance of tumours. Tumours were 
removed aseptically and re-established in culture (Section 2.3.1.). Samples of these tumours 
were frozen and further samples embedded in parafin for H/E staining (Section 2.4.2).
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2.5. 1MMUNOSCINTIGRAPHY
2.5.1. Antibodies Used in Immunoscintigraphy
Three therapeutic grade monoclonal antibodies were kindly donated by Unipath Ltd., Bedford, 
U.K. The HMFG-1 antibody was first described by Taylor-Papadimitriu el al, (1981). 
HMFG-1 is an IgG! immunoglobulin and it reacts primarily with human milk fat globulin-1. 
F(ab’)2 fragments of HMFG-1 were also used in this study. The second antibody used was 
termed AUA-1, a murine IgG antibody which was first described by Arklie el al. (1980). The 
third antibody, H17E2, a mouse IgGl against the placental alkaline phosphatase (PLAP) 
antigen which was first reported by McDicken et al. (1983).
2.5.2. Sterile, Pyrogen and Metal Free Treatment of IgG & F(ab’)2 Fragments
The use of deionised water (injection grade, Boots), sterile and depyrogenated plastics and the 
depyrogenation of tubing, magnetic stirrers and gel filtration apparatus was essential, as these 
materials were for human use. Tubing and magnetic stirring bars were rendered metal-free by 
soaking overnight in 0.1 N nitric acid followed by extensive washing with water (injection 
grade) under sterile conditions. Ultrafiltration devices were kindly sterilised by gamma 
irradiation by Baxter (Castlebar) Ltd. The use of deionised water and the absence of metal 
or glass materials was necessary as DTPA will chelate any metal in the water prior to labelling 
with the appropriate metal radionuclide, thus resulting in poor specific labelling efficiency.
2.5.3. Conjugation of DTPA to IgG and F(ab’)j Fragments
A bifunctional chelator, diethyl triaminepentacetic acid (DTPA), was attached to IgG and used 
to chelate free Indium-III to the DTPA-IgG conjugate ( Hnaiowich el al., 1983). Antibody was 
dialysed against HEPES buffer (0.05 M, pH 8.0) in the presence of free DTPA (approximately 
100 pg). Dialysis tubing was boiled in 100 mM EDTA and rinsed in sterile water for 
injection. Sterilised dialysis clips and magnetic stirrers were used (Section 2.5.2.). Following 
dialysis, the antibody was concentrated to > 10 mg/ml by centrifugal ultrafiltration (Centrifugal 
Ultrafree, Millipore). DTPA was dissolved in anhydrous dimethyl sulphoxide, DMSO 
(Aldrich) at a concentration of 10 mg/ml, immediately prior to use. Sufficient DTPA was 
added to the antibody to give a molar ratio of 3.5:1, DTPA : IgGl or 1.5:1, DTPA : Fiab’^. 
The DTPA was added slowly to the antibody, mixed for 30 seconds and left at room 
temperature for 15 minutes. A 100 pi sample was removed [i.e. in order to find the number
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of DTPA molecules which were bound to each mab (Section 2.3.5.)]- Separation of the 
DTPA-mab from free DTPA was achieved by gel filtration column (PD-10 column containing 
Sephadex G-25, Pharmacia) with 0.1 M sodium acetate (anhydrous) buffer, pH 5.5, under 
gravity filtration. 1 ml fractions were collected using an LKB Redirac 2112 Fraction Collector. 
Protein determination was carried out (Section 2.5.6.) and aliquots of 1-2 mg of antibody 
conjugate were filter sterilised with a 0.22 pm filter and stored at 4°C.
2.5.4. Reduction of F(ab’)2 Fragments for Technetium-99M Labelling
Antibody F(ab’)2 fragment was labelled with technetium ("MTc) following the reduction of 
intrinsic disulphide bonds with the reductant 2-mercaptoethanol (2-ME). The reduced F(ab’)2 
was labelled with 99MTc in the presence of methylene diphosphonate (MDP), a weak 
competing ligand, as described in detail by Mather and Ellison (1990). One ml of F(ab’)2 
fragment (Section 2.3.1.) was concentrated by ultrafiltration to approximately 10 mg/ml in 
0.9% sodium chloride for injection (Baxter). The F(ab’)2 fragment was reduced by reaction 
with a molar excess of 2-mercaptoethanol to F(ab’)2 of 1000:1 at room temperature for 30 
minutes. It was then purified by gel filtration (PD-10 column, Pharmacia) using saline as the 
eluent. F(ab’)2 was recovered in the void volume and was stored under sterile and pyrogen- 
free conditions. The radioactive labelling procedure was undertaken on the day of 
administration to the patient and will be described in Section 2.5.14.
2.5.5. Determination of the Labelling Efficiency of DTPA Coupled Monoclonal 
Antibodies Using Indium-III and Technetium-99m.
A thin layer chromatographic (TLC) technique was used to determine the number of DTPA 
molecules bound to each monoclonal antibody as a percentage of the total number of DTPA 
molecules initially added. This percentage is termed the labelling efficiency of DTPA per 
antibody. Using the sample of DTPA-IgG and free DTPA described in Section 2.3.3., 10 pi 
of sample was added to Indium-III which had been previously reacted with 5M sodium acetate, 
pH 5.0 (detailed in Section 2.5.15.). This was mixed thoroughly and left at room temperature 
for 15 minutes. Strips of TLC - DC cards (10 cm Riedel-de-Háen) were cut. A spot of water 
soluble ink was placed 0.5 cm from the bottom of the card to mark both the solvent front and 
the application line. Using a micropipette, 1 pi of the IgG bound and free DTPA mixtures 
were spotted onto the centre of the application line on the pre-marked card. All used 
radioactive materials were disposed of into a suitable waste container. An equal volume of 
free In-m was also spotted on the card as a control marker. The TLC solvent consisted of 
lOmM EDTA and 0.1M sodium acetate, pH 5.5, (1:1). The developed TLC plate was imaged
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using a GE 400 AC Gamma Camera. The level of radioactivity recorded at the base and top 
of the card represent gamma emitter bound to DTPA-Ig and free DTPA, respectively, from 
which the labelling efficiency can be calculated. This procedure was also used to determine 
the gamma emitter labelling efficiency of F(ab’)2 -DTPA - In"1 and F(ab’)2 - 99MTc binding.
2.5.6. Protein Concentration Determination
Two methods were used to determine the concentration of protein in a sample: a miniaturized 
Bradford Assay (Bradford, 1976) and a miniaturized Bicinchoninic Acid (BCA) Protein Assay 
(Smith et al., 1985). The reagents for both assay systems were obtained in kit form from 
Pierce Chemical Co.
(a) Bradford Coom assie Protein Reagent K it Procedure
A miniaturized version of the assay kit was developed in order to minimise the amount of 
sample required. The assay had the advantage of providing a rapid indication of the protein 
level. However, many of the samples to be analysed contained the bifunctional chelator, 
DTPA, which interferes with the accuracy of the assay by complexing in the acid environment. 
Aliquots of 10 pi of diluted standard (0.01 - 0.1 mg BSA) or unknown protein samples were 
pipetted into a 96 well plate (Flow) to which 200 pi of Pierce Protein Assay Reagent was 
added. The plate was mixed and the absorbance read immediately at 595 nm ona Tilertek 
Twin Reader Plus (Flow).
(b) BCA Protein Assay Reagent Kit Procedure
In this assay Cu^ combines with protein under alkaline conditions to form Cu* which reacts 
with BCA to give a coloured product. Two separate reagents are supplied: Reagent A, an 
alkaline bicarbonate buffer and Reagent B, 4%  (w/v) copper sulphate solution. The BCA 
protein assay working reagent was made up by mixing 50 parts of Reagent A with 1 part of 
Reagent B, and was stable for one week at room temperature. Two different miniaturized 
protocols were followed. One used incubation at 37°C for 30 minutes for expected protein 
concentrations of 0.02 - 1.5 mgAnl. The second method used incubation at 60°C for 30 
minutes for expected protein concentrations in the range of 0.001 - 0.25 mg/ml. In both cases, 
a standard BSA stock solution of 2 mg/ml was prepared to give a range of suitable standards 
on dilution with PBS. Then 10 pi of each standard or unknown protein sample was pipetted 
into a well of a 96 well plate and 200 pi of BCA working reagent was added to each well. 
For control wells, 10 pi of diluent was used. The tubes were incubated at the selected 
temperature and time and absorbance readings taken at 562 nm ona Titertek TwinPlus Reader. 
All samples and standards were prepared in duplicate. The BCA gave more accurate protein
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readings than the Bradford Assay, as less interference was obtained from detergents and 
chelating agents. However, the assay system required incubation at pre-set temperatures and 
results were not as rapid as the Micro-Bradford Assay.
2.5.7. Immunoreactivity Testing of Radiolabelled IgG and F(ab’)2
Fragments Using the Lindmo Cell Binding Assay
Lindmo et al. (1984) described a method of assessing antibody reactivity following 
radiolabelling based on the amount of radioactivity bound to cells expressing the relevant 
antigen. A constant amount of radiolabelled antibody is incubated with serial doubling 
dilutions of antigen. The amount of radiolabelled antibody is chosen such that the antigen is 
always in excess, even at low dilution. MCF-7 cells were used to test the immunoreactivity 
of both intact HMFG-1 antibody and its F(ab’)2 fragment. A431 and LOVO cells were used 
to test AUA-1 and H17E2. Dilutions of unlabelled antibody (250 yg/ml) and labelled antibody 
(30 - 50 ng/ml) were prepared in PBS containing 1% BSA (w/v). All procedures were carried 
out behind lead-perspex shielding and all waste was placed in a radioactive disposal unit. 
Cells were prepared at a concentration of 1 - 5 x 106 cells in 1% BSA (w/v) in PBS. 
Duplicate dilutions of neat, 1/2, 1/4, 1/8, 1/16 and 1/32 were prepared in 1% BSA (w/v) in 
PBS. Two extra vials of the neat cell suspension were also prepared as non-specific binding 
controls, to which 50 pi of unlabelled antibody was added and incubated for 30 minutes at4°C. 
Following the incubation of the unlabelled control antibody, 250 pi of radiolabelled antibody 
was added to both the test and non-treated control tubes, placed at 4°C, mixed and incubated 
for 4 to 6 hours. Cells were subsequendy centrifuged in a Biofuge A (Hereaus) for 5 minutes 
at 3,000 rpm, washed three times in PBS containing 1% BSA(w/v), and finally resuspended 
in 500 pi of PBS containing 1% BSA (w/v). The gamma ray emission at each cell dilution 
was counted by a NE Scalar-Ratemeter SR5. This procedure was adapted for use with 
technetium labelled F(ab’)2 fragments.
2.5.8. Immunofluorescence Analysis of Antibody Conjugates
Pleural effusion and ascites fluid specimens were obtained from patients with ovarian 
carcinoma. Tumour samples were collected into 0.9% (w/v) sodium chloride and stored at 
4°C. Cells were isolated from the suspension by centrifugation at 1,200 rpm for 10 minutes. 
These cells were then washed three times in PBS containing 0.02% (w/v) sodium azide. A 
portion of the tumour specimen was frozen according to the method outlined in Section 2.3.4. 
Approximately 4 x  106 cells were added in duplicate to ependorph tubes. Samples of ovarian 
tissue which had been previously shown either to express or not to express the antigen, were
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included as positive and negative controls. 100 pi of antibody (0.25 mg/ml) was added to each 
tube and incubated at room temperature with gentle shaking. The same antibody was used for 
both immunofluorescence analysis and immunoscintigraphy of the tumour. The cells were then 
washed twice and incubated for 10 minutes with 100 pi fluorescein isothiocyanate (FITC) 
conjugated anti-mouse antibody (1/300 dilution, Dakopatts). Labelled cells were washed twice 
and resuspended in 90% glycerol. Cells were counted on a Neubauer haemocytometer and 
fluorescent cells were viewed on a Nikon Type 104 fluorescence microscope with B2 
combination filter.
2.5.9. Enzyme-Linked Immunosorbent Assay, ELISA
ELISA was used to determine whether or not the conjugation procedures used on antibodies 
had altered their ability to bind to target tumour cells in culture. MCF-7, A431 and LOVO 
cells were used to test the HMGF-1, AUA-1 and H17E2 antibodies, respectively. Cells were 
prepared in medium and 5 x 103 cells were dispensed into 96 well plates. Cells were then 
grown to approximately 75% confluency under aseptic conditions. The medium was then 
removed and the wells were washed with PBS containing 0.1% (v/v) Tween-20 (wash 
solution). Non-specific binding sites were blocked with 1% (w/v) BSA in PBS (100 pl/well) 
for one hour at 37°C. The plates were then washed and 50 pi of P-galactosidase-linked sheep 
anti-mouse Ig, F(ab’)2 fragment (Amersham) was added and incubated at 37°C for one hour. 
After a thorough washing to remove unbound conjugate, 100 pi of substrate (ONPG; o- 
nitrophenyl-3-galactopyranoside) was added to each well. When sufficient colour had 
developed, the reaction was stopped by the addition of 50 pi of 1 M sodium carbonate; this 
step also enhances the colour in positive wells. The absorbance was recorded at 405 nm on 
a Titertek TwinPlus Microplate Reader (Flow).
2.5.10. SDS-Polyacrylamide Gel Electrophoresis
Conjugated and unconjugated monoclonal antibodies and their fragments were subjected to 
sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) using modifications 
on the method of Laemmli (1970). Proteins were separated on a resolving gel containing 7.5% 
(w/v) acrylamide, 0.33% (w/v) bis-acrylamide, 0.75 M Tris, 0.2% (w/v) SDS, 0.1% (v/v) 
TEMED and 0.1% (w/v) ammonium persulphate, pH 8.8. A stacking gel containing 3.5% 
(w/v) acrylamide 0.08% /(w/v) fresh ammonium persulphate, pH 6.8, was used. The electrode 
buffer contained 0.025 M Tris, 0.192 M glycine and 0.1% (w/v) SDS in distilled water, pH
6.8. Samples for electrophoresis were resuspended in a buffer containing 0.062 M Tris, 2.0% 
(w/v) SDS, 10% (v/v) glycerol and 0.001% (w/v) bromophenol blue. 2-mercaptoethanol (0.5%
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(v/v)) was included in the sample buffer only when reducing conditions were required. The 
samples were prepared at a concentration of 0.1 mg/ml in the loading buffer and boiled for 3 
minutes at 100°C before being applied to the gel (5 - 10 pi volumes were used). 
Electrophoresis was carried out al a constant current of 40 mA for about 30 minutes at 4“C 
using an LKB 2050 Midget Electrophoresis UniL Following electrophoresis, the gels were 
fixed by immersion in a methanol:distilled water (1:2) solution containing 11.4% (w/v) 
trichloroacetic acid and 3.4% (w/v) sulphosalicylic acid, for one hour. They were then stained 
with 0.25% (w/v) Coomassie Brilliant blue R-250 in a 5:1:1 solution of methanol, acetic acid 
and distilled water for one hour. De-staining was carried out overnight in a solution of 
ethanol, acetic acid and distilled water (1:3:6).
2.5.11. Sterility Testing of Immunoconjugates
The presence of bacterial contamination was monitored by the use of microbial tests outlined 
in the US Pharmacopoeia (reviewed by Brown, 1990). Test tubes containing lOmls of either 
fluid thioglycollate medium (TG:Oxoid) or Soyabean-Casein-Digest Medium (SCD:Oxoid) 
were inoculated in duplicate with 1 ml of test antibody which had been previously diluted in 
sterile water for injection. The tubes were incubated for 30 days at 30 - 35°C for TG medium 
and 20 - 25°C for those samples in SCD medium under aerobic conditions. Turbidity after 30 
days indicated the presence of microbial contamination and the exclusion of the antibody from 
clinical use.
2.5.12. Quantitative Endotoxin Testing Using a Limulus Amoebocyte Lysate 
(LAL) Assay System
The CoAtest/Endotoxin kit (KabiVitrum) was used to detect the presence of bacterial pyrogens 
from gram negative bacteria. These pyrogens may lead to inflammatory and febrile reactions 
in patients after the conjugates are administered. This test must be carried out under sterile 
and pyrogen-free conditions. Glassware and aluminium foil were rendered pyrogen free by 
heating at 180“C for 4 hours. It is important to adhere exactly to the incubation times and 
temperatures in the assay in order to obtain an accurate result Endotoxin standards containing 
between 1.0 - 12.5 pg/ml were prepared in sterile water for injection (Boots). Freeze-dried 
limulus amoebocyte lysate (LAL) was carefully reconstituted and incubated at room 
temperature for 15 minutes in order to rehydrate the enzymes present in the lysate and then 
placed in an ice bath. Standards and test samples (50 pi) were placed in a 96 well plate at 
25°C for 3 - 5 minutes. LAL solution (50 pi) at 37°C was added to each well and the plate 
was incubated for exactly ten minutes. The substrate which converts the activated LAL into
58
a colourimetric product was added (100 pi) and the reaction was slopped after three minutes 
by the addition of 4% (v/v) acetic acid and the absorbance at 405 nm was obtained using 
TwinPlus Plate Reader (Flow). The degTee of colour produced was directly proportional to
the concentration of endotoxin present in the sample.
2.5.13. Labelling of DTPA Conjugated IgG and Indium-III
Sterile pyrogen free DTPA labelled monoclonal antibody (Section 2.3.3.) was brought to room 
temperature and added to Indium chloride (In-III) (Mallinckrodl Diagnostics). mInCl3 had been 
activated by the addition of 5 pi 5M sodium actetate pH 5.0 per 1.0 ml inInCl3 at room
temperature for 15 minutes. The IgG-DTPA-mIn solution was mixed and left at room
temperature for 30 minutes before separation on a 10 ml sterile Sephadex G-25 gel filtration 
column (PD-10, Pharmacia). IgG-DTPA-In-III fractions were eluted in 0.9% sodium chloride 
containing 1% human serum albumen (HSA:Albumar). 1 ml fractions were collected and their 
radioactive counts determined. Radiolabelled antibody fractions were combined, filter sterilized 
through a 0.22 pM filter (Flow) and diluted to 50 mis in 0.9% sodium chloride, which 
contained 1% HSA for subsequent administration. Thin layer chromatography was used to 
confirm antibody binding (Section 2.3.5.).
2.5.14. Labelling of Reduced F(ab’)2 Fragments with Technetium
On the day of administration, one vial (1 mg) of 2-mercaptoethanol- reduced F(ab’): fragments 
was thawed to room temperature (Section 2.3.4.). The fragment was labelled with 
99Mtechnetium ("MTc) using a methylene diphosphate (MDP) bone scintigraphy kit, [Amerscan 
Medronate II (Amersham)]. The MDP vial was reconstituted with 0.9% saline(w/v) for 
injection. MDP solution (50 pi) was added to the antibody, mixed and to this solution 
approximately 700 MBq of [59MTc] - pertechnetate was added. The conjugation between 
F(ab’)2 - 99MTc was allowed to proceed for 10 minutes before the solution was filtered through 
a 0.22 pM filter and subsequently diluted to 50 mis in 0.9% sodium chloride with 1% human 
serum albumen. The amount of 99MTc bound to antibody was assessed by thin layer 
chromatography, as outlined in Method 2.5.5.
2.5.15. Clinical Administration and Imaging of Immunoconjugate
Patients were premedicated with hydrocortisone (100 mg iv) by a physician, before iv infusion 
of immunoconjugate over 30 - 60 minutes in 100 mis of 0.9% sodium chloride(w/v) containing 
1% human serum albumen (w/v). Planar images were obtained after one hour on the day of
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administration of DTPA-mIn immunoconjugates (Day 0). Subsequent images were obtained 
from these patients on Day 1, Day 3 and Day 6. Tomographic images were obtained on Day 
3 and Day 6, where required. Planar images were recorded after 1 hour, 6 hours and 24 hours 
for patients who had received techetium-labelled F(ab’)2 ("MTe-F(ab’)j) fragments. Images 
were recorded by the attendant physicist using a General Electric Gamma Type 400 AC 
Camera.
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2.6. METHODS USED IN PHOTODYNAMIC THERAPY
All procedures involving photoactive compounds were carried out in conditions of minimal 
natural light in order to minimise the non-specific activation of these photoactive components.
2.6.1. Preparation of Hematoporphyrin Derivative
Hematoporphyrin Derivative (HpD) was derivatized from hematoporphyrin dichloride according 
to the protocol described by Bonnet (1981) under conditions of minimal natural light. Hp (345 
mg) was slowly added to 15 mis of 5% (v/v) sulphuric acid in acetic acid at room temperature. 
HpD was then precipitated following the addition of 3% (v/v) sodium acetate trihydrate (19 
volumes). The resulting precipitate was collected by centrifugation and washed twice in 
distilled water. The liquid was redissolved in a minimum volume of distilled water and freeze- 
dried using a Heotosicc CD-52 freeze drier (Heto). The HpD was frozen at -20°C and 
protected from light.
2.6.2. Preparation of Hp-Monoclonal Antibody Conjugates
Hematoporphyrin dichloride (Sigma) was conjugated to the monoclonal antibody HMFG-1 
(Section 2.3.1.) according to the method outlined by Mew et ai., (1983). All procedures were 
carried out in darkened conditions. Hp (20 mg) in 1.2 ml of distilled water and 0.8 ml of 
N'jN",-dimethyIformamide (DMF) was added to 20 ml of l-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide-HCL (EDC) in 0.6 ml of H20 . The mixture was then mixed with 15 mg HMFG- 
1 to give a molar ratio of 3.5:1 (EDC : Hp) and 300:1 (Hp : HMFG-1). The pH was 
maintained between pH 6 and 7. Ethanolamine (50 pi) was added to stop the reaction. The 
mixture was then dialysed extensively against PBS at 4°C in order to remove unconjugated Hp. 
The antibody-Hp conjugate was then lyophilised using a Hetosicc CD-52 freeze drier and 
stored at -20°C. The Hp content of conjugate was determined spectrophotometrically from a 
standard curve (2 - 10 pg/ml) which had been measured at an absorbance of 383 nm. The 
protein content of the conjugate was assessed by the BCA assay outlined in Section 2.3.6.
2.6.3. Preparation of Stock Hematoporphyrin and Coumarin Compounds
A stock solution of 5 mM coumarin was dissolved in 1 ml of ethanol and diluted with 99 ml 
PBS. This 5 mM solution was filtered through a 0.2 pM filter prior to use. A 5 mM stock 
solution of 7-hydroxycoumarin was prepared in PBS and autoclaved at 2.7 bar for 30 minutes.
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Slock hemaioporphyrin (0.1 mg/ml) was prepared in 1 ml of ethanol to which 99 ml of PBS 
was added. HMFG-l-Hp conjugate (1 mg/ml) was prepared in DMEM and filter sterilised by 
filtration through a 0.22 pM filter.
2.6.4. In vitro Assay to Assess the Toxicity and Phototoxicity of Coumarin 
and Hematoporpbyrin Compounds
Landschiitz acites tumour cells (LAT cells) were grown overnight in RPMI-1640 containing 
10% FCS to a density of 1 x 106 cells/ml at 37°C. Drug solutions of Hp and HpD (0.01 - 0.1 
mg/ml), acridine orange (0.05 - 1.0 mg/ml), coumarin, 7-hydroxycoumarin and AMCA (0.1 
mM - 1.0 mM) were prepared from stock concentrates (Section 2.6.4.) in RPMI medium. 
Cells were incubated for one hour and irradiated with 200 mW of broadband light from a 
Xenon Arc Lamp (Applied Pholophysics) for 20 minutes. UV wavelengths were minimised 
by the polypropylene lid on the tissue culture plates. Cells were then incubated for 18 hours 
at 37°C in 5% C 02 and the final cell viability was assessed by ethidium bromide/acridine 
orange and/or trypan blue dye exclusion (Section 2.3.3.). Controls containing PBS, PBS 
containing ethanol (1% v/v) and RPMI were also included. All control experiments and test 
experiments were also carried out without irradiation, to monitor any non-specific irradiation 
effects generated in vitro.
2.6.5. Effect of HMFG-l-Hp as an Immunophotosensitiser
The HMFG-1 monoclonal antibody binds strongly to the human milk fat globule antigen which 
is expressed on the surface of the MCF-7-human breast adenocarcinoma cell line but it does 
not bind to the EJ-138 human bladder carcinoma cell line. Therefore, MCF-7 was used to 
determine if the HMFG-lHp conjugate specifically caused cell death while EJ-138 cells were 
used as controls to monitor non-specific effects. MCF-7 cells (or EJ-138 cells) were added 
to 6 well plates at a density of 1 x 10s cells/ml and incubated overnight. Concentrations of 
HMFG-l-Hp conjugate (0.02 - 1.0 mg/ml), Hp (0.01 - 0.025 mg/ml), HMFG-1 (1.0 mg/ml) 
and combined free Hp and free HMFG-1 (0.01 and 1.0 mg/ml, respectively) were prepared in 
DMEM containing 10% (v/v) FCS and added to the cells for a 30 minute incubation period 
at 37°C and then removed. Cells were washed twice in medium. Cultures were then irradiated 
for 20 minutes with 200 mW of broadband light and were incubated for 36 hours to allow cells 
to divide. Two further control assays were undertaken. In the first control experiment, the test 
samples and control samples were not removed prior to irradiation. This determined if Hp 
conjugated to HMFG-1 behaved in the same manner as unconjugated Hp. It was also 
necessary to investigate whether the HMFG-l-Hp conjugate bound non-specifically to the EJ-
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138 cell line. A second control experiment, in which the cells were not irradiated was also 
undertaken. All experiments were carried out in duplicate.
2.6.6. Assessment of Cell Viability by Cell Transplantability in Schofield Mice
The ability of Landschutz ascites tumour cells to grow in the intraperitoneal cavity of Schofield 
mice has been used to assess and confirm their viability (Smyth, el al„ 1977). An inoculum 
of treated cells (1 x 10s cell/ml) was prepared in PBS, and injected i.p. into Schofield mice. 
The resultant tumour was harvested after 12 days and dry weights of the tumour were 
recorded.
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SECTION 3 : M Y E L O M A -DERIVED CELL LINES
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3.1. HUMAN MONOCLONAL ANTIBODIES : IMMUNISATION STRATEGIES.
Normal human B-cells can be immunised in vivo and in vitro to express antibodies which react with 
specific antigens or immunogens. These B-cells do not grow indefinitely in vitro and techniques such 
as viral transformation, recombinant antibody technology and fusion to myeloma or lymphoblastoid 
cells, have been developed to immortalise these cells. Once immortalised and cloned to grow from a 
single B-cell, these cells can secrete human monoclonal antibodies (hmabs) (reviewed in more detail 
in Section 1.3).
In 1967, Moore and his colleagues reported that normal or somatic human lymphocytes could be grown 
in culture when transformed by the Epstein-Barr virus, EBV. This technique was used by Steinitz et 
al. (1979) to make hmabs which reacted with a group A streptococcal carbohydrate antigen. B-cells 
are transformed by EBV in the supernatant of B95-8 marmoset leukaemia cells, or, alternatively by 
active EBV present in a patient’s blood (Lewin et al., 1990). However, the hazards of using a 
transforming virus, the difficulties in producing EBV transformed cells which are stable in vitro and 
the unwillingness of regulatory authorities to licence products of viral origin, have led to the 
development of other immortalisation strategies.
Human antibody fragments have been produced in myeloma cells, yeast, bacteria and plants using 
genetic engineering techniques. The methods used to produce these recombinant hmabs and the impact 
of this technology are discussed in more detail in Section 1.4.
Functional recombinant human mabs are not yet available for clinical use, while the more conventional 
human hybridoma technology has been used by many researchers. Recombinant human mab technology 
is a rapidly developing area of research (Winter and Milstein, 1991). Mab technology has been 
revolutionised by the ability to produce a library of hmab fragments which can then be expressed in E. 
cob. However, the ability to produce such fragments for use in vivo has neither been licenced nor 
commercialised to date.
Most of the human hybridomas produced to date have been immortalised by fusion with myeloma cells. 
Human, mouse and human x mouse heteromyelomas have all been used for this purpose (reviewed by 
James and Bell, 1987). Myeloma is classified as a tumour of monoclonal plasma cells (Millar et al.,
1988). These cells typically have well-defined cytoplasmic inclusions, abundant rough endoplasmic 
reticulum and well developed golgi-apparatus (Kozbor and Croce, 1985). It is these characteristics that 
allow myeloma cells to secrete high levels of immunoglobulin light and heavy chains of ‘M’ proteins 
both in vitro and in vivo. These properties also allow the myeloma cell, when fused to a B-cell, to
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♦secrete large quantities (1 - 10 pg/ml) of a single type of antibody. Human myeloma cells which are 
used as fusion partners include drug-resistant variants of RPMI-8226 (Matsuoka el al., 1967) and SKO- 
007 (Olsson and Kaplan, 1980). The difficulties encountered in establishing myeloma cells in culture 
and the patent restrictions which already limit the availability of myeloma cells established in culture, 
have severely hindered the production of stable hmabs.
Human lymphoblastoid cell lines (LCLs) have also been used as fusion partners for human B-cells. 
LCLs show a constant association with EBV, have numerous free polyribosomes, less well developed 
rough endoplasmic reticulum and secrete less immunoglobulin than myeloma cells. Unlike myeloma 
cells, LCLs are easily maintained in vitro and generally have doubling times between 17 - 30 hr 
(Kozbor and Croce, 1985). Human lymphoblastoid cell lines, such as GM1500 (Croce el al., 1980), 
LICR-LON-HMy-2 (Edwards el a l., 1982) and UC729-6 (Glassy el al., 1988) have been used to 
produce human hybridomas.
Murine myeloma cell lines have also been used as fusion partners in both heterohybridoma and 
heteromyeloma cell line production, but many researchers have found that these mouse-human hybrid 
cells preferentially shed human chromosomes, making stable antibody production difficult (Jahn el al.,
1987). Teng el al. (1983) described the use of a human-mouse hybrid myeloma, or heteromyeloma to 
produce human monoclonal antibodies. They constructed a heteromyeloma between a human 
lymphoblastoid cell line (FU-266) and a murine myeloma (Ag-8) and isolated a non-secreting TG- 
resistant, HAT-sensitive clone into which the pSV 2neo  plasmid with G-418 resistance was transfected. 
Fusion of this heteromyeloma with human lymphocytes gave rise to stable monoclonal antibody 
production. The major advantage of these heteromyeloma cell lines is their fast doubling time in vitro 
and the ability to culture large quantities of heterohybridomas for production purposes (Foung et al.,
1984).
In this section, the development of myeloma cell lines for use as potential fusion partners in monoclonal 
antibody production will be described. Two main experimental aims were explored:
(a) To establish a human myeloma-derived cell line for use in hmab production studies. The 
C23/11 cell line was established from a patient with multiple myeloma. This cell line was 
characterised by its morphology, cellular ultrastructure, antigenic expression, isoenzyme 
analysis and DNA fingerprinting studies.
(b) In the second experiment, a heteromyeloma cell line, HET 37, was established following the 
fusion of C23/11 with the mouse myeloma cell line NSO. The characterisation of HET-37 and 
a comparison of C23/11 and NSO with HET 37 was also undertaken.
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3.2. ESTABLISHMENT OF C23/11
3.2.1. Patient Samples.
Lymphocytes were isolated from a total of 106 blood samples and 5 bone marrow aspirates taken from 
patients with myeloma (56), multiple myeloma (44) and plasma cell leukaemia (11), using the method 
outlined in Section 2.4.1. The lymphocytes were placed in RPMI-S10 and were maintained in culture 
for 40-80 days. Only 3/111 samples were still growing after this initial stage in culture and only one 
sample maintained viability after 5 sequential subcultures or at p = 5. The cell line was called C23/11, 
and was established from a patient with multiple myeloma. At the time of removing the blood sample, 
this patient had a serum protein level less than 0.15 g/1 and had no Bence-Jones proteins in the urine. 
A quantitative paraprotein determination showed elevated levels of (32 globulin. C23/11 was grown in 
vitro up to passage number 67 and is, therefore, considered to be an established cell line.
3.2.2. Growth of C23/11 In Vitro and In Vivo.
Though C23/11 was established from a patient with multiple myeloma it grows with lymphoblastoid 
growth characteristics in vitro. The clump-like morphology in vitro is shown in Figure 3.2.1.(a). 
C23/11 has a cell doubling time of between 16 - 18 hours, calculated for C23/11 [passage numbers less 
than 10], while a slower doubling time of between 20 - 23 hours was observed in later passage numbers 
(p = 42). As C23/11 was established in vitro with the aim of using this line for hmab production, the 
growth of the cell line in nude mice was particularly relevant. Figure 3.2.1.(b) shows that C23/11 (p 
= 4) grew as solid tumours following subcutaneous injection. However, C23/11 did not form ascitic 
tumours in MFl-nu-nu-old-Hsd mice.
3.2.3. Morphological Characteristics of C23/11.
Despite the lymphoblastoid-like growth of C23/11 in vitro, this cell line has a typical plasma-cell-like 
morphology. Figure 3.2.2. shows C23/11 cells (p = 10) stained with Giemsa (Section 2.4.2.). This 
diagram shows that C23/11 has an excentric nucleus with coarse heterochromatin and extensive golgi 
apparatus, which are features of plasma cells. Both Giemsa staining and haematoxylin and eosin (H/E)
staining showed a number of mitotic cells. Further analysis of the ultrastructure of C23/11 was
undertaken using transmission electron microscopy, which will be described in Section 3.
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Figure 3.2.1: In vitro and in vivo growth of C23/11 when grown (a) in vitro in
RPMI-1640 supplemented with 10% FCS, and (b) transplanted 
subcutaneously into an athymic MFI-nu-nu-old/Hsd mouse.
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Figure 3.2.2: C23/11 ceils stained with Giemsa stain, showing immature plasma cell 
morphology such as excentric nucleus, extensive golgi apparatus and 
coarse heterochromatin.
Table 3.2,1; Immunohistochemical Analysis of C23/11
Antibody Used C23/11
P = 6 P = 42
Polyclonal anti-human X + -
light chain
Polyclonal anti-human k - -
light chain
Monoclonal anti-human \ - -
light chain
Monoclonal anti-human Ig - -
light chain
anti-EBVNA + +
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3.2.4. Immunohistochemical Analysis of C23/11.
Repeated immunohistochemical analysis of C23/11 with polyclonal antibody showed that at early 
passage numbers, the cell line retained some human X light chains (Table 3.2.1.). The patient from 
which this sample was established also expressed X Bence-Jones proteins in urine and X chains on 
electrophoresis, at the time of initial diagnosis. These proteins were not seen in later passage numbers.
However, the monoclonal antibody to human anti-X light chains did not show any reactivity with 
C23/11 at either passage number 6 or passage number 42. The polyclonal antibody did not react with 
FCS or albumen when added to negative controls. It was thought that C23/11 may express an altered 
X chain. Such abnormal antibody secretion may be associated with EBV transformation (Wang el al., 
1990). This would be consistent with the presence of the Epstein-Barr viral antigen (EBVNA) on the 
surface of both early and late passages of C23/11. Further confirmation of the presence of EBVNA was 
provided by DNA probing performed with specific probes for EBV mRNA (analysis performed by D. 
Purtilo, University of Nebraska, USA).
3-3.1. Generation of C23/11 Cells Resistant to G-418.
In order to produce successful hybrid cell lines, it is necessary to select the new hybrid cell lines from 
parent cell lines present in the culture. A drug-resistant variant of C23/11 was prepared by the 
electroporation of the plasmid pSV2neo which carries the gene for G-418 or geneticin resistance. Table
3.2.2. shows that a voltage of 0.75 mV resulted in a moderate reduction in cell viabilities, and, was 
chosen for all further experiments. Following electroporation, two separate cultures were initially 
selected in 200 jjg/ml geneticin and variants which were resistant to up to 1 mg/ml geneticin were 
obtained. However, these cells lost their G^418 resistance on reculturing following long-term storage 
in liquid nitrogen (Section 2.3.4.), and failed to establish following reculturing.
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Table 3-3.1: Optimisation of Electrical Conditions for Electroporation.
Voltage (ntV) Average Cell Viability (48 hours) %
0.0 95.7
0.5 100.0
0.75 78.3
1.0 52.6
1.25 43.3
1.50 55.5
1.75 37.5
2.0 25.0
where: capacitance = 25 i^FD; time constant = 0.1 sec.
Cells were transfected wit.h 0.5 pg pSV2/ieo DNA /  10s cells. 
Viability was assessed by trypan blue dye exclusion.
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3.4.1. Generation of the Mouse-Human Heteromjeloma, HET-37.
C23/11 cells fused with cells from the murine myeloma cell line NSO, to produce a heteromyeloma cell 
line, HET-37. Table 3.4.1. shows that pre-treatment of C23/11 cells with neuraminidase prior to fusion 
increased the number of clones formed following selection in both 96 well and 24 well plates. A total 
of eight heteromyeloma clones (Table 3.4.2.) were expanded into 24 well plates and into 25 cm2 flasks. 
Both HET-A1 and HET-H8 were then cloned to monoclonality by limiting dilution (Section 2.3.6.). 
Four clones from HET A1 were re-cloned and of these monoclonal heteromyelomas HET-37 was found 
to be the fastest growing clone in RPMI-Si0 without BriClone as a media supplement.
3.4.2. Characterisation of HET-37.
In order to determine (confirm) whether HET-37 was a true hybrid cell line and not a HAT or ouabain- 
resistant variant of C23/11 or NSO, various characterisation studies were undertaken.
3.4.2.2. Electron Microscopy.
The ultrastructural characteristics of a cell line can be used to determine the function of a cell and to 
classify cell types. Plasma cells and other lymphocyte types have defined ultrastructural features which 
represent stages of differentiation in B-cell lineage. Electron micrographs of C23/11 (p = 11) and HET- 
37 (p = 4) were prepared and their ultrastructural components were identified.
C23I11:
Figure 3.4.2. is an electron micrograph of C23/11 (p = 11). The nucleus of the cell is typical of an 
immature plasma cell, though the dispersed chromatin is more typical of a less differentiated 
lymphocyte. The invaginations or vacuole-like bodies, seen in the nucleus are more typical of a 
lymphoma cell than a plasma cell. In Figure 3.4.3., extensive arrays of endoplasmic reticulum in sheet­
like morphology can be seen, which is typical of plasma cells (Klein el al., 1977). The cytoplasm 
contained some ribosomes and mitocondria and this gave the cells their granular texture. Further 
electron micrographs showed both binucleated and trinucleated cells, which are again typical of 
myeloma cells. However, the irregular shape of many of the cells observed is typical of lymphoblastoid 
morphology (Bassan et al., 1981).
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Table 3.4.1: The Effect of Neuraminidase on the Number of Clones Formed Following
the Fusion of C23/11 and NSO Cells.
Neuraminidase treated C23/11 
(no. of clones formed/plate + s.d.)
Non-neuraminidase treated C23/11 
(no. of clones formed/plate + s.d.)
24 well plate 96 well plate
14.7 + 1.9 17.0 + 4.5
24 well plate 96 well plate
1.3 + 1.8 1 .7+1.2
Table 3.4.2: Growth Characteristics of Heteromyelomas.
Clone No. Growth Morphology Growth in Absence of BriClone
HET-B6 lymphoblastoid slow
HET-A1 single cell good growth
HET-D6 single cell slow
HET-E7 single cell very slow
HET-H8 single cell good growth
HET-C10 lymphoblastoid no growth
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Figure 3.4.1: Chromosome preparation of (a) C23/11 cells (p = 11) in metaphase showing
metacentric chromosomes, and (b) HET-37 cells (p = 3) showing two bi-armed 
chromosomes which may be of human origin. Chromosomes were stained with 
Giemsa stain 5% (v/v).
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Figure 3.4.2: Electron Micrograph of C23/11 (p = 10) [magnification x 5,000] showing two
mononucleated plasma-like cells with dispersed chomatin and granular cytoplasm 
containing ribosomes.
Figure 3.4.3: Electron Micrograph of C23/11 (p = 10) [magnification x 7,000] showing
extensive rough endoplasmic reticulum and lysosomal inclusions containing 
ribosomes.
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Figure 3.4.4: Electron Micrograph of HET-37 (p = 4) [magnification x 7,000] which shows a
euchromatic nucleus, many mitochondria, endoplasmic reticulum and microvilli­
like surface projection.
HET-37:
Figure 3.4.4. is an electron micrograph of HET-37 (p = 2). This cell shows both an accentric nucleus 
and prominent nucleolus, which may be plasma cell in origin. The giant mitochondrion is a feature of 
a cell with a rapid turn-over. The granular cytoplasm is comprised of ribosomes and some lysosomes. 
The projections seen on the surface of the cell are not usually seen in either plasma or lymphoblastoid 
cell lines and are more typical of a hairy cell - leukaemia cell.
3.4.2J. Isoenzyme Analysis.
Cell lines and tissue types differ in enzyme activities. These differing enzyme activities can be 
compared qualitatively between cell strains or between clones of cells. Isoenzymes or isozymes may 
be separated chromaiographically or electrophoretically and the distribution pattern obtained may be 
used as an enzyme ‘finger print’ for a species, tissue type or cell line (O’Brien el al., 1977). The 
distribution patterns of isoenzymes in C23/11, HET-37 (p = 4) were determined (Table 3.4.2.3.).
3.4.2..4 Immunophenotyping by FACS Analysis.
Faller et al. (1990) used immunophenotyping, or the profile o f antigens expressed on a cell’s membrane, 
to characterise a heteromyeloma cell line. In this experiment, FACS analysis was used to determine 
the immunophenotype of C23/11, NSO and HET-37 (p = 5) (Table 3.4.2.4.).
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Table 3.4.2.3: Isoenzyme Profiles of C23/11, HET-37 and NSO Cell Lines.
Isoenzyme Electrophoretic Migration Distance (mm)
C23/11 HET-37 NSO
Glucose-6-phosphate dehydrogenase 5.5 1.0 1.0
Lactate dehydrogenase -2.5, 0.5, 5.0, 10.0, 16.0 0.5, 1.0, 10.0 1.0
Mannose phosphate isomerase 6.5 N.D. N.D.
Malate dehydrogenase -3.0, 5.0 N.D. N.D.
Peptidase B 6.0 N.D. N.D.
Nucleoside phosphorylase - 1.0
(-) indicates a negative result; N.D. = not determined.
Table 3.4.2.4: Immunophenotype of C23/11, HET-37 and NSO.
Surface Antigen C23/11 (p = 10) HET-37 (p = 3) NSO
control - - -
IL-2 receptor - + +
human Ig - - -
mouse Ig - - -
HLA-DR - - +
CD 19 - + +
CD 23 + - -
CD 38 + + +
EBVNA + - -
+ indicates cells which express antigen, and, - indicates cells which do not express the antigen.
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3.4.2.S. DNA Fingerprinting.
DNA when treated with restriction endonucleases breaks down into smaller DNA fragments. These 
fragments are unique to a cell line. Similarly, each parent contributes a portion of their banding patterns 
to their offspring. These unique banding patterns are termed DNA fingerprints, and have found many 
applications in both forensic and basic science since their discovery (Jeffreys et al., 1985). DNA 
fingerprinting was performed by Cellmark Diagnostics Ltd., Abingdon, U.K. DNA was extracted from 
each cell line and probed with the multi locus-probes 33.6 and 33.15, as well as a cocktail of the single 
locus probes, G3, MS43A and MSA.
The results in Table 3.4.2.5. suggest that HET-37 (p = 10) does not contain detectable human DNA, 
though some bands in HET-37 could not be attributed to either NSO or C23/11. Statistical analysis on 
the bands formed was performed by Cellmark Diagnostics Ltd., (Table 3.4.2.6.). This suggests that a 
portion of HET-37 DNA (= 3%) is not contained in the NSO cell line used in the fusion experiments. 
As DNA fingerprinting was performed a number of months after the fusion experiments, the extra bands 
may be from a sub-clone of NSO used in fusion, which did not appear in the cells sent for DNA 
fingerprinting.
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Table 3.4.2.5: Summary of the Number of Bands found when using various DNA probes on
C23/11, HET-37 and NSO.
Probe Used No. of Bands Produced
C23/11 HET-37 NSO
(p = 9-10) (P = 10)
multi-locus 33.6 + 33.15 44 43 42
single-locus G3, MS43A, MSA 6 - -
Table 3.4.2.6: Percentage Multilocus Band Shares between C23/11, HET-37 and NSO Cell Lines.
C23/11 HET-37 NSO
C23/11 100% 17% 14%
HET-37 17% 100% 87%
NSO 14% 87% 100%
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3.4.2.Ó. Summary of the Characterisation Studies on HET-37.
The cell line characterisation studies undertaken to date show that:
Chromosom e S tudies: HET-37 (p = 4) contained a modal number of 60 chromosomes, two of 
which were bi-armed and may have been from the C23/11 human cell line.
Electron M icroscopy: HET-37 (p = 4) retained few myeloma-like ultrastructural inclusions. 
However, numerous mitochondria and extensive endoplasmic reticulum 
suggests that the line may secrete antibody and has a fast-doubling time.
Isoenzyme Analysis: HET-37 (p = 4) contained C23/11 -like LDH patterns and did not express 
nucleoside phosphorylase. However, the murine glucose-6-phosphate 
dehydrogenase isoenzyme pattern was dominant
FACS Analysis: HET-37 (p = 5) expressed cell surface markers contained on either NSO or 
C23/11 parent cells.
DNA Fingerprinting: HET35 (p = 10) contained a total of 87% DNA which showed homology 
with the NSO cell line. The absence of bands of DNA from C23/11 in 
HET-37 suggests that at this passage number, HET-37 may have lost the 
human DNA component which was observed in chromosome studies.
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3.5. DISCUSSION
3.5.1. The Establishment and Characterisation of C23/11.
The aim of this experiment was to establish a human myeloma cell line for use in human monoclonal 
antibody production. Even though C23/11 was derived from a patient with multiple myeloma, many 
of the characteristics of this cell line are typically lymphoblastoid.
3.5.1.1. C23/11, A Lymphoblastoid or A Myeloma Cell Line?
C23/11 has a doubling time of between 16 to 23 hours, myeloma-like golgi-apparatus, myeloma-like 
intracellular inclusions and was shown to express EBVNA and grow in a lymphoblastoid clump-like 
manner in vitro. These characteristics suggest that C23/11 is an EBV transformed plasma cell.
It is of interest to examine both the source of EBV and the transformation of such a differential cell 
type. The blood sample was not deliberately transformed by EBV in vitro suggesting that these plasma 
cells were transformed in vitro by EBV in the patient’s own blood sample. A similar natural 
transformation of blood lymphocytes, co-cultured with EBV infected lymphocytes from the same 
patient, has been described by Lewin et al. (1990). C23/11 is, therefore, more characteristic of a 
lymphoblastoid rather than a myeloma cell line.
3.5.12 .  Growth and Morphology of C23/11.
Table 3.5.1. summarises many of the characteristics of the lymphoblastoid cell lines (LCL) used in 
hmab production. Doubling time of between 18 to 30 hours were observed for LCLs, while faster 
doubling times of between 16 to 23 hours were observed in C23/11. Myeloma cell lines have a much 
slower growth rate, with average doubling times of between 36 to 37 hours in vitro (Kozbor and Croce,
1985). This slower growth rate leads to long and costly fermentation runs in the large-scale production 
of hmab from human hybridomas. The morphology of C23/11, observed following Giemsa staining 
(Figure 3.2.2.), is typical of an immature plasma cell. This cell shows extensive golgi apparatus, which 
would be useful for the secretion of monoclonal antibodies. The ultrastructural characteristics of C23/11 
also show golgi apparatus and extensive endoplasmic reticulum. However, the established myeloma 
cell lines such as RPMI-8226 have more prominent golgi apparatus and endoplasmic reticulum 
(Matsuoka et al. 1967) than observed in C23/11. Several bi-nucleated and tri-nucleated cells were also 
recorded by electron microscopy and Giemsa staining, and, these are features of normal plasma cells 
and myeloma (Karpas et al. 1985).
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Table 3.5.1: Characteristics of the main lymphoblastoid cell line used in hmab production.
Cell Line Parent Cell 
Line
d.t.
(Hrs)
EBVNA Fusion
Frequency
Ig Reference
GM-1500
-GTG
GM-1500 18.25 + 18 IgG2(k) Croce et al., 
1980
LICR-LON 
-HMY 2 
-8AG
PGLC33H N.D. + N.D. IgM(k) Chiorazzi et 
al., 1982
PGLC33H
-8-AG
ARH77 20-30 + 0.1 - 10 IgGl(k) Edwards el 
al., 1982
MC/MNS-2
-8AG
MC/CAR N.D. + 100 N.S.
Ritts et al., 
1983
In this figure, the abbreviations are as follows:
d.t. = doubling time in hours; Ig = antibody secreted; N.D. = not determined; N.S. = non-secretor
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3.5.13. Antibody Secretion Patterns and Surface Antigen Expression.
The majority of LCL produce intact immunoglobulin, a heavy chain or a light chain, in vitro (Table
3.5.1.)- C23/11 appeared to express the human X light chain (Table 3.2.1.) in early passages but not 
in later passage numbers. FACS analysis (Table 3.4.2.4.) showed that C23/11 did not produce human 
Ig in vitro. C23/11, therefore, appears to be a non-secretor. The use of a non-secreting fusion partner 
is preferable in hmab production as the absence of non-specific antibody would simplify downstream 
purification procedures. Gregory et al. (1987) suggested that a small proportion of myeloma and 
lymphocytes are ‘sterile’. This may result from a gene-rearrangement during cell immortalisation. 
FACS analysis was also used to investigate the immunophenotype of this cell line. Cluster determinants 
(CDs) are a nomenclature used to classify antigens expressed on the surface of haemapoetic cell lines. 
Both CD19 and CD38 are expressed on B lymphocytes at different stages of differentiation while CD19 
is expressed on less mature B cells, CD38 is expressed on plasma cells with multiple restricted lineage 
(Nacheva el al. 1990). From Table 3.4.2.4., it can be seen that C23/11 expressed CD38, the plasma 
cell marker but did not express the CD19 antigen which is associated with lymphoblastoid cells (Tazzari 
et al. 1987). Interestingly, C23/11 expresses the CD23 blast-antigen. The co-expression of CD23 and 
CD38 is further evidence that C23/11 is an EBV-transformed plasma cell.
3.5.1.4. Isoenzyme Analysis of C23/11.
C23/11 has a type a G-6-P profile (Table 3.4.2.3.), indicating that C23/11 is of human caucasian origin. 
The five band LDH pattern is also associated with human lineage. Both the presence of 2-MDH bands 
and the absence of NP can be used as indicator markers of C23/11. Isoenzyme analysis of RPMI-8226 
showed a similar G-6-P profile (Matsuoka et al. 1967), while Edwards e t al. (1982) showed that LICR- 
LON-HMy2 had multiple type bands on analysis.
35.1.5. Chromosomal Analysis of C23/11.
C23/11 contained a modal number of 51 chromosomes, similar to the modal chromosome number 
recorded for LCLS such as LICR-LON-HMy2 (n = 43) (Edwards et a l., 1982) and GM-1500 (n = 46) 
(Croce et al., 1980). However, myelomas have several structural changes to their chromosomes which 
can affect secretion of antibodies. Myeloma cells have several marker chromosome abnormalities such 
as translocations involving the long arm of chromosome 15 at the band q32 (Rabbitts et al., 1988) and 
chromosome 11 at ql3 with partners other than chromosome 14, at lq32.1, 8q24.22 and 13ql4.3 
(Nacheva et al., 1990). The presence of oncogenes in fusion partners may increase the number of tests 
required to validate this cell line for use in the production of a mab for human use (Brown, 1990).
86
Gazdar et al. (1986) have reported the over-expression of c-myc in the myeloma cell line NC1929. The 
identification of myeloma-like translocations and the location of oncogenes in C23/11 would be essential 
before C23/11 could be used to immortalise hmabs for in vivo human use.
3.5.2. Generation of C23/11 with geneticin resistance.
Procedures for the transfection of the plasmid pSV2 neo were optimised and mutant cell lines of C23/11 
which were resistant to geneticin or G 418 (lmg/ml) were isolated. Wabl et al. (1989) reported on the 
instability of this plasmid mediated drug resistance in B cells. Continuous culture in G-418 without 
long-term storage in liquid nitrogen (Section 2.3.4.), should maintain the plasmid in C23/11 by selective 
pressure.
3.5.3. Future Work with C23/11.
C23/11 was used to generate the heteromyeloma cell line HET-37, but the fusion of C23/11 G-418 to 
immunised B cells has not been attempted to date. The success of neuraminidase pre-treatment in 
increasing the number of hetexomyeloma clones produced following fusion, coupled to the favourable 
ultrastructural characteristics observed in C23/11 implies that further work on hmab production using 
C23/11 as a fusion partner may be fruitful.
3.5.4. Generation of HET-37, a Heteromyeloma Cell Line.
33.4.1. The Effect of Neuraminidase on C23/11-NSO Cell Fusion.
In order to bring C23/11 and NSO cells into closer contact before fusion, several enzyme pre-treatment 
systems were investigated. As C23/11 cells grow as clumps and these clumps re-form, a successful 
enzyme pre-treatment method was required to minimise the number of C23/11 to C23/11 fusions which 
occurred. Igarashi and Bando (1990) proposed that EBV-transformed cells, pre-treated with 
neuraminidase, should reduce spontaneous blast formation by removing sialic acid from the cell 
membrane of the human blast cell. This should increase the association between C23/11 and NSO 
mouse myeloma cells. However, the exact mechanism involved is not clear. Similarly, Rosenberg et 
al. (1972) have suggested that sialic acid residues on the surface of a cell membrane can mask cell 
surface proteins from detection by cells ex' antibodies. In addition, electron microscopy studies have 
shown that there is intimate association of cells after neuraminidase treatment (Bentwich et al., 1973). 
Igasashi and Bando (1990) recorded a 6.8-fold increase in the number of Ig producing clones when cells 
were pre-treated with neuraminidase prior to human-mouse cell fusion. In this experiment, a 10.7-fold 
overall increase in the number of clones formed was recorded in neuraminidase pre-treated cells.
87
Marginally higher clone formation was observed when equal numbers of newly fused cells were plated 
in 96 well plates (17 clones) when compared with fusions cultured in 24 well plates (15 clones).
3.5.4.2. Characterisation of HET-37.
HET-37 was established from a parent heteromyeloma clone, HET A l. This parent line was selected 
from a number of heteromyelomas following fusion of neuraminidase-treated C23/11 cells with NSO 
cells (Section 3.4.1.). HET A l grew as a single cell suspension rather than as lymphoblastoid clumps, 
and, it had a faster growth rate than other hybrids obtained after fusion.
(a) Chromosomal Studies:
Chromosomal analysis of HET-37 (p = 3) showed that the cell line contained a modal number of 60 
chromosomes. Two of these chromosomes were bi-armed, and may be of human origin (Figure 3.4.2.). 
No bi-armed chromosomes were observed in the mouse parent line. Attempts to distinguish human 
from mouse chromosomes by the differential uptake of Hoechst 33258 stain were unsuccessful. Teng 
e t al. (1985) reported that hybridoma clones resulting from fusions using a heteromyeloma with high 
proportion of human chromosomes (5 - 10) secreted higher levels of hmab in vitro. However, these 
heieromyelomas were shown to be unstable over longer periods of time. Heterohybridomas 
(heteromyelomas x human B cells) retain variable amounts of human DNA while clones resulting from 
the fusion of SHM-D33 (Table 3.5.3.1.) with immunised tonsil lymphocytes, contained between 20% 
to 50% human DNA. However, loss of antibody production in these heterohybridomas is often 
accompanied by the loss of structural immunoglobulin genes and generally resulted in the loss of greater 
than 95% of the human component of hybrid DNA (Koropatnick et a i ,  1988). HAB-1 (Table 3.5.3.1.) 
contained a total of 75 - 85 chromosomes (50 mouse and 25 - 35 human chromosomes) after one year 
in culture. Conversely, F3B6 contained 48 chromosomes (46 mouse and 2 human chromosomes) and 
also retained both the ability to immortalise human B cells and chromosome stability in vitro. 
Therefore, the effect of low human chromosome content and the potential of HET-37 as a 
heteromyeloma fusion partner, cannot be predicted by comparison of retained chromosomes in other 
heteromyelomas and must be determined by future HET-37 x B cell fusion experiments.
The retention and loss of human chromosomes in human x mouse fusions is not a random process. It 
is known that human chromosome 14 (heavy chain) and 22 (X light chain) are preferentially retained 
(Teng et al., 1985) whereas chromosome 2 (k chain) is preferentially lost (Croce et al., 1979). 
Translocations between human chromosomes and mouse chromosomes in heteromyelomas have also 
been reported (Weiss and Green, 1967) explaining how some heteromyeloma cell lines, with low human 
chromosome content can still assemble mabs in vitro.
88
HET-37 grows as a single cell suspension in vilro, allowing the cell line to be used in both chemical 
and electrofusion experiments (Zimmermann, 1982) and similarly, HET-37 would be easier to transfect 
with plasmid DNA than C23/11 or other lymphoblasloid-like cells.
(b) Growth and M orphology o f  HET-37.
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Table 3.5.3.1: Summary of Heteromyeloma Cell Lines.
Hetero-
myeloma
Mouse
Origin
Human
Origin
EBVNA Ig
Sec.
Drug
Markers
Reference
SHM-D33 X63.Ag8
653x
U226 * N.S. 6-TH 
OUA 
G-418
Teng et al. 
1983
3HL3 SHM-D33 B Cell N.D. N.S. 6-TG
OUA
Östberg et 
al. 1983
SBC-H20 Sp2/08A2 B Cell - N.S. 6-TG
OUA
Foung et al. 
1985
MHH-1 X63.Ag8
653
B Cell N.D. N.S. 6-TG
OUA
Van Meel et 
al. 1985
K6H6/B5
K6H9/G12
NS-1 Lymphoid N.D. N.S. 8Ag
6-TG
OUA
Carroll et al. 
1986
F3B6 NS-1 B Cell N.D. N.S. 6-TG
OUA
Pollack et al. 
1987
E62 D3-8 X63.Ag8
653
Tonsil 
B Cell
N.D. * 8Ag
6-TG
OUA
Hirata et al. 
1987
SP5/HPT Sp2/0 PBLxTonsil
Cells
* N.S. 6-TG
8Ag
Martin et al. 
1988
CB-F7 X63.Ag8
653
B Cell N.D. N.S. 6-TG
OUA
Grunow et 
al. 1988
SPA2^ Ag8 Tonsil Cell N.D. N.S. 6-TG Goldstein et 
al. 1990
HAB-1 Ag8 B Cell 
Lymphoma
- - 6-TG Faller et al. 
1990
mouse-
human
P3U1 Mediastinal
Lymphocytes
N.D. IgG
+
IgM
N.D. Uchiyama et 
al. 1987
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Electron microscopy showed that HET-37 contained a cuchromatic nucleus which is indicative of a 
primative nucleus (P. Dervan, personal communication). The lysosomes appear to be full of 
polyribosomes and abundant mitochondria can be detected. A large or giant mitochondrion may be 
observed adjacent to the cell. Several giant mitochondria were seen in the cell line. HET-37 had some 
endoplasmic reticulum but more golgi apparatus and sheet-like endoplasmic reticulum would be 
expected in a human-mouse myeloma cell line (Hirata and Sugawara, 1987). The microvilli-like 
projections seen in HET-37 were also observed in some murine myelomas (X63 - Ag8.653) and some 
heteromyeloma cell lines (HE62, D3-8). This apparent anomaly between the ultrastructure of a normal 
murine plasma cell and a murine myeloma in vitro, results from the alteration or adaptation of a cell 
to tissue culture over a period of time (reviewed by Kozbor, 1985).
(c) isoenzyme Analysis.
Isoenzyme analysis showed that HET-37 retained LDH isoenzymes from both C23/11 and NSO cells 
(Table 3.4.2.3.). HET-37 has a murine species G-6-P profile, with a migration distance of 1.0 mm, 
while HET-37 lacks the NP band which is a marker for the NSO cell line. Isoenzyme studies by 
Uchiyama el al. (1987) showed that the mouse-human heteromyeloma retained a murine G-6-P profile 
following fusion, confirming the dominance of the murine chromosomes.
(d) FACS Analysis o f  Surface Markers on HET-37.
HET-37 lost the expression of the EBVNA antigen following cell fusion. Table 3.5.3. shows that all 
heteromyelomas lost the EBVNA antigenic phenotype on fusion to murine myeloma cells. The loss 
of EBVNA expression has favourable implications for the heterohybridomas and hmab products. As 
these products do not express EBVNA, fewer regulatory and safety processes are required to ensure the 
safety of these hmabs for human use. The absence of the EBVNA antigen also reflects the loss of the 
CD23 blast antigen from the HET-37 cell membrane, confirming that HET-37 lost many of the 
lymphoblastoid characteristics of C23/11 on fusion. However, the expression of both CD38 and CD19 
suggests that HET-37 did indeed retain some of the human C23/11 immunophenotype following cell 
fusion. HET-37 was also shown not to express human or mouse Ig on its cell surface.
That HET-37 (p = 3) is negative for EBVNA and does not produce immunoglobulin suggests that HET- 
37 may be a useful fusion partner for human lymphocytes.
(e) DNA Fingerprinting.
At passage number 10, HET-37 could not be shown to contain any C23/11-derived DNA, when probed
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with multilocus probes and human single locus probes. As the previous characterisation studies had 
shown HET-37 to have altered chromosome and isoenzyme profiles from its parent lines, it was felt that 
HET-37 may have lost its human chromosomes at this passage. Further cloning of earlier passage 
number (p = 3) cells and DNA fingerprinting should be undertaken to confirm the presence of human 
DNA in the HET-37 cell line.
3.5.5. Future Work with the HET-37 Cell Line.
In order to use HET-37 as a fusion partner, the cell line must be made resistant to some drug, by which 
fusion products may be selected. Drug selection systems which are commonly used in heieromyelomas 
(Table 3.5.3.1.) include ouabain and thioguanine resistance (Cole and Arlett, 1976), 8-azaguanine 
resistance (Myhr and DiPaolo, 1975), and G-418 resistance (Section 2.4.7.). Further characterisation 
of the chromosomes of a stabilised HET-37 clone should reveal the major translocation and 
chromosomal abnormalities in the cell line.
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3.6. THE FUTURE OF HUMAN MYELOMA CELL LINES AND hmab 
PRODUCTION.
3.6.1. Generation of Human Myeloma Cell Lines.
Difficulties in establishing continuous cell lines from samples obtained from patients with myeloma, 
are well documented (Kozbor et al, 1985; James and Bell, 1987). In the experimental work outlined, 
only one of the myeloma samples isolated from patients was successfully established in vitro even 
though over 100 samples were processed), and, it appears that this occured by transformation.
Several researchers have tried other culture systems to try to establish myeloma cells m vitro. Millar 
et a i ,  (1988) used a clonogenic assay system in semi-solid agar to establish granulocyte and 
granulocyte-macrophage colony forming units. This system used a feeder-layer of irradiated HL-60 
promyelocytic leukaemia cells, to support growing cells. To date, only the short-term growth of 
myeloma cells has been accomplished with this technique (Devereux and Linch, 1989).
Haemapoetic cells are supported in vivo by a system of pluripotent cytokines. The range of cytokines 
in the blood and their role in blood cell development is currently under investigation. The effect of 
media supplements containing interleukin-rich culture supernatants and purified interleukins on the 
growth of myeloma cells has also been investigated (Christie et al., 1987; ; Kishimoto, 1985; Fakoi et 
al., 1990; Yokoi et al., 1990).
3.6.2. Human Monoclonal Antibody Production
In 1980, Croce and his colleagues produced human monoclonal antibodies to the measles virus. During 
their investigations, it became apparent that the hybridoma production processes developed for murine 
monoclonal antibody production did not transfer directly to human B-cells and human myeloma cells. 
Initial problems involving the source of human B-lymphocytes have largely been solved by in vitro 
immunisation technology (Section 1.3.2.). Increased numbers of clones have been formed by strategies 
such as EBV-transformation before fusion to a myeloma or LCL (Kozbor and Croce, 1985) 
electrofusion (Zimmermann, 1982) and gene cloning technology (Winter and Milstein, 1991).
Many of the LCLs, human and heteromyeloma fusion partners used may not secrete antibody, but 
continue to synthesise heavy and/or light chains in the cytoplasm. Hybridisation often leads to 
resecretion of these chains and results in mixed immunoglobulin molecules being produced which are 
both antigen-specific and non-antigen-specific (Strelkaukas and Taylor, 1986). Many human
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hybridomas have very poor secrelory capacity and are relatively unstable when compared to murine 
hybridomas. Low levels of antibody secretion have been related to the low levels of endoplasmic 
reticulum and golgi apparatus in these cells (Kozbor et al., 1985). Many human hybridomas produce 
hmabs which build up in the cytoplasm and are not secreted in vitro. Crawford (1985) suggested that 
adding HLD-Dr-matched-specific helper T cells or antibody to HLA-Dr may help secretion. This 
approach was less successful than the attempts to demethylate ‘inhibitory’ genes (Olsson and Brams, 
1985) and treatment with phorbol esters (Polke et al., 1986). Alternatively, it may be possible to 
transfect cells with specific enhancer sequences to promote transcription of the antibody genes (Gillies 
el al., 1983) and thereby increase hmab secretion rates.
The limited success of human monoclonal antibody technology has resulted in much collaboration 
between immunologists and molecular biologists in the production of humanised and human 
recombinant antibodies.
3.6.3. The Impact of Molecular Biology o d  Human Monoclonal Antibody Production.
Several strategies have been developed for preparing specific antibody-secreting human cell lines. 
These strategies include the transfection of normal B lymphocytes with tumour cell-derived DNA (Jonak 
et al., 1984) and conversly, the transfection of permanent human cell lines with DNA from antibody- 
secreting lines (Neuberger, 1985) and lastly, the introduction of natural or recombinant antibody genes 
into a suitable cell line to produce chimaeric and humanised monoclonal antibodies (Section 1.4). The 
use of these recombinant antibodies in vivo will be discussed in more detail in Section 4. Site-directed 
mutagenesis of existing human monoclonal antibodies has also been proposed as a mechanism to 
increase the repertoire of available hmabs (Wabl et al., 1989). These products of so-called conventional 
genetic engineering are currently providing human and human-like antibodies for use in vivo. Newer 
recombinant antibody techniques such as the expression of antibody fragments, which will make 
functional human Fv fragments using phage display libraries (Clackson et al., 1991), rather than naive 
B-cells, and E. coli rather than human myelomas, will increase both the range of antibodies available 
for use and the cost-effectiveness of hmab technology. However, these second generation recombinant 
antibodies are still at the developmental stages. Problems are still encountered with screening, post- 
translational modification and with purificiation (Coughlan, 1991).
Conventional hmabs have not proved as easy to construct as their murine counterparts. The human 
antibodies which have been produced to date (reviewed by Borrebaeck et al., 1990) will be useful in 
optimising techniques for monoclonal antibody-mediated diagnosis and therapy, before more 
recombinant human monoclonal antibodies and antibody fragments become widely available for human
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SECTION 4 : IMMUNOSCINTIGRAPHY
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4.1. THE USE OF RADIOLABELLED MONOCLONAL ANTIBODIES IN THE 
EVALUATION OF OVARIAN CARCINOMA.
Recent advances in human, humanised and chimaeric antibody technology have renewed interest in the 
detection and treatment of cancer using targeted monoclonal antibodies (mabs). Immunoscintigraphy, 
or the use of radiolabelled mabs as detection systems in vivo has been shown to be particularly useful 
in the evaluation of disease in patients with ovarian carcinoma. Conventional radiological examinations 
such as X-ray are of limited use in these patients, while CAT scan and ultrasound often fail to locate 
small volume disease or non-tumour masses (Chatal et al., 1985). Metastasis of ovarian carcinoma is 
found primarily in the peritoneal cavity and may be distributed as large tumour masses matted to the 
bowel or omentum, as diffuse peritoneal seedlings, or as ascites. Ovarian carcinoma may also be found 
in the pleural cavity as a pleural effusion. Immunoscintigraphy can therefore be used to locate antigen- 
bearing masses in these areas and to differentiate them from non-antigen bearing masses. These 
immunoscans may indicate the distribution of the disease within the intraperitoneal and pleural cavities 
without the need for surgery.
Earlier studies in immunoscintigraphy used isotopes of iodine, ie. 1231, 125I and 13,I (reviewed by Lamki 
et al., 1988). These isotopes were readily available and conjugation techniques such as chloramine T 
and iodogen were already developed to label proteins with iodine. However, on administration, iodine- 
mab conjugates were found to be less stable in vivo than in vitro (Finn et al., 1991). High levels of 
uptake by the thyroid and inefficient imaging by the gamma cameras which are currently available, all 
pointed to the need for more suitable isotopes for tumour immunoscintigraphy. Attention was then 
focussed on using mIn and 99MTc which have more suitable imaging properties for gamma imaging.
mIn has two gamma energies at 173 keV and 247 keV and has a half-life of 72 hours. Mabs are easily 
labelled with InIn after conjugation to a variety of chelating agents. Diethylenetriaminepentaacetic acid 
(DTPA) is the most commonly used bifunctional chelator for antibody labelling and DTPA-mab 
conjugates are relatively stable in vivo. In recent years, macrocyclic bifunctional chelators such as the 
nitrobenzyl derivatives of DTPA, EDTA and tetraazacyclododecane-N-N',N”>N'"-tctraacetic acid (DOTA) 
have been shown to have improved stability over DTPA in vivo (Meares et al., 1990). Despite 
favourable imaging properties, it has been shown that patients who were administered with IDIn 
experienced problems with increased accretion and residence of conjugates in the liver and spleen. The 
uptake by these organs leads to a waiting period of a number of days, during which non-tumour bound 
conjugate is removed before images can be obtained. Unlike 99MTc, mIn is not routinely available in 
Nuclear Medicine Departments and this increases both the expense and the waiting time before
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immuniscintigraphy can take place. In terms of availability, cost, gamma ray energy (140 keV) and 
user familiarity, 99MTc is the most desirable of all isotopes currently available for imaging. As 99MTc 
has a six hour half-life, it is essential to use F(ab’)2 fragments of mab (Figure 1.2) to expedite the 
clearance of unbound conjugate from the blood stream and non-tumour regions. Blood pool clearance 
is also affected by the choice of antibody (Section 1.8 ). F(ab’)2 fragments clear more quickly from 
the circulating blood pool and have less non-specific interactions with the liver, due to the absence of 
the Fc receptor (Buraggi et al., 1987). 99MTc-F(ab’)2 fragments have been used to image colorectal and 
liver metastases (Granowska et al., 1990; Hertel et a l ., 1990). Improvements in the quality of 99MTc- 
mab images result from the availability of improved labelling methods, especially in newly reported 
reduction procedures. The preparation of most 99MTc-F(ab’)2 conjugates involves the reduction of 99MTc- 
pertechnate and the subsequent non-specific binding of the reduced technetium to donor groups present 
in the protein (such as thiol, amide, amino and carboxylate groups). Most of the 99MTc- 
immunoscintigraphy studies to date have used stannous chloride as the reducing agent (Rhodes and 
Burchel, 1983). Increasing numbers of reductants have been used for conjugation procedures with the 
aim of increasing the stability of 99MTc-mab conjugates in vivo. These reductants include dithiothrietol 
(DTT) (Pak et al., 1989), dithioerythritol (DTE) (Del Resallo et al., 1989), ascorbic acid, (Thakur and 
DeFulvio, 1991), dithionate (Fitzberg et al., 1988) and recently, 2-mercaptoethanol (Mather and Ellison,
1990).
In this section, the preparation of InIn-mab conjugates by the DTPA anhydride method and of 99MTc-mab 
conjugates by 2-ME reduction are described. These conjugates were administered to patients with 
ovarian cancer and the results of the immunoscans will be discussed in detail.
A total of three IgG mabs which react with ovarian carcinoma cells were conjugated to DTPA. The 
antibodies used were HMFG-1, AUA-1 and H17E2; these antibodies are described in more detail in 
Section 2.5.1. Twenty one patients with ovarian carcinoma were administered with mIn-DTPA-mab 
conjugates. F(ab’)2 fragments of HMFG-1, (F(ab’)2), were conjugated with 99MTc following reduction 
with 2-ME. One patient with ovarian carcinoma had residiual tumour and was imaged with 99MTc- 
F(ab’)2. Extensive testing of both raIn-mab and 99MTc-F(ab’)2 was undertaken to ensure that conjugates 
used were able to bind to tumours and antigen-bearing cells before administration to patients. In order 
to ensure the safety of the immunoconjugated antibody for administration to patients, the sterility and 
absence of pyrogenicity were determined. The results of the immunoscans were compared with the 
results of other non-invasive techniques which were used to evaluate patients with suspected ovarian 
carcinoma and the advantages and disadvantages of raIn-mab and 99MTc are discussed.
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4.2. PREPARATION AND CHARACTERISATION OF [nIn-MAB AND ""Tc-Fiab’^
CONJUGATES
4.2.1. Preparation of ‘"In-mab Conjugates.
HMFG-1, AUA-1 and H17E2 were labelled with '"In by the DTPA anhydride method, which is outlined 
in Section 2.5.3. Hnatowich el al. (1983) showed that the conjugation of between 1 and 5 DTPA 
molecules to a range of IgG antibodies had no effect on antibody binding capacities of the resulting 
DTPA-mab conjugates. A molar ratio of 3.5:1 DTPA : antibody was used with all antibodies. As 
DTPA has a long shelf-life, it was possible to prepare DTPA-mab conjugates in batch form and to store 
in aliquots of 2 mg at 4°C. All conjugates were tested for their ability to chelate inIn, to bind to target 
cells in vitro as well as for sterility and pyrogenicity before administration to patients. Since DTPA 
forms strong chelates with a large number of metals, it was important to minimise trace metal 
contamination prior to mIn-chelation. Sterile plastics, sterile water for injection ( which was free of 
trace metals ) and acid-treated glassware were used to minimise the competition between trace metals 
in the mab preparation and IDIn.
4.2.2. Preparation of WMTc-F(ab’)2 Conjugates.
Though some investigators prepared 99MTc-mab conjugates using the DTPA anhydride method, the 
stability of these 99MTc-DTPA-mab conjugates in vivo was low (Childs and Hnatowich, 1985). Mather 
and Ellison (1990) showed that by reducing the di-sulphite bond in the F(ab’)2 with 2-mercaptoethanol 
(2-ME) and reacting 2-ME-F(ab’)2 with the weakly competitive reductant methylene diphosphonate 
(MDP), stable 99MTc-F(ab’)2 conjugates could be formed. F(ab’)2 fragments of HMFG-1 (referred to 
as F(ab’)2) were reacted with 2-ME at a molar ratio of 1:1000 F(ab’)2 : 2-ME. Details of this procedure 
are given in Section 2.5.4. The effect of reduction on the F(ab’)2 structure and antibody binding 
capacity will be reported in detail.
4.2.3. SDS-PAGE Analysis of "in-mab and 9,MTc-F(ab’)2 Conjugates.
SDS-PAGE was used to determine the effect of DTPA conjugation and 2-ME reduction on mabs and
F(ab’)2. While unconjugated HMFG-1 (Figure 4.2.1., Lane 2) appeared to be a homogenous intact IgG, 
conjugation of DTPA to HMFG-1 resulted in the formation of both higher and lower molecular weight 
complexes. As DTPA is a bifunctional chelator, more than one antibody molecule can bind to each 
DTPA molecule allowing for protein dimer and polymer formation. These aggregates would account 
for the higher molecular weight species seen in Lane 3. A significant proportion of DTP A-HMFG-1
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Figure 4.2.1: SDS-PAGE Polyacrylamide Gel Electrophoresis (SDS-Page) of
HMFG-1, DTPA-HMFG-1, F(ab’)2 and 2 ME - F(ab’)2 conducted under non- 
reducing conditions.
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conjugated also formed a low molecular weight protein product The extremes of pH used in the 
conjugation of DTPA to HMFG-1, and to a lesser extent, physical disruption during the manipulation, 
may have caused this fractionation of HMFG-1. These fragments may be light chains. The sterility 
and endotoxin tests showed there were no bacteria present in DTPA-HMFG-1 and therefore bacterial 
proteases were not responsible for this fractionation. Similar results were obtained for both DTPA- 
H17E2 and DTPA-AUA-1 conjugates. The reduction of F(ab’)2 by 2-ME did not appear to result in 
F(ab) fragments or other light and heavy chain fragmentation (Lanes 4 and 5).
4.2.4. Immunoreactivity of DTPA-mab and 2-ME reduced WMTc
DTPA conjugation or 2-ME réduction may affect the ability of a monoclonal antibody to bind to target 
and non-target antigens. Four techniques were used to assess DTPA-mab and 2-ME-reduced-F(ab’)2 
( referred to as 2-ME-F(ab’)2) conjugates. The non-radioactive methods used were FACS, ELISA and 
immunofluorescence and the Lindmo assay, which assesses the ability of ,DIn-mab and 99MTc-F(ab’)2 
to bind to antigen-expressing and non-antigen expressing cells in vitro. The results of each method are 
considered in turn.
4.2.4.I. FACS Analysis
FACS was used to determine the number of cells which bound the mab as a percentage of the total cells 
which were incubated with antibody. Where the percentage of cells which bound DTPA-mab or 2-ME- 
F(ab’)2 differed from the percentage of cells which bound unconjugated antibodies, the immunoreactivity 
was said to be altered. Figure 4.2.2.(a) shows that HMFG-1 bound to 88.2% of MCF-7 cells, while 
93.4% of MCF-7 cells bound DTPA-HMFG-1 on their surface membrane. Differences in the 
concentration of DTPA-HMFG-1 and HMFG-1 may explain the apparent increase in immunoreactivity 
of the DTPA-HMFG-1 conjugate. Plots 4.2.2. (b)-(d) show that there was no alteration in DTPA- 
HMFG-1 binding to EJ-138 cells, LOVO cells or RT-112 cells, when compared with unconjugated 
HMFG-1. While HMFG-1 did not react with EJ-138 or RT-112 bladder cell lines, the LOVO 
adenocarcinoma cell appears to express HMFG-1-like antigens. This cross-reactivity with colon 
adenocarcinoma was also observed by Taylor-Papadimitriou et al. (1981). The results of FACS analysis 
of DTPA-H17E2, DTPA-AUA-1, and 2-ME-F(ab’)2 using cell lines known to express these antigens, 
are shown in Figure 4.2.3 (a)-(c). No alteration in immunoreactivity can be seen between these 
chemically modified antibodies and their unconjugated equivalents.
ELISA a very useful initial test to examine the effects of conjugation or reduction on antibodies, but 
these results were not as reproducible as the results obtained by FACS analysis. Indirect
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Figure 4,2.2: Assessment of the immunoreactivity of HMFG-1 and DTPA-HMFG-1 on cells
lines using FACS analysis with (a) MCF-7 cells [which express the HMFG 
antigen], (b) EJ-138 cells, (c) LOVO cells and (d) RT-112 cells.
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Figure 4.2.3: Comparison of the immunoreactivity of H17E2, AUA-1 and F(ab’)2 before and
after chemical modification using FACS Analysis.
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immunofluorescence analysis was also carried out to assess whether the antibodies bound to various cell 
types, and like ELISA, was used as a preliminary indicator of the immunoreactivity of the modified 
antibodies.
4.2.4.2. ELISA and Immunofluorescence
A solid phase ELISA capture assay was used to determine immunoreactivity in vitro; details of the 
experimental technique used are given in Section 2.5.9. These results confirmed that all batches of 
conjugated antibody bound to target antigens. The ease of access to all necessary equipment made both 
ELISA and immunofluorescence convenient assays for the peliminary assessment of immunoreactivity.
4.2.4.3. Lindmo Assay
The Lindmo assay assesses the immunoreactivity of a radiolabelled antibody by measuring the amount 
of radioactivity bound to varying dilutions of cells in vitro. Cells were incubated with excess 
radiolabelled antibody. The amount of radiolabelled antibody bound to the cells [B] is related to the 
total amount of radioactivity added to the cells [T] by the following equation:
The ratio [T]/[B] is related to the reciprocal of cell concentration by a constant 1/r, where r is defined 
as the immunoreactivity fraction of that conjugation. C defines the concentration of free antigen and 
K, is the association constant. The immunoreactivity fraction is independent of the cell numbers and 
the excess of antibody used is also a valuable indicator of batch-to-batch variations in different 
preparations of radiolabelled monoclonal antibodies (Lindmo et al., 1984). Figure 4.2.4. illustrates the 
Lindmo plot of mIn-HMFG~l (Batch 3) when bound to MCF-7 cells in vitro. The intercept with the 
ordinate axis shows at 1/r = 0.51, r = 1.967. Three different batches of DTPA-labelled HMFG-1 were 
prepared and found to have immunoreactivity fractions of n = 2.5, 1.75 and 2.0, respectively. Single 
batches of DTPA-AUA-1 (r = 0.666), DTPA-H17E2 ( r = 1.176) and 99MTc-F(ab’)2 (r = 1.81) were also 
prepared.
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Figure 4.2.4: Determination of the immunoreactivity fraction, r, of mIn-HMFG, assessed by
the Lindmo Assay.
104
4.2.5. Thin Layer Chromatography
Thin layer chromatography was used to determine the number of DTPA molecules which bound to each 
antibody molecule. It was also used as a quality control procedure to ensure radiolabelling of antibody 
prior to administration to the patient TLC was carried out behind lead shielding and the plates were 
visualised using a GE type 400 AC Gamma Camera system. After the samples were resolved, images 
of the radiolabelled components were obtained using the General Electrics Software accompanying the 
camera system. Protein (mab) which had taken up the radiolabel was unable to migrate with the solvent 
front through the silica matrix and could be resolved from both the unbound radiolabel and DTPA- 
radiolabel which migrated to the top of the plate. Therefore, the number of radioactive counts at the 
bottom of the TLC plate represented radiolabel bound to antibody while the counts at the top of the 
TLC plate represented a mixture of both free and DTPA-bound radiolabel, respectively. Figure 4.2.5.(a) 
illustrates the image of the TLC plate obtained after scanning with the gamma camera. The three lanes 
in the centre of the picture indicate the three TLC samples which were resolved. Lane 1 contained a 
sample of DTPA-HMFG-1 taken before free DTPA was separated. The gamma camera used to acquire 
the TLC plate image was unable to resolve inIn from 1DIn-conjugated to DTPA. The densitometry scan 
shown above the TLC plate shows that 18.2% of the total mIn in this lane migrated to the top of the 
TLC plate. This implies that 18.2% of the DTPA did not bind to HMFG-1, and the actual molar ratio 
of DTPA : mab was 3.07:1, or 87.8% efficiency, in conjugating 3.5 moles of DTPA. Lane 2 represents 
a sample of IDIn-mab immediately before injection to the patient. Further analysis of this sample 
showed that there was no free mIn present in the sample. Lane 3 contained free ,nIn, and, was included 
as an experimental control.
Figure 4.2.5.(b) illustrates the images obtained on TLC analysis of various 99MTc samples. Lane 1 
contains free 99MTc. The scan above the TLC plates relates to Lane 1 only and shows that the majority 
of the 99MTc migrated to the top of the plate. Lane 2 contained 99MTc mixed with 2-ME-F(ab')2 
immediately after mixing with the MDP kit, while Lane 3 shows 99MTc-F(ab’)2 before administration 
to the patient. This final 99MTc-mab mixture contained 19.72% unconjugated 99MTc. As the 99MTc- 
F(ab’)2 was eluted in the same fractions as unconjugated 99MTc, further purification using gel filtration 
(Section 2.4. .) was not possible. Granowska et al. (1990) achieved between 85-95% labelling 
efficiency by this method. However, Mather and Ellison (1990) commented that efficiency obtained 
when HMFG-1 was labelled with 99 ^ Tc was lower than the efficientcy of H17E2-F(ab’)2 fragment 
labelling.
105
4.2.6. Pyrogen Detection
Bacterial lipopolysaccarides when administered to patients are known to cause a pyrogenic or fever 
reaction. All procedures were carried out under sterile and pyrogen-free conditions to avoid bacterial 
contamination. Each stage of the DTPA-mab and 2-ME-F(ab’)2 procedures was monitored for the 
presence of pyrogens using a KabiVitrum CoATest kit (Section 2.5.12.). All antibodies for 
administration had pyrogen levels below the sensitivity level of this kit (0.1 EU/ml = 12 pg/ml) and no
inhibition of the enzyme reaction was observed. All final batches of antibody for injection were also 
tested by the less quantitative Rabbit Pyrogen Test at Biological Laboratories (Ballina) Ltd., Carrentrila, 
Ballina, Co. Mayo, Ireland.
4.2.7. Sterility Assessment
All antibodies were tested according to the protocols oudined in Section 2.5.11. None of the samples 
for injection in vivo had detectable microbial contamination (Biological Laboratories (Ballina) Ltd., 
Ballina, Co. Mayo, Ireland).
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Figure 4.2.5: Images obtained following gamma camera scanning of 111 labeled antibody (A)
Lane 1 contained lIIIn, Inln-DTPA and niIn-DTPA-HMFG-l; Lane 2 contained 
niIn-HMFG-l before administration and Lane 3 contained free "‘In, and (B) 
9,MTc-F(ab’)2 samples where Lane 1 contained unbound 99MTc, Lane 2 contained 
99MTc-MDP-F(ab’)2 and Lane 3 contained 99MTc F(ab’)2. A densitometry scan of 
one lane of TLC each plate (Lane 1) is also shown in these photographs. 
Indicators showing radioactive intensity are also shown in each photograph.
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4 J . CLINICAL STUDIES
4.3.1. Patient Selection
1DIn-mab immunoscintigraphy was carried out on 21 patients with ovarian carcinoma at the end of their 
treatment with chemotherapy. mIn-mab immunoscintigraphy was carried out in parallel with a number 
of routine non-surgical investigations, including measurment of serum CA-125 levels, CAT scan, X-ray 
and, in some cases, ultrasound (in 6 of 21 patients included in this study). Surgical evaluation by either 
laparotomy or laparoscopy was carried out where possible (in 17/21 patients). The histological findings 
following surgery were taken as the ‘gold standard’ result for the detection of ovarian carcinoma. In 
a separate study, one patient who also had an elevated serum CA-125 level, was evaluated using 99MTc- 
F(ab’)2 immunoscintigraphy soon after surgery to remove ovarian tumour.
4.3.2. Choice of Monoclonal Antibody.
The tumour to background ratio is the term used to describe the ratio of antibody which was taken up 
by the tumour versus the amount of non-specific uptake of radioactivity in an area without tumour (in 
this case the pelvis or sacro-ileal crest) there days after the administration of !DIn-mab. Fifteen patients 
were administered mIn-HMFG-l, three patients received lnIn-AUA-l and three patients received mIn- 
H17E2. Preliminary studies showed that inIn-AUA-l had a tumour to background ratio of 1.9 : 1, while 
inIn-H17E2 had a tumour to background ratio of 1.44:1, indicating that these antibodies were not as 
efficient in distinguishing between areas of specific uptake by neoplastic tissue and non-specific uptake 
as were HMFG-1 conjugates (Section 2.4.1.). mIn-HMFG-l had the lowest non-specific uptake or the 
highest tumour to background ( 2.4:1) ratio of the three antibodies examined and was therefore used 
for the majority of the patients in the study.
43.3. Interpretation of Inln-mab Immunoscans.
All patients had planar (2-dimensional) scans of the chest and abdominal areas one hour after ,aIn-mab 
injection (Day = 0). Follow-up scans were performed after 24 hours (Day = 1), Day 3 and, in some 
cases, on Day = 6. Tomographic (3-dimensional) scans were taken on Day 3 where the planar images 
showed abnormal uptake of IDIn.
Free IDIn is normally taken up by the liver, and, to a lesser extent, by vascular areas such as the bone 
marrow, spleen and kidney. In the absence of tumour, radioactivity recorded in these areas after the 
injection of mIn-mab was reported as normal uptake or a negative immunoscan. Figure 4.3.1. shows
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Figure 4.3.1: Gamma camera image of the chest area. Image 1 shows abnormal uptake in the
lung, while Image 2 shows normal uptake in the liver, spleen and sternum.
Figure 4.3.2: Gamma camera images of the abdominal areas of patients administered mIn-
mabs. Image 3 shows uptake in the umbilical node, Image 5 shows diffuse 
uptake indicating peritoneal seedlings, while, Images 4 and 6 show 
background or normal uptake.
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Inln uptake patterns in a positive (Image No. 1) and a negative (Image No. 2) immunoscan of the chest 
area. Image No. 2 shows Inln-mab uptake in the top of the liver and in the sternum area. This was 
reported by the physician as background or normal uptake. Image No. 1 shows a diffuse uptake on 
the right hand side of the sternum. This represents uptake by a metastatic ovarian carcinoma in the 
right lung. The presence of metastatic tumour was confirmed by histology. Figure 4.3.2. represents 
planar immunoscans of the abdomen. The luIn-mab uptake in the liver, spleen, bone marrow and pelvis 
(sacro-ileal crest) is normal uptake (Figure 4.3.2., Image No. 4). However, in Image No. 4 (Figure
4.3.2.), there was a small tumour nodule below the liver, which, on tomography was seen to be at the 
anterior of the patient. Surgery soon after the scan showed that this umbilical node was malignant 
The distribution of ovarian cancer in the peritoneal cavity may affect the type of treatment that the 
patient will receive. Image No. 5 shows how a patient with peritoneal seedings was differentiated from 
a patient with a solid tumour using abdominal immunoscintigraphy. The diffuse uptake in the entire 
peritoneum was confirmed by laparotomy. Image No. 6 is a copy of Image No. 3 and was included 
for comparison purposes only. These scans show how ,nIn-mab scans can be used to locate tumours. 
Their importance as part of a panel of investigations must also be evaluated, in order to determine if 
mIn-mabs are a useful method of detecting disease routinely.
4.3.4. ,nIn-mab Immunoscans as a Non-Invasive Diagnostic Technique.
The immunoscans shown in Figures 4.3.1. and 4.3.2. are among the clearest images obtained in the inIn- 
mab study and these patients were known to have extensive disease. It is of much more relevance to 
be able to detect disease in patients with low levels of tumour, that is, to determine the lower limits of 
mIn-mab sensitivity. The results of IDIn immunoscans were compared with the results obtained from 
other non-surgical evaluations such as serum CA-125 levels, CAT scan and chest X-ray. Where 
available, all of these non-surgical techniques were then related to the ‘gold standard’ result obtained 
from the histological evaluation of tumour tissue taken from patients during surgery (laparotomy or 
laparoscopy) or to disease progression. The results of all these evaluations are summarised in Table
4.3.1. and the relationship between inIn-mab immunoscintigraphy and each technique is discussed.
4.3.4.1. Chest X-ray in Ovarian Cancer
Chest X-ray is used to detect abnormal fluid in a patient’s pleural cavity. This may indicate metastatic 
ovarian carcinoma in the form of a pleural effusion. Although patient no. 1 had a positive pleural 
effusion (Figure 4.3.1. [Image No. 1]), the results of the chest X-ray did not clearly indicate this. This 
patient also suffered from pulmonary sarcoidosis which would also have led to an abnormal X-ray 
result. Immunoscans were particularly useful in differentiating antigen-bearing tumour fluid from non­
antigen bearing sarcoid tissue in this particular patient.
I l l
Table 4.3.1: Results of the evaluation of 21 patients with ovarian carcinoma post-chemotherapy.
Patient FIGO
Stage
Serum CA-125
(IU/ml)
CAT Scan Chest X-Ray niIn-mab Histology
1 IV 1558 +/- +/- + +
2 I I ^ 400 +/- +/- + +
3 IV 192.1 - - + +
4 III 77 +/- - - +
5 m 49.9 - - - +
6 hi 76.4 - - + +
7 hi 74.6 - - - ND ( )
8 IHr* 15.0 - - - +
9 i 59.8 - - + -
10 HI 18.4 - - - -
11 III 18.5 - - - ND (-)
12 III 8.9 - - - +
13 III,« 101.1 + - + +
14 nA 9.1 - - - -
15 n B 26.0 - - - -
16 hi 62.5 +/- - + +
17 Ic 21.4 - - • ND (-)
18 HI 26
' '
■*
19 III 252.5 + - + +
20 III 67.8 + - + +
21 IV 26.8
where: + = positive result; - = negative result; +/- = equivocal result; ND ( )  = not determined by histology 1 
determined by tumour progression.
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4.3.4.2. CAT Scan and Ovarian Cancer
Computerised Axial Tomography (CAT) scan is used clinically to determine the density of tissue. 
Abnormal density changes in tissues may indicate the presence of a tumour mass. CAT scan is used 
routinely in the follow up of patients with ovarian carcinoma. The first line of treatment for these 
patients is usually surgical removal of the tumour and, in many cases, hysterectomy, bi-lateral salpingo- 
oophorectomy (BSOH), and further debulking surgery are also undertaken. As a result of surgery, many 
of these patients have scar tissue and fibroid masses which have abnormal tissue densities. Such masses 
can not be distinguished from residual or recurrent tumour in the peritoneal cavity using present CAT 
scan techniques. Table 4.3.1. shows that while 8/13 patients had true positive immunoscans, 3/13 
patients had true positive CAT scans. An IDIn immunoscan would, therefore, appear to be more 
sensitive than a CAT scan in the evaluation of ovarian carcinoma in this patient group.
4.3.43. Serum CA-125 and Ovarian Cancer
The OC-125 monoclonal antibody was first reported by Bast et al. (1981)and it reacts with CA-125 
. CA-125 is an ovarian cancer-associated antigen (200,000 kD molecular weight) that is expressed in 
80% of non-mucinous epithelial ovarian carcinomas. This antigen is detected in the sera of patients 
with intra-peritoneal disease and it has been shown to be a sensitive, but non-localising indicator of 
persistent and recurrent disease and has also been used to monitor a patient’s response to treatment 
(Muto et a l ,  1989). A normal CA-125 is given as less than 35 IU/ml. Levels of serum CA-125 greater 
than 35 IU/ml are considered a sensitive indicator of disseminated disease in ovarian carcinoma patients 
(Tholander et al., 1990). From Table 4.3.2. it can be seen that 10/13 patients with elevated CA-125 
levels had detectable disease, while 9/13 of these patients had positive immunoscans. All patients with 
positive immunoscans had elevated serum CA-125 levels. The correlation between serum CA-125 
levels and raIn-mab scanning is examined in more detail in Table 4.3.2. Three distinct groups can be 
observed on the basis of serum CA-125 levels. The first group contained five patients with serum CA- 
125 levels greater than 100 IU/ml. All of these patients had positive immunoscans regardless of which 
antibody was used. The second group contained seven patients with serum CA-125 levels between 35- 
100 IU/ml. No direct correlation between the results of immunoscintigraphy, serum CA-125 and 
histology could be determined in this patient group. While three patients had positive immunoscans and 
histology, another group of three patients had false negative immunoscans. One patient (No. 9) had 
false-positive serum CA-125 and immunoscans. This gives an overall accuracy of 42% in this patient 
group, while CAT scan had a 14% accuracy level in this patient group. The third group contained nine 
patients with normal serum CA-125 levels (less than 35 IU/ml). All patients with negative serum CA- 
125 levels had negative immunoscans. However, two patients (Nos. 8 and 12) had false negative 
immunoscans and serum CA-125 levels when compared to the histology results.
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Table 4.3.2. Relationship between serum CA-125 levels and ’"In immunoscans.
Patient 
(No. from Table)
,nIn-immunoscan 
(Antibody, [Result])
Serum CA-125 
(IU/ml)
Histology
1 HMFG-1 + 1558 +
2 HMFG-1 + 400 +
19 H17E2 + 252.5 +
3 HMFG-1 + 192.1 +
13 HMFG-1 + 101.1 +
6 HMFG-1 + 76.4 +
20 H17E2 + 67.8 +
16 AUA-1 + 62.5 +
9 HMFG-1 + 59.8 -
4 HMFG-1 - 77 +
7 HMFG-1 - 74.6 N.D. (+)
5 HMFG-1 - 49.9 +
21 H17E2 - 26.8 -
15 HMFG-1 - 26.0 N.D. (-)
18 AUA-1 - 26 -
17 AUA-1 - 21.4 N.D. (-)
11 HMFG-1 - 18.5 N.D. (-)
10 HMFG-1 - 18.4 -
8 HMFG-1 - 15 +
14 HMFG-1 - 9.1 -
12 HMFG-1 - 8.9 +
Where: (+) = positive result, (-) = negative result, N.D. ( )  = result of clinically observed tumour 
progression and not at histological evaluation.
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In summary, serum CA-125 appears to be a more sensitive indicator of the presence of ovarian 
carcinoma than IHIn-mabs. ,nIn-mabs are particularly useful in determining the distribution of tumour 
in patients with elevated serum CA-125 levels greater than 100 IU/ml.
43.5. Sensitivity and Specificity of n,In-mabs Conjugates.
The sensitivity and specificity of radiolabelled mabs are terms which are used to assess the overall 
success of tumour localisation and for comparison purposes between studies. Sensitivity is calculated 
by expressing the number of true positive (TP) tumours which were visualised as a percentage of the 
number of TP plus false negative (FN) scans, i.e. (TP/[TP + FN]) x 100%. The specificity is defined 
as the number of true negative patients (TN) expressed as a percentage of TN and false positive (FP) 
results, i.e. (TN/[TN + FP]) x 100%.
Table 43.3. Sensitivity and Specificity of niIn-mabs.
Number of Patients TP FN TN FP Sensitivity Specificity
21 8 3 9 1 72.7% 90%
Where TP -  true positive, TN -  true negative, FN = false negative, FP = false positive
The results contained in Table 4.33. relate to the overall study, and, will be compared to the results 
obtained by other groups.
4.3.6. WMTc-F(ab’)2 Immunoscintigraphy.
99MTc-F(ab’ )2 was administered to one patient with residual ovarian carcinoma. This patient had had 
extensive surgery a number of weeks before immunoscintigraphy and also had a negative CAT scan 
at that time. Her serum CA-125 level at the time of immunoscintigraphy was 294.2 IU/ml, indicating 
significant residual disease. Non-specific or non-tumour uptake of 99MTc-F(ab’)2 differs from the uptake 
already seen with Inln-mab conjugates. 99MTc uptake was observed in the kidney, stomach and bladder. 
Free 99MTc would normally be seen in the stomach, but, 99MTc-F(ab’)2 appears to bind to the colon area. 
Four planar scans of the peritoneal and pleural cavities were recorded at 10 minutes, 2 hours, 6 hours 
and 26 hours after 99MTc-F(ab’)2 administration. These scans are shown in Figure 4.3.3.(a). After 10 
minutes, the blood pool was observed in the kidneys, liver and bladder areas. The diffuse area below 
the left kidney could not be explained by blood pool. The scan taken at 2 hours again showed blood
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pool levels in the kidney and bladder. By 6 hours, some colon uptake was apparent. The high level 
of radioactive uptake seen in the right kidney was attributed to overlap with the liver and colon areas. 
The area of abnormal uptake in the right lower abdomen may be neoplastic and was reported as a 
positive scan (Figure 4.3.3.(b)). The image obtained after 26 hours showed 99MTc-F(ab’)2 uptake in the 
colon. This uptake was considered to be normal uptake. As this patient had undergone recent surgery, 
a follow-up laparotomy was not performed. However, significant residual ovarian cancer in the 
peritonealical method of immunoseintigraphy than mIn-mab immunoscanning and its application to 
othertumour will be discussed in Section 4.4,4.
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Figure 4.3.3: Gamma camera immunoscans of a patient who was administered **MTc-F(ab’)2
conjugate. (A) shows images after 10 minutes (Image No. 5), 2 hours (No. 6) 6 
hours (No. 7) and after 26 hours (No. 8). (B) is an enlargement of the image 
obtained after 6 hours (No. 7).
4.4. DISCUSSION
4.4.1. Preparation of "'In-mab and WMTc-F(ab’)2 Fragments.
The aim of any protocol by which antibodies are labelled for use in clinical studies is to produce a 
conjugate with high stability in vivo using a procedure with minimal effects on the immunoreactivity 
of the antibody. The physical stability of DTPA-mab and of 2-ME-F(ab’)2 was monitored by SDS- 
PAGE. Figure 4.2.1. (Lane 3) shows that higher molecular weight complex and some mab 
fragmentation could be seen in DTPA-HMFG-1 conjugates; these were also seen in DTPA-H17E2 and 
DTPA-AUA1 conjugates. The lower molecular weight fragments accounted for a large proportion of 
the total antibody injected. They may have resulted from dénaturation of antibody due to the pH or 
other physical conditions arising during the labelling procedure. Dimer and polymer formation were 
found to increase with the molar ratio of DTPA : mab. Hnatowich et al. (1983) estimated that 
approximately 15.5 - 18.7% of the DTPA : mab conjugate would be in the form of higher molecular 
weight conjugates. The presence of larger DTPA-mab polymers has significant clinical implications. 
Firstly, larger complexes are more immunogenic and may lead to a HAMA reaction (Section 1,2.1.). 
However, no patient in this study developed a detectable HAMA reaction following inIn-mab 
immunoscintigraphy. As no patient received more than one dose of antibody, it must be noted that few 
patients were expected to develop HAMA reactions. Secondly, larger molecular complexes may have 
altered immunoreactivity with the target antigens. FACS analysis showed that the overall 
immunoreactivity of DTPA-HMFG-1 remained virtually unchanged when compared with unconjugated 
HMFG-1. Finally, larger molecular weight complexes may also accumulate in the liver, increasing the 
non-specific background in the scan and reducing the target to background ratio. The precise effect of 
mIn-mab accumulation in the liver in this study could not be determined. However, Peltier et al. (1987) 
reported that the target to background ratio of IDIn-F(ab’)2 fragments was far superior to that of mIn- 
mabs. The absence of Fc receptors and a molar ratio of 2 DTPA : 1 F(ab’)2 significantly reduced the 
non-specific uptake of these conjugates. New macrocylic chelators are more stable in vivo and can bind 
sufficient radiolabel when using lower molar ratios of chelator. Meares et al. (1990) showed that 
chelation of inIn to nitrobenzyl-DOT A resulted in no fragmentation or complexation. Despite the 
relatively severe reduction step, no bands corresponding to possible antibody fragments were seen in 
the F(ab’)2 fragments reduced by two 2-ME. Other 99MTc-labelling techniques have been shown to lead 
to colloid complex formation and polymer formation when analysed by high pressure liquid 
chromatography (HPLC) (Thakur and DeFulvio, 1991).
Neither DTPA conjugation nor 2-ME reduction affected the immunoreactivity of the antibody 
conjugates. Each of the four methods used to assess immunoreactivity had its own specific merits. The
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cell based ELISA used here provided a very rapid assay system requiring the use of very small amounts 
of antibody. However, some problems were encountered with the reproducibility of the assay due to 
the growth pattern of the LOVO cells used in measure immunoreactivity of DTPA-H17E2 and 
unconjugated H17E2.
This cell line grows in multi-layers rather than as a sheet of single cells. This leads to uneven 
sloughing of cells from the 96 wells during the washing procedures and therefore to inaccurate results. 
The high cost of purified antigens precluded the use of antigen capture ELISA system in this study.
Immunofluorescence was found to be a useful method for assessing the immunoreactivities of antibodies 
on a wide range of cells and tissues. All of the cell-lines used for immunofluorescence analysis were 
tumour derived. The inclusion of normal colon tissue in the immunoreactivity assessment might have 
indicated the high levels of uptake of mIn-AUA-l and inIn-H17E2 by colon cells before immunoscans 
were performed. Immunofluorescence analysis on primary tumour samples from Patients 8 and 12 may 
also have shown that these tumours did not express HMFG-1 before IDIn-mab immunoscintigraphy was 
carried out Facilities for performing immunofluorescence and ELISA were available locally. Both 
techniques gave qualitative assessments of alterations in immunoreactivities of DTPA-mab and 2-ME- 
F(ab’)2 and were useful for preliminary investigations into immunoreactivity without the use of radio­
isotopes.
FACS analysis provided a quantitative measure of the immunoreactivity of each antibody with various 
tumour cells. The patterns of antibody binding (Figures 4.2.2. and 4.2.3.) were useful in comparing 
variabilities between the three preparations of DTPA-HMFG-1. No variability between preparations 
was observed. FACS analysis showed that HMFG-1 and DTPA-HMFG-1 reacted with a subpopulation 
of LOVO cells. The results of the Inln-HMFG-1 immunoscans did not show significant uptake by 
normal colon. The uptake observed in the 26 hour 99MTc-F(ab’)2 immunoscan by normal colon or non- 
tumour tissue (Figure 4.3.3.(a)) was thought to be due to the vascularity of the colon rather than the 
presence of antigen-bearing cells. Immunofluorescence analysis of these conjugates on normal colon 
tissue may have indicated this uptake before in vivo administration.
ELISA, immunofluorescence and FACS were used to assess immunoreactivity. All these techniques 
compared mab to DTPA-mab and 2-ME-F(ab’)2. However, the Lindmo assay assessed the 
immunoreactivity of radiolabelled Inln-mab and 99MTc-F(ab’)2 conjugates. The determination of 
numerical values for immunoreactivity which could be compared from batch-to-batch and from 
laboratory-to-laboratory was a further control which ensured the safety of conjugates for human 
administration. The Lindmo assay showed that both intact HMFG-1 (r = 2.08 + 0.3) and F(ab’)2 
fragments of HMFG-1, (r = 1.81) had similar immunoreactivity fractions. Thus, pepsin digestion of
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the intact mab to produce F(ab’)2 fragments had little effect on the immunoreactivity fraction in vitro.
The safety of the DTPA-mab and 2-ME-F(ab’)2 conjugates for human administration was assessed by 
pyrogen and sterility testing. The rabbit pyrogen test is still used by the FDA as the definitive method 
for determining the pyrogenicity of a product. This test is particularly unsuitable for the testing of 
murine antibody products as the rabbit may have anti-mouse antibodies, (RAMA). This pyrogen test 
result would falsely indicate the toxicity of the immunoconjugate (Brown, 1990). However, the LAL 
assay provides a quantitative and reproducible method for the determination of bacterial endotoxin levels 
during conjugate preparation. Endotoxins were not detected within the assay range (0.1 - 1.2 EU/ml). 
The maximum permitted endotoxin level for immunoglobulin products for human administration is 350 
EU/ml (or per 70 kg body weight) (Brown, 1990). As less than 1 ml (2mg) of antibody was 
administered to each patient, all antibody preparations were considered pyrogen-free.
4.4.2. IUIn-mab Immunoscintigraphy.
mIn-labelled monoclonal antibody was successfully used to determine the distribution of tumours in 
ovarian carcinoma patients. The results of mIn-mab immunoscintigraphy which was performed on 
these patients will be discussed. The usefulness and potential of IDIn-mabs in routine evaluation of 
ovarian cancer will be determined and compared with the current non-surgical techniques used, such 
as X-ray, CAT scan and serum CA-125.
4.4.2.I. Choice of Antibody.
mIn-HMFG-l, mIn-H17E2 and Inln-AUA-1 conjugates were all used to localise ovarian cancers. The 
IDIn-HMFG-l antibody was found to have a tumour to background ratio of 2.4:1 (in organs except the 
liver), whileinIn-AUA-l and inH17E2 had slightly lower tumour: background ratios of 1.9:1 and 1.44:1, 
respectively. As a result of this ratio, two further batches of HMFG-1 were prepared. The high tumour 
to background ratio seen with Inln-HMFG-1 was also reported by Hird et al, (1990), (10:1) and by 
Epenetos et al. (1982), who recorded a ratio of 8.5:1, and is thought to result from the high levels of 
expression of HMFG on breast and ovarian tissues (Verhoeyn et al., 1990). Epenetos et al. (1985), 
reported the use of inIn-H17E2 for the detection of neoplasms of the testes, ovary and cervix. Patients 
(n = 6) with cystadenocarcinoma of the ovary, who had pelvic masses were successfully imaged, but 
patients with tumour deposits of 1 - 2 cm diameter were not successfully imaged. The reduced 
sensitivity of H17E2 was thought to be due to the presence of trace levels of PLAP, the target antigen 
of H17E2, on many healthy tissues (McLaughlin et al., 1984). As PLAP is not ovarian tumour-specific, 
it was used by Pectasides et al. (1990) to image patients with germ cell tumours of the testes. They 
found that the accuracy of 131I-H17E2 imaging was related to the degree of differentiation of the
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primary tumour. In their study, heterogeneity of H17E2 was observed and higher levels of PLAP were 
found on active germ cell tumours than on more differentiated tumours.
A similar heterogeneity of tumour expression was found in studies using the AUA-1 antibody. Lohde 
et al. (1990) reported a higher target to background ratio for well differentiated colon tumours (5.88:1) 
when compared with less differentiated tumour (0.81:1) when using I31I-AUA-1. Immunohistochemical 
analysis of bladder carcinomas confirmed this heterogeneous expression of the AUA-1 antigen 
(Anagnostaki el al., 1990). Therefore, the higher tumour to background ratio observed with mIn- 
HMFG-1 appears to be related to the expression of the human milk fat globule antigens on 90% of both 
undifferentiated and well differentiated ovarian tumours (Ward et al., 1987). The high tumour to 
background ratio observed with KMFG-1 has led to novel applications for this mab. Y90-HMFG-1 has 
been used in the immunotherapy of patients with minimal residual ovarian carcinoma (Hird et al., 1990) 
and studies to produce humanised HMFG-1 by CDR grafting (Section 1.4.2.) are at an advanced stage 
(Verhoeyen el al., 1990) for both imaging and therapy. Snook et al. (1991) reported the use of a 
reshaped or humanised monoclonal HuZ PLAP (reshaped H17E2) labelled with DOTA-mIn on six 
patients with colon adenocarcinoma. However, 3/6 patients developed anti-DOTA responses, and 
tumours were not imaged.
4.4.2.2. Sensitivity and Selectivity of "'In-mab Immunoscintigraphy.
In order to determine the usefulness of IDIn-mab immunoscintigraphy in the evaluation of ovarian 
carcinoma, the results of this study were compared with other studies using similar mabs to locate 
ovarian cancers. The sensitivities and selectivities (as defined in Section 4.3.5.) obtained in these 
studies are summarised in Table 4.6.
In the research described in this thesis, an overall sensitivity of 73% and a selectivity of 90% was 
obtained. These results appear to be comparable to those obtained in other studies (Table 4.6.1.) which 
use a variety of radioisotopes and antibody types. The sensitivity observed in studies using F(ab’)2 
fragments (Chatal et al., 1987) does not appear to be significantly greater than that observed with intact 
antibodies, despite faster blood clearance and lower liver accumulation.
4 .4 .2 3 . Comparison of the Results of Chest X-ray and CAT Scan with HIIn-mab.
Chest X-ray and CAT scan are used routinely in the follow-up of patients with ovarian carcinoma 
(Goldhirsh et al., 1983). In this study, both chest X-ray and CAT scan were of limited value in the 
detection of residual disease. CAT scan detected tumours in 3/13 patients having histologically positive 
tumour at second-look laparotomy (or by disease progression) while 9/13 patients had positive
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Table 4.4: Summary of the Sensitivities and Selectivity obtained in studies using 
immunoscintigraphy of ovarian cancer patients.
Antibody Type Isotope No. of 
Patients
%
Sensit.
%
Select.
Reference
HMFG-l/HMFG-2 IgG mi 15 62 - Epenetos el 
al. (1982)
HMFG-2 IgG 123j 91 Granowska et 
al. (1984)
HMFG-2 IgG ISlj 17 90 Paleisky et al. 
(1985)
OC-125 F(ab’)2 U1ln 15 67
'
Chatal et al. 
(1987)
OC-125 F(ab’)2 U1ln 20 72 86 Chatal et al. 
(1987)
CEA/OC-125 F(ab’)2 U1ln 23 88 50 Hunter et al. 
(1987)
CEA/OC-125 F(ab’)2 nlIn 12 91.6 Liehn et al. 
(1987)
79IT/36 IgG2D 131I 2 100 Liehn et al. 
(1987)
OC-125/HMFG-2 IgG/F(ab’)2
F(ab’)2
niln/i3il
luIn
1311 
123 j
78
405
97.5
87
78.9
67
McPowell et 
al. (1987 
Foon et al. 
(1990)
OVTL-3
F(ab’)2
H1In 42 86 - Kenemans et 
al. (1990)
OC-125 IUIn 47 94 67 Dulin et al. 
(1991)
HMFG-1
AUA-1
H17E2
IgGla ,nIn 21 72.7 90 This study
Select. = selectivity = (TN/[TN + FP]) x 100% as in Section 4.3.5.).
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immunoscans. The increased sensitivity of "'In immunoscintigraphy over CAT scan has also been 
reported by Chatal et al. (1985), and with 131I-mabs by Granowska et al. (1984), Benner et al. (1990), 
Barzon et al. (1991) and Dulin et al. (1991) stressed the complementary roles that may be played in 
tumour diagnosis by each of these techniques, rather than the advantage of immunoscans over CAT 
scans in the evaluation of ovarian cancer.
4.4.2.4. Relationship Between Serum CA-125 Levels and Immunoscintigraphy.
mIn-mab immunoscintigraphy located neoplastic tissue in 9 tumours out of a total of 13 patients with 
ovarian carcinoma while abnormal serum CA-125 levels were observed in 11 out of 13 patients. 
Tholander et al. (1990) observed that serum CA-125 levels can be related to the extent of disease. 
Their study found that patients with limited ovarian epithelial caricnoma had a mean serum CA-125 
level of 151 IU/ml, while a mean of 805 IU/ml was determined for patients with extensive disease. 
Many immunoscintigraphy studies have shown that intact antibodies in particular are unable to 
specifically localise tumour in patients with limited disease (Thomas et al., 1990). In this study, the 
accuracy of Inln-mab immunoscintigraphy in patients with limited disease (CA-125 levels between 35- 
100 IU/ml) was compared with the accuracy of immunoscintigraphy observed in patients with more 
extensive disease (serum CA-125 levels greater than 100 IU/ml). From Table 4.3.2., it can be seen that 
all patients with serum CA-125 levels greater than 100 IU/ml had positive immunoscans, while the 
accuracy (3/6) of immunoscintigraphy in patients with serum CA-125 levels between 35 - 100 IU/ml 
was much lower. This suggests that serum CA-125 is a sensitive indicator of the presence of limited 
disease, while immunoscintigraphy is a less sensitive technique for the localisation of tumours in 
patients with limited disease.
Many immunoscintigraphy studies using mIn-OC125 and 131I-OC125 (Table 4.4.) have also reported on 
serum CA-125 levels of patients used in these studies. This antigen is present in the blood stream as 
serum CA-125 and on the surface of the tumour as tumour associated (t) CA-125. mIn-OC125 bound 
to serum CA-125 increases the level of label in the blood stream and reduces the target to background 
ratio. The production of human anti-murine (OC-125) antibodies following immunoscintigraphy has 
been shown to interfere with serum CA-125 assays conducted following immunoscintigraphy (Muto et 
al., 1989). Problems with interference by anti-OC-125 antibodies in immunoscintigraphy were not 
reported (Chatal et al., 1987; Kenemans et al., 1990) although some interference by HAMA antibodies 
was found in subsequent serum CA-125 assays (Muto et al., 1989). In studies by Peltier et al. (1987) 
and Chatal et al. (1987) few patients with serum CA-125 levels less than 100 IU/ml were included 
Chatal et al. (1987) found that 18/24 (75%) of patients with proven ovarian carcinoma and CA-125 
levels greater than 100 IU/ml had positive immunoscans, while 2/4 (50%) with serum CA-125 levels
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in the range 35 - 100 IU/ml had positive scans. Patients in the study by Hunter et al. (1987) were pre­
selected for immunoscintigraphy on the basis of the results of pelvic examination and CAT scan, and 
not their serum CA-125 level. A similar pre-selection of patients on the basis of a positive ultrasound 
scan was seen by Peltier el al. (1987) and Barzon et at. (1991). The increased sensitivity and selectivity 
of ,DIn-OC125 immunoscintigraphy observed by Dulin et al. (1991) may reflect this pre-selection of 
patients with highly elevated CA-125 levels (94%) for immunoscintigraphy.
4.4.2.5. Usefulness of mIn-tnab Immunoscintigraphy in Ovarian Carcinoma.
The results of this study suggest that mIn-HMFG-l immunoscintigraphy is a useful method for 
determining the distribution of tumour in patients with ovarian carcinoma. The technique proved to be 
most sensitive in patients with more extensive disease and serum CA-125 levels greater than 100 IU/ml. 
Though chest X-ray and CAT scan are less sensitive techniques, they complement the results of CA-125 
assays and mIn-mab immunoscans. Finally, inIn-mabs may be an effective, if costly method to assess 
ovarian carcinoma when used as part of a panel of non-invasive techniques.
4.4.3. Limitations of niIn-mab Immunoscintigraphy.
A realistic assessment of mIn-mabs immunoscintigraphy must take into account several limitations which 
exist with mIn. Firstly, mIn is not readily available in most Nuclear Medicine Departments and it is 
costly to purchase. The delay incurred in the delivery of the isotope increases the time taken to process 
immunoscan request. Aside from these logistic problems, raIn is not an ideal isotope. Inln- 
immunoscintigraphy may still take up to 72 hours to complete (Britton et al., 1989) even using F(ab’)2 
and F(ab) fragments. Advances in the digital subtraction of non-specific uptake of mIn in the liver have 
reduced the interference of mIn blood pooling to minimal levels (Vaughan et at., 1987), but further 
models would be needed to reduce this blood pool to the levels seen with 99MTc (Thomas et at., 1990). 
The energy emissions of mIn are not optimal for the gamma camera equipment available in most 
Nuclear Medicine Departments. Inln has two gamma ray energies; the higher 247 keV energy requires 
that the gamma camera is used with a heavier collimator which reduces the sensitivity and resolution 
which may be achieved. 99MTc has a gamma ray energy of 140 keV which is optimal for the standard 
equipment in Nuclear Medicine Departments. An example of the improved sensitivity of 99MTc-F(ab’)2 
over mIn-mabs can be seen in the TLC analysis of these conjugates. The spots recorded for IDIn 
samples (Figure 4.2.5.(a)) are significantly less clear than those seen for 99MTc (Figure 4.2.5.(b)), even 
though equal levels of radioactivity were recorded in each scan. As mIn has a 72 hour half-life, the 
radiation dose absorbed by the patient is higher than that absorbed by patients administered with 99MTc- 
F(ab’)2 which has a half-life of six hours. When mIn-labelled antibodies are metabolised in the
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reticuloendothelial system, the ,nIn is deposited in tissues giving high liver and bone marrow background 
and, in some cases, high activity in the large bowel. Ovarian tumours located in these areas are often 
more dificult to locate with mIn-rnabs. Buy et al. (1988), have reported that CAT scanning is 
particularly sensitive in locating tumours in the perihepatic and subdiaphramal regions which ,nIn-mabs 
that second look laparotomy often fails to detect. This strengthens the proposal that Inln-mab is most 
useful as part of a panel of non-invasive and invasive techniques for tumour localisation.
4.4.4. WMTc-mab Immunoscintigraphy in Ovarian Cancer.
Stable "MTc-labelled HMFG-1-F(ab’)2 fragments were successfully used to locate ovarian carcinoma 
in a patient with known residual ovarian carcinoma in the peritoneal cavity. Figure 4.3.(a) shows that 
the images obtained after 6 hours were of diagnostic quality. The absence of free 99MTc in the stomach 
demonstrated the stability of the 99MTc-conjugate in vivo. The clearance of free 99MTc-conjugate from 
the blood pool by 6 hours was also reported by Granowska et al. (1990; 1991), using 99MTc-PRIA3 in 
colorectal cancer. In these studies, target to background ratios of up to 63:1 were obtained. The 
stability of these 99MTc-labelled antibodies in vivo has been attributed to the 2-ME reduction procedure 
used. Intact mabs labelled with 99MTc by the 2-ME method were also used to image granulocytes 
associated with inflammatory processes (Lind et al., 1990). An overall sensitivity of 95% was observed 
in this study, but some residual uptake in the colon was also found. Eary et al. (1990) used 99MTc- 
F(ab’)2 and F(ab) fragments to image patients with melanoma. These fragments were labelled with the 
bifunctional chelating agent dithionite (Fritzberg et al., 1988). F(ab) fragments had faster clearance 
rates than F(ab’)2. No details were given referring to the stability of the antibody conjugate in vivo, 
but the presence of intestinal activity and images of stomach activity indicated free isotope.
99MT c is continuously available in all Nuclear Medicine Departments. It is cheap and gives a low 
radiation absorbed dose and it is ideally suited to the modern gamma camera collimator. The stability 
of 99MTc-F(ab’ )2 conjugates produced by the 2-ME/MDP reduction method has overcome the problem 
of free 99MTc interference in imaging. The major advantages of 99MTc-F(ab’)2 over ,nIn-mab scanning 
are the efficiency in terms of both cost and convenience. A request for immunoscintigraphy received 
in the morning can be undertaken and a provisional result given at the end of the same afternoon. This 
result may be confirmed by imaging after 26 hours. This shows that the immunoscintigraphy of cancer 
can be a routine, rather than a specialised technique.
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4.4.5. Future Role of Immunoscintigraphy in Cancer Diagnosis.
The ability to produce 99MTc-labelled mabs shows that the chemistry associated with antibody labelling 
has advanced significantly in recent years. Further development in bifunctional chelators and methods 
for the protection of the antibody binding site during conjugation (Krohn and Eary, 1991) will further 
increase the efficiency of mab conjugations. Parallel developments in the identification of newer 
tumour antigens, the production of second generation mabs and the application of new software to 
analyse the images obtained, and improved gamma cameras, will all increase the sensitivity and 
selectivity of immunoscintigraphy.
The ideal tumour antigen for use in immunoscintigraphy should be present on tumour cells but not on 
normal tissue. This ideal antigen should be abundant on the surface of the cell (greater than 106 antigen 
sites per cell), and should be present at all stages of tumour differentiation (Larson, 1985). The antigen 
should be present on the surface of the cell but not shed into the blood stream to neutralise injected 
antibody and delay rates of clearance from the blood pool. Studies have shown that antigen sites inside 
the cell may also be available for imaging (Ronay et al., 1990). Although the HMFG and CA-125 
antigens have been useful in a large proportion of ovarian cancers, and CEA, PLAP, AUA-1 and hCG 
have been useful markers in a wide range of other tumour types, new antigens are constantly being 
found. Tumour associated glycoprotein (TAG72) (Correale et al., 1991), the TAC antigen (Brown el 
al., 1991) and certain oncogene-related antigens such as p97 (Rose et al., 1986), neu-oncogene (Drebin 
et al., 1988) and c-myc (Chan and Sikora, 1987) have all been proposed as potential targets for 
immunoscintigraphy. However, the low levels of expression of many of the oncogene markers and their 
homology with normal antigens on the surfaces of cells has reduced their potential as imaging antigens 
(Hellstrom and Hellstrom, 1989).
Developments in murine antibodies, human mabs (hmabs) and recombinant or second generation 
antibodies, are constantly being applied to immunoscintigraphy. The difficulties encountered in the 
production of stable hmab have limited their applications in tumour imaging to date. Studies by 
Masuho et al. (1990) showed that the half-life of human mab in vivo is between 22 - 26 days and they 
also found a six-fold increase in stability in vivo over murine antibodies. Although these properties are 
of greater significance for mab-therapy than imaging, their reduced immunogenicity in vivo would allow 
repealed application of antibody for both imaging and therapy. Ryan et al. (1988) used hmab mIn-IgM 
conjugate to image patients with ovarian carcinoma. The slow clearance of IgM (i.e., increased 
circulation time required to clear blood pool) and poor resolution of images appears to suggest that IgM 
hmabs have few advantages over cheaper, more easily produced murine mabs. However, cardiac 
imaging with a human IgG anti-myosin monoclonal antibody is now commercially available in kit form. 
Centocor, the immunopharmaceutical company, have launched a product called ‘Myoscinct’, for imaging
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myosin-associated myocardial necrosis (Strauss et al. 1991; Van Dam Mieras et al., 1991). Reulander 
et al. (1991) have also shown that these mabs may be of use in imaging neonatal and infantile tumours 
with a higher myosin content than normal tissue. The production of ‘Myoscinct’ represents a landmark 
in mab technology. The commercialisation of one mab product provides a test case for future mab 
products (Spalding, 1991).
Recombinant mabs are currently being produced (Section 1.4.) and evaluated for use in imaging and 
therapy. Chimaeric antibodies which consist of the entire variable region of the mouse antibody with 
a human constant antibody fragment have been used in vivo. Chimeric antibodies are easier to produce 
in large quantities than human mabs but are, in theory, less immunogenic. However, when the 
chimaeric anti-OKT3 antibody was used in patients, much of the antibody response was directed against 
the human variable region rather than the mouse constant region (Jaffers et al., 1986) a human anti­
human (HAHA) reaction. Chimaeric antibodies appear to be more immunogenic if their light or heavy 
chain V region is not homologous to any human V region (Co and Queen, 1991(b)). However, studies 
by Bischof-Delalyoe et al. (1989) showed that the 99MTc-chimaeric CEA antibodies were less 
immunogenic than 99MTc-murineCEA antibodies when used to image patients with colorectal carcinoma. 
With the general trend towards using F(ab’)2 murine antibody fragments in immunoscintigraphy, the 
advantages of chimeric antibodies over murine monoclonal antibodies appear to be minimal. 
Theoretically, the immunogenicity of humanised or re-shaped hmabs which consist of only six murine 
complementary-determining regions (CDRs) embedded in a framework region should be lower than 
murine or chimeric antibodies. To date, few studies have used humanised mabs for imaging, but they 
have been used to treat patients with non-Hodgkins lymphoma (Hale et al., 1988). Both of the patients 
in this study experienced allergic responses after repeated therapy. These reactions were not attributed 
to HAMA production. The fast rate of clearance from the blood stream seen with humanised anti-TAC 
antibody suggests that these antibodies have favourable clearance properties. Hu-mabs have improved 
half-lives, stabilities and are less immunogenic when compared to murine antibodies in vivo (Coughlan,
1991). These properties will allow multiple therapy and imaging protocols to be established using 
humanised mabs. Humanised HMFG-1 and H17E2 are currently being evaluated for use in clinical 
trials on ovarian carcinoma (Verhoeyn et al., 1990; Snook et al., 1991).
Chemically produced bifunctional antibodies (BFAs) (Section 1.5) have been used to image patients 
with colorectal carcinoma (Stickney et al., 1988). One arm of the antibody bound to the CEA antigen 
while the second arm of the antibody bound mIn-benzyl-EDTA, Approximately 95% of the known 
lesions were detected by this system with efficient blood clearance. There are some limitations to the 
use of BFAs in vivo. When the two arms of an antibody bind to antigens, the binding is said to be co­
operative. By binding only one arm of an antibody to the cell, the immunoconjugate bound less tightly 
than a monoclonal antibody and is more sensitive to shearing factors from blood. One approach used
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to improve, or to exploit, this concept was proposed by Wong et al. (1987). BFAs which bound to CD3 
and CD4, and a second BFA which bound to CD3 and CD8 antigens were produced, Cell binding and 
cell toxicity were increased by 25 - 31 times by this stimulated co-operative binding. As there are two 
antigens available to BFA binding, there is an increased in the antigen density or number of binding 
sites for antibody on tumours. By targeting combinations of antigens which react with both well- 
differentiated and undifferentiated cells, increase in the tumour to background ratio is achievable. This 
approach may prove more effective than the cocktails of murine, human or humanised mabs proposed 
by Glassy and Dillman (1988) and Fanger et al. (1991).
Attempts to reduce non-specific uptake of isotopes and antibody in the liver by the administration of 
a BFA reacting with a breast carcinoma antigen and a hapten 3-(3’-iodo-, 4 ’-hydroxy)-phenyl propionic 
acid have also been proposed (Bator and Reading, 1990). This hapten forms the labelling group of 
iodinated Bolton-Hunter reagent (IBH). The administration of the non-radiolabelled antibody before 
the radiolabelled IBH, allows minimal non-specific absorption of the radiolabelled BFA. Similar two 
stage immunotherapy strategies such as the delayed administration of the radiolabel using streptavidin- 
labelled antibodies and biotinylated radioisotopes have also been suggested with the aim of reducing 
non-specific background levels of radiolabel using the BFA concept (Paganelli el al., 1991). The use 
of BFAs comprised of hmabs or other recombinant mabs will be of clinical importance in the 
application of second generation mabs in vivo (Nolan and O’Kennedy, 1990; Fanger et a i ,  1991).
Recombinant and bifunctional mabs may allow more stable conjugates to be administered with a greater 
frequency. This is particularly important when both immunoscintigraphy and immunotherapy are 
conducted on the same patient Further developments in the use of alternative routes of administration, 
such as immunolymphoscintigraphy (Lehtovirta et al., 1990) and improvements in the time-course of 
antibody and isotope administration (using the avidin/biotin systems) may increase the attainable target 
to background ratio. The use of imaging during surgery, as proposed by Jäger et al., (1990), may also 
help identify tumour sites during second-look surgery.
Progress in imaging technology will also affect the future role of monoclonal antibodies in the 
evaluation of tumours. Position emission tomography, (PET), allows the detection of smaller lesions 
and will permit quantitative imaging (Larson, 1991). By combining the information obtained from 
magnetic resonance imaging, (MRI), PET, CAT scan with images obtained from immunoscintigraphy, 
a more complete panel of non-invasive techniques will be available. Fusion of these images by 
computer graphics techniques (Davis, 1990; Kramer el al., 1991) will enhance the potential of non- 
invasisive tumour diagnosis by such techniques rather than by repeated surgery.
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SECTION 5 : IMMUNOPHOTODYNAMIC THERAPY
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5.1 INTRODUCTION
When a monoclonal antibody (mab) which reacts with a tumour associated antigen (Taa), is 
administered to a patient, many non-tumour cells such as Kupffer cells and macrophages bind the Fc 
portion of the mab non-specifically. In Section 4 it was shown that the use of F(ab’)2 fragments and 
digital subtraction techniques can minimise the effect of this non-specific uptake when tumours are 
localised by immunoscintigraphy. However, when mabs are conjugated to toxic agents such as drugs, 
toxins and istopes, this non-specific uptake leads to the killing of non-tumour cells.
In Section 1.10, various two-stage immunotherapy strategies such as the use of prodrugs, biotin-avidin 
and photodynamic therapy (PDT) with mab-photosensitiser immunoconjugates were outlined. PDT 
relies on the interaction of light with a photosensitiser to produce a localised toxic effect in a cell or 
organ. Photosensitisers are only partially selective for tumour tissue and light can only be delivered 
to an area, not a tissue type. This leads to the destruction of healthy tissue in the irradiated area. By 
increasing the ability of photosensitisers to selectively accumulate in tumour cells rather than healthy 
cells, non-specific phototoxicity to normal cells could be minimised. Such targeting of these 
photosensitisers to tumour sites in vivo may be achieved by coupling the photoactive agent to a mab 
with specificity for antigens on the surface of tumour cells. The use of mab-directed photosensitisers 
is termed immunophotodynamic therapy, (IPDT).
The major objectives of this experimental section were:
(a) To compare two known photosensitising agents, hematoporphyrin (Hp) and its more 
photoactive derivative, HpD, with acridine orange, coumarin, 7-hydroxycoumarin, 4- 
hydroxycoumarin and amino-methylcoumarin acetic acid, (AMCA) using an in vitro assay 
system. All of these compounds have known fluorescent and photochemical properties, and, 
some have been used clinically as laser dyes. However, their potential as photosensitisers has 
not been fully explored to date.
(b) The second experimental objective was to produce an immunophotosensitiser for use in IPDT. 
Although HpD is an effective photosensitiser, the chemical composition of the photoactive 
components of HpD is still disputed (Byme et al., 1990). This chemical complexity makes 
the stoichiometry of reactions between HpD and proteins difficult to predict and monitor. As 
Hp is a single compound, the reaction chemistry with a mab is more defined and accurate
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molar ratios for conjugation can be predicted. Hp was conjugated to the mab HMFG-1 which 
reacts with antigens on the surface of breast and ovarian tumours. HMFG-1 has been used for 
both immunoscintigraphy (Section 4) and immunotherapy (Epenetos et ah, 1985). The 
techniques which were used to assess the immunorectivity of mabs following conjugation to 
DTPA (Section 4.2) were also used to determine if chemical conjugation of Hp to HMFG-1 
altered the immunoreactivity of the mab. Preliminary experiments to determine the ability of 
HMFG-l-Hp to selectively kill MCF-7 breast adenocarcinoma cells following irradiation were 
undertaken using an in vitro assay system.
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Figure 5.1.: Schematic view of the system used to irradiate cells in vitro. Broadband light
(200 mW) from a Xenon Arc Lamp was reflected by a mirror onto the cells to 
be irradiated. Cells were irradiated for a total of 20 minutes.
5.2. THE EVALUATION OF HEMATOPORPHYRINS, ACRIDINE ORANGE AND 
COUMARIN COMPOUNDS AS PHOTOSENSITISERS
The effectiveness or efficacy of Hp, HpD and other test compounds as photosensitisers was determined 
by their ability to kill Landschiitz ascites tumours (LAT cells) in vitro following irradiation. An in vitro 
assay system was designed which used LAT cells in 24 well and 6 well tissue culture plates and 
broadband Xenon Arc Lamp light. The method used is outlined in Section 2.2.5. The experimental 
irradiation system which was used is shown schematically in Figure 5.1. All work was undertaken in 
darkened conditions to minimise non-specific activation of photosensitisers. A large number of control 
experiments were necessary to eliminate the effects of light and drug toxicity. These control 
experiments included cells which were treated with drug but which were not irradiated. This control 
was included in order to assess drug toxicity in the absence of light, i.e. its drug toxicity. Similarly, 
cells irradiated in the absence of drugs, were included to determine the effect of the irradiation protocol 
(200 mW irradiation for 20 minutes) on the viability of cells in culture, i.e. light toxicity.
From Figure 5.2.1.(B), it can be seen that at a concentration of 0.1 mg/ml, Hp exhibits greater 
phototoxicity than drug toxicity. The IC50 is the term used to describe the concentration of drug at 
which 50% of the cells are growth inhibited. The IC^ for Hp is 0.048 mg/ml following irradiation but 
is greater than 0.1 mg/ml for drug when not irradiated. Similarly, Figures 5.2.1.(A) and 5.2.3. give ICJ0 
values of 0.02 mg/ml and 0.042 mg/ml for HpD and acridine orange respectively, following irradiation. 
However, when higher doses of HpD (0.1 mg/ml) and acridine orange (1.0 mg/ml) were added to the 
cells, some cells were killed in the absence of light. These figures also show that IC50 drug toxicity 
values for both HpD and acridine orange in the absence of irradiation were greater than 0.1 mg/ml and 
1.0 mg/ml, respectively. Table 5.1.1. summarises the IC50 values obtained for hematoporphyrin and 
other test photosensitisers.
Viability was assessed in these experiments by dye exclusion methods (Section 2.3.3.). However, it has 
been suggested that such staining techniques detect membrane damage and do not directly measure cell 
viability (Yuhus et al., 1974). As Hp and HpD are known to result in membrane lipid oxidation, cell 
viability following irradiation was also assessed by LAT cell transplantability studies (Section 2.5.7.). 
Table 5.2.2. shows that the average dry weight of the untreated control cells was 0.44 g + 0.16 g (mean 
weight of tumour + standard deviation) after 7 days growth in vivo. The average weight of tumour 
obtained from mice (n = 5) whose cells had been treated with HpD and irradiated was 0.05 g + 0.02 
g. This value represents a significant reduction in cell dry weight (p < 0.002, Student’s t-test) 
confirming the results shown in Figure 5.2.2. Therefore, the toxicities of Hp, HpD and acridine orange 
are considerably increased following irradiation.
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Figure 5.2.I.: The effect of HpD (A) and Hp (B) on the viability of Landschiitz ascites tumour
(LAT) cells in the presence ( • )  and absence (O) of 200 mW Xenon Arc Lamp 
broadband light (Bars indicate standard deviation).
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Figure 5.2.2.: The effect of acridine orange on the viability of LAT cells in the presence ( • )
and absence (O) of 200 mW Xenon Arc Lamp broadband light (Bars indicate 
standard deviation).
Table 5.2.1. shows that incubation of LAT cells with varying concentrations of coumarin, 
7-hydroxycoumarin, 4-hydroxycoumarin and AMCA for 18 hours, in the presence or absence of 
irradiation, had no effect on tumour viability in vitro. None of these compounds showed any potential 
as photosensitisers under the conditions used.
Several researchers have shown that coumarin affects the growth of cells in culture (reviewed by Egan 
et al„ 1990). LAT cells were incubated with coumarin and AMCA for two days before washing and 
transplantation into Schofield mice. Table 5.2.3. showed that incubating LAT cells with coumarin for 
two days (short-term) before tansplanting the cells had no effect on the mean weight of that was tumour 
harvested when compared to the transplanted cells which were not pre-incubated with coumarin.
The effect on LAT cell viability following incubation with coumarin for 9 days in vitro before 
transplantation are shown on Table 5.2.3. and in Figure 5.2.3. (IC50 = 0.375 mM). From these results, 
7-hydroxycoumarin appears to have cytostatic rather than cytotoxic effects on LAT cells in vitro. 
Figure 5.2.3. shows that the number of LAT cells fails to increase following treatment with 7- 
hydroxycoumarin even though the viability of the cells was unaltered (Figure 5.2.4.).
136
Table 5.2.1; Summary of the IC50 values recorded for compounds in the presence
and absence of light.
Compound ICS0 (irradiated) ICS0 (not irradiated)
Hp 0.048 mg/ml >0.1  mg/ml
HpD 0.02 mg/ml >0.1  mg/ml
Aeridine orange 0.042 mg/ml >0.1  mg/ml
Coumarin > 1 mM > 1 mM
7-hydroxycoumarin > 1 mM > 1 mM
4-hydroxycoumarin > 1 mM > 1 mM
AMCA > 1 mM > 1 mM
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Table 5.2.2. The Results of a Transplantability Study to Determine the Effect of Photodynamic 
Irradiation on the Growth of Landschiitz Acites Tumour Cells In Vivo
Treatment
Concentration 
of HpD 
(per m l1) Irradiation
Tumour wt.*
(g)
None 0.00 + 0.44 + 0.16(5)
0.00 - 0.47 + 0.1 (4)
HpD 0.025 + 0.05 + 0.02 (5)**
0.025 - 0.41 +0.11 (4)
* Mean dry weight of tumour in g + S.D.; number of determinations in parenthesis 
** Significantly different from control (P < 0.002)
Table 5.2.3. The Results of a Transplantability Study on LAT Cells Treated 
with Coumarin Compounds
Treatment
Concentration 
of Coumarin 
of Derivatives 
(mM)
Drug Incubation 
Period, in vitro 
(days)
Tumour wt.*
(g)
None 0.00 2 0.30 + 0.04 (5)
Coumarin 1.00 2 0.30 + 0.08 (5)**
AMCA 1.00 2 0.30 + 0.01 (3)**
None 0.00 9 0.43 + 0.10 (6)
Coumarin 0.20 9 0.25 + 0.06 (6)
Coumarin 1.00 9 0.05 + 0.04 (6)+
AMCA = Amino-methyl-coumarin acetic acid
* Mean dry weight of tumour in g + S.D.; number of determinations in parentheses 
** Not significantly different from control
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Figure 5.2.3.: The effect of coumarin (A) 7-hydroxycoumarin ( • )  and control medium (O) on
the growth of LAT cells during a 9-day incubation period in vitro. Drugs were 
used at a concentration of 0.5 mM. (Bars indicate standard deviation of mean).
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Figure 5.2.4.: The effect of coumarin (O) 7-hydroxycoumarin ( • )  and AMCA (6) on the
growth of LAT cells during a 9-day incubation period. (Bars indicate standard 
deviation of mean).
S 3 . PREPARATION OF THE IMMUNOPHOTOSENSITISER HMFG-l-Hp
The aim of attaching a mab to a photosensitiser is to increase the selectivity of the drug for target 
tissues expressing antigens for that mab. The conjugation procedure used should also ensure that the 
monoclonal antibody retains its specificity for the target tissue following chemical modification, i.e. that 
the antibody retains its specific immunoreactivity (Lindmo el al., 1984). Moreover, chemical 
conjugation may also alter the drug toxicity of a compound (reviewed by Koppel, 1990). Therefore, 
control experiments were undertaken to monitor the effect of conjugation on the selectivity of the 
antibody and the efficacy of Hp.
5.3.1. Conjugation of Monoclonal Antibody to Hp
HMFG-1 was linked to hematoporphyrin dichloride by reaction with the water soluble carbodiimide, 
l-ethyl-3-(-3-dimethylaminopropyl) carbodiimide (EDC) as outlined in Method 3.5.2. EDC was used 
to activate the carboxyl groups on the Hp molecule forming an 0-acyl-isourea intermediate compound. 
This intermediate then reacted with amino groups on the protein forming an amide linkage and releasing 
N-acetyl urea. The amino groups were provided by the lysine residues in HMFG-1. A molar ratio of 
300:1 (Hp : HMFG-1) was selected for this conjugation following preliminary experimentation with a 
range of mabs including H17E2 and AUA-1. The results obtained following SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) are shown in Figure 5.3.1. Lane 4 indicates that the covalent conjugation 
of Hp to HMFG-1 resulted in the formation of larger molecular weight compounds which were not 
present in unconjugated HMFG-1 (Lane 2). These complexes may be due to cross-linking reactions 
between HMFG-1 molecules resulting in HMFG-l-HMFG-1 conjugates. As the antibody contains both 
free carboxyl groups and amino groups, this cross-linking can be mediated by EDC. Non-covalent 
attachment of Hp to HMFG-1 had no effect on the molecular weight observed (Lane 3).
The SDS-PAGE gels were run under non-reducing conditions, and, as a result of this, the exact 
molecular weights of the HMFG-l-Hp conjugate and higher molecular weight species were not 
determined. BSA-Hp conjugates were also prepared and were used as control conjugates in IPDT 
experiments in vitro to monitor toxicity which was not caused by HMFG-l-Hp. Such toxicity may have 
been caused by the presence of undialysed EDC and hydrolysed 0-acyl-isourea intermediate compounds 
in the BSA-Hp or HMFG-l-Hp preparations.
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Where: Lane 1 = molecular weight markers 
Lane 2 = HMFG-1 (unconjugated)
Lane 3 = HMFG-1 (unconjugated) + free Hp 
Lane 4 = HMFG-l-Hp, following dialysis
Figure 5.3.1.: Determination of the effect of EDC conjugation and non-covalent attachment of
Hp to the monoclonal antibody HMFG-1, using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE).
142
5.3.2. Determination of the Hp content of H M FG-l-Hp
Protein molecules adsorb porphyrin molecules in a non-specific manner by non-covalent association 
(Mew et a i ,  1983). Thin layer chromatography was used to determine the proportion of Hp which was 
non-covalently attached to HMFG-l-Hp and the amount of Hp which was chemically conjugated to 
HMFG-1. Though dialysis removed most of the unconjugated Hp, the HMFG-l-Hp conjugate contained 
approximately 19% Hp which was non-covalently attached to HMFG-1. Spectrophotometric analysis 
of the conjugate at 383 nm, showed that an average 0.270 mg Hp were bound to each mg HMFG-1, 
representing a molar ratio of 87.1:1 (Hp : HMFG-1). However, only 60 of the total of 90 amino sites 
present in the antibody molecule are available for carbodiimide conjugation (Goodfriend et al„ 1964). 
The excess of Hp molecules in the HMFG-l-Hp was attributed to non-specific absorption. Mew et al. 
(1983; 1985), used gel filtration to purify the HMFG-l-Hp conjugate after dialysis. Attempts to purify 
HMFG-l-Hp by gel filtration were unsuccessful due to the absorption of HMFG-l-Hp onto the G-25 
column. The limited availability of HMFG-l-Hp and the high cost of HMFG-1 prevented further 
experimentation to optimise the conditions used for gel filtration. Ultrafiltration using a 30,000 m.w. 
cut-off membrane (Millipore) replaced gel filtration and reduced the unconjugated Hp content in 
HMFG-l-Hp from approximately 30% to approximately 19%, while recording a 90% recovery of 
protein.
5.3.3. FACS Analysis of HMFG-l-Hp
In Section 4.2.4., methods for assessing the effect of chemical modification on the specific binding of 
mab-conjugates to various cells (i.e. the immunoreactivity of the conjugates) were outlined. FACS 
analysis may be used to establish if conjugation has altered the percentage of cells which bound 
unconjugated HMFG-1. Figure 5.4.1. shows that HMFG-l-Hp conjugate bound to a higher proportion 
of MCF-7 cells (97.4%) than an equal concentration of free HMFG-1 (86.6%). The MCF-7 cell line 
is estimated to express 2 - 5 x 105 HMFG-antigens on the surface of each cell ( M. Verhoeyn, Unipath 
Ltd., Colworth, UK, personal communication), and is, therefore, considered highly reactive with the 
HMFG-1 antibody. Fluorescence by Hp molecules (or autofluorescence) was not detected at the 
scanning wavelengths used. Both HMFG-1 (55%) and HMFG-l-Hp (76.6%) bound to a portion of 
LOVO colon adenocarcinoma cells suggesting the LOVO cells may express a HMFG-1 like antigen at 
some stages of the cell cycle. Similar binding patterns were observed when FACS analysis was carried 
out on HMFG-1, DTPA-HMFG-1 and HMFG-l-Hp conjugates (Section 4.2.4.). Free HMFG-1 did not 
bind to the RT-112 bladder carcinoma cell line while HMFG-l-Hp bound to the cells under identical 
conditions. Neither HMFG-l-Hp nor HMFG-1 bound to the EJ-138 bladder carcinoma cells. These 
results were confirmed by cell-based ELISA (data not shown).
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Figure 5.3.2: Assessment of the immunoreactivity of the monoclonal antibody HMFG-1 and
the immunophotosensitiser HMFG-l-Hp using FACS analyst, on (a) MCF-7 
cells; (b) EJ-138 cells; (c) LOVO cells and (d) RT-112 cells.
5.4. EVALUATION OF HM FG-l-Hp AS AN IMMUNOPHOTOSENSITISER
5.4.1. In Vitro Assay
An in vitro assay system was developed to test whether Hp which was bound to HMFG-1 retained 
its phototoxic potential. Details of the assay system are given in Section 2.4.6. The control 
experiments conducted to monitor non-specific irradiation, cytotoxic effects of the monoclonal antibody 
and drug effects are described in Section 5.4.2.
MCF-7 and EJ-138 cells were incubated with varying concentrations of HMFG-l-Hp and were 
irradiated with 200 mW Xenon Arc Lamp light for 20 minutes. Graph 5.4.1. shows that HMFG-l-Hp 
had significant effects on MCF-7 cell viability following irradiation, but had no effect on viability in 
the absence of light. The IC50 (with irradiation) for HMFG-l-Hp was found to be 2.75 x 10'2 mg/ml 
HMFG-l-Hp. As it was previously shown that HMFG-l-Hp contains 87.1 Hp molecules per HMFG-1 
molecules, this suggests that this concentration of HMFG-l-Hp contains a maximum of 7.6 x 10'3 
mg/ml of Hp (both conjugated and non-specifically bound). This also suggests that HMFG-l-Hp is 
significantly more toxic than equivalent concentrations of free Hp in vitro (Figure 5.4.1 .(A)). Incubation 
of HMFG-l-Hp with EJ-138 cells, in the presence or absence of irradiation, had no significant effects 
on overall cell viability (Figure 5.4.1.(B)). These results indicate that HMFG-l-Hp can be used as an 
immunophotosensitiser to selectively kill cells which express the HMFG-1 antigen.
5.4.2. Non-specific Controls in Immunophotodynamic Therapy.
A large number of control experiments were conducted in order to ensure that the MCF-7 cell killing 
seen in Figure 5.4.1. was not non-specific toxicity. As in Figure 5.4.1., EJ-138 cells were included as 
non-antigen bearing control cells. Two types of controls were conducted. The first group of controls 
monitored the effects of light and various compounds on the viability of MCF-7 and EJ-138 cells, where 
the compound was removed after an incubation period of 30 minutes. These controls monitored 
antibody binding and the uptake of unconjugated Hp during the 30 minute HMFG-l-Hp incubation 
period. In the second group of controls, the test compound were not removed before irradiation. These 
were included to determine if HMFG-l-Hp had sufficient phototoxicity to kill MCF-7 and EJ-138 cells 
irrespective of binding to antigens on the tumour cell surface. All controls were irradiated. The results 
of these controls are shown in Figure 5.4.2.
Control 1 was included as a standard, and showed maximal EJ-138 and MCF-7 cell growth. 
Unconjugated Hp is only weakly soluble in DMEM-S10. Therefore, Hp was dissolved in a minimal
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volume of ethanol, before being diluted to the appropriate drug concentration. Control 2 showed that 
this minimal volume of ethanol had no significant effect on MCF-7 or EJ-138 viability. Controls 3 and 
4 showed that a small amount of unconjugated Hp was taken up by both EJ-138 and MCF-7 cells. The 
uptake appeared to be proportional to the concentration of free drug in the medium. Hp concentrations 
greatly exceeded the total amount of Hp (bound to HMFG-1) that was added to MCF-7 and EJ-138 cells 
which was reported in Figure 5.4.1. Therefore, non-specific uptake of Hp during the 30 minute 
incubation period was not responsible for the MCF-7 toxicity shown in Figure 5.4.1. Control 5 was 
included to see if non-covalent attachment of Hp to HMFG-1 resulted in cell toxicity. A reduction in 
the viability of both cell types EJ-138 (82.5%) MCF (86%) was observed. This toxicity was due to 
non-specific uptake of Hp and not due to HP which was non-covalently attached to HMFG-1. This 
effect was evident in both antigen-bearing and non-antigen bearing cells.
In Control 7, Hp was not removed. Both the Hp which had been taken up by the cell, and Hp in 
DMEM-S10 could produce singlet oxygen following light activation, leading to cell death. Similarly in 
Control 6, the HMFG-l-Hp which had bound to the antigen and unbound HMFG-1-Hp were available 
for light activation and singlet-oxygen production. However, the HMFG-l-Hp conjugate (0.1 mg/ml) 
contained a maximum of 0.027 mg/ml Hp. That HMFG-l-Hp killed similar numbers of EJ-138 and 
MCF-7 cells shows that binding to the MCF-7 cells was not necessary to cause cell damage using 
HMFG-l-Hp.
The BSA-Hp control (8) contains total of 0.023 mg/ml of Hp (bound and free) which did not have a 
significant effect on cell viability. This suggests that undialysed EDC and O-acyliso-urea intermediates 
did not cause cell death. Control 9 was included to examine whether or not HMFG-l-Hp bound to the 
same antigen as free HMFG-1. Pre-incubation of MCF-7 cells with HMFG-1 (0.1 mg/ml), should block 
all antigens to which HMFG-l-Hp could bind. The failure of HMFG-l-Hp to kill cells following pre­
incubation with HMFG-1 confirms that pre-binding of HMFG-1 to MCF-7 cells blocked subsequent 
binding by HMFG-l-Hp and that antigen recognition by HMFG-1 was not adversely affected by 
coupling to Hp. A similar control was included in the Lindmo Assay in order to detect altered binding 
of mabs which had been conjugated to DTPA (Section 4.2.4.3.). Further controls which were not 
irradiated did not effect MCF-7 or EJ-138 cell viability. All these control experiments confirm that the 
selective killing of MCF-7 cells shown in Figure 5.4.1. was due to the immunophotosensitiser HMFG-l- 
Hp and not the non-specific absorption of Hp by the cells.
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Figure 5.4.1: The effect of the immunophotosensitiser HMFG-l-Hp on (A) MCF-7 cells and
(B) EJ-138 cells, in the presence of ( • )  and absence (O) of 200 mW Xenon Arc 
Lamp light.
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Figure 5.4.2: Determination of non-specific antibody and drug effects associated with the use
in immunophotodynamic therapy (IPDT) in vitro. HMFG-l-Hp was used as the 
immunophotosensitiser and 200 mW Xenon Arc Lamp light was used to irradiate 
the cells.
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immunophotosensitiser and 200 m\V Xenon Arc Lamp light was used to irradiate 
the cells.
5.5. DISCUSSION
The hematoporphyrins, acridine orange and coumarins and the immunophotosensitiser HMFG-l-Hp 
were shown to affect cancer cell growth in vitro. Each of the following topics will be discussed in 
more detail.
(1) The toxicity and phototoxicity of acridine orange and hematoporphyrins.
(2) The cytotoxic and cytostatic effects of coumarin compounds.
(3) The potential of HMFG-l-Hp as an immunophotosensitiser.
(4) The evaluation of the potential of IPRT, ADEPT and other two-stage immunotherapy systems 
and to look at other delivery systems such as liposomes and polymer systems in cancer 
therapy.
5.5.1. Hematoporphyrin Compounds and Acridine Orange as Photosensitisers in PDT.
Dougherty and his colleagues (1976) showed that incubating TA-3 mouse carcinoma cells with between 
0.36 - 0.54 mg/ml Hp resulted in the death of 90% of the cells (IC90) in vitro. In another set of 
experiments by Gomer et al. (1983; 1985), using a different incubation time and different irradiation 
system, concentrations of Hp (0.060 mg/ml) and HpD (0.025 mg/ml) resulted in 50% growth inhibition 
of of Chinese Hamster Ovary (CHO) cells. Figure 5.2.1. shows Hp (0.048 mg/ml) and HpD (0.020 
mg/ml) resulted in the death of 50% of LAT cells in vitro. As these results agree with the studies by 
Gomer and his colleagues. Therefore, the LAT cell assay appear to be a useful system to determine the 
potential of various compounds as photosensitisers.
The IC50 of acridine orange (0.042 mg/ml) was determined using this assay system. This confirms the 
results of in vitro studies using acridine orange which were undertaken by Tomson et al. (1974), and 
Alvarez (1975). However, acridine orange is a known mutagen that intercalates DNA. Although many 
of the chemotherapeutic drugs which are currently in use are extremely mutagenic, the large doses of 
acridine orange which would be needed to cause phototoxicity would limit the potential of acridine 
orange in PDT.
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5.5.2. Toxicity of Coumarin Compounds.
None of the coumarin compounds investigated showed any phototoxicity in the presence or absence of 
irradiation in the LAT assay system previously described. Photodynamic activity had been previously 
reported for some coumarin compounds including the furocoumarins (Rodighiero el al., 1984), and 
benzyl-coumarin derivatives (Kaidbey Klingman, 1981; Opdyke, 1981). However, both coumarin and 
7-hydroxycoumarin inhibited the growth of LAT cells, when incubated with the cells for 9 days. The 
IC30 for coumarin (9 days) was found to be 375 pM, while 7-hydroxycoumarin appeared to have 
cytostatic effects. Cox el al. (1989) found that both coumarin and 7-hydroxycoumarin inhibited Sp2/0 
myeloma cells. In a separate study, Moran (1990) showed that 7-hydroxycoumarin (500 pM) had a 
cytostatic rather than a cytotoxic effect on G-CCM and G-UVM human brain cell lines while Conely 
and Marhsall, (1987) also showed evidence of the cytostatic action of 7-hydroxycoumarin on ACHN 
and Caki-2 renal cells and on the K562 erythroleukemic cell line. Conely and his colleagues reported 
that coumarin acted by arresting cells in the G J G l stage of the cell cycle, preventing entry into the S 
phase. The 18 hour incubation period which was used in the LAT cell PRT assay system was too short 
to observe the cytotoxic and cytostatic effects of coumarin. Variations in the metabolism of coumarin 
by different animal species (Raunio e l  al., 1988; Dominguez et al., 1990) and metabolic activation of 
the cytochrome p450 multienzyme complex (reviewed by Egan et al, 1990) may account for some of 
the conflicting reports on the cytotoxic/cytostatic actions of coumarin compounds.
5.5.3. Evaluation of the Immunophotosensitiser HMFG-l-Hp.
Photosensitisers have been conjugated directly to mabs or have been attached via carrier molecules and 
spacer molecules (including dextran and polyvinyl alcohol) and they have also been encapsulated in 
microspheres and liposomes (summarised in Table 5.5.1.).
The HMFG-l-Hp immunophotosensitiser used in this experimental section, was prepared by labelling 
HMFG-1 directly with Hp. HMFG-l-Hp was shown to contain 87.1 Hp molecules per HMFG-1 
molecules with approximately 19% of the Hp non-covalently attached to the mab. Mew et al. (1983; 
1985) reported conjugation ratios in excess of 60 Hp/mab, while Steele et al. (1988) reported that ratios 
of up to 100 Hp/mab could be obtained by direct conjugation using EDC. They also reported that at 
these higher conjugation ratios, the antigen-binding capacity of the immunophotosensitiser was severely 
limited. The results of FACS analysis (Figure 5.3.2.) and ELISA showed that steric hindrance by Hp 
did not reduce the specificity of the HMFG-l-Hp.
The results of SDS-PAGE (Figure 5.3.1.) showed that there were large molecular weight complexes in 
the HMFG-l-Hp preparation. Excess EDC may have led to the conjugation of HMFG-1 to HMFG-1,
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resulting in complex formation. A HAMA response may be produced when large molecular weight 
complexes are injected into patients. Steele et al. (1988) also reported significant antibody-antibody 
complexing when the anti-T suppressor factor B16G was conjugated to Hp by the EDC method outlined 
above. They also reported a significant decrease in the solubility of the mab after conjugation to Hp 
in aqueous solutions.
Oseroff el al. (1985) conjugated Hp dihydrazine to a number of anti-leukaemic mabs via the 
carbohydrate residues on the Fc portion of the mab. Conjugation ratios of 0.85 - 3 Hp/mab were 
recorded with no alteration in immunospecificity. In a later series of experiments, Oseroff and his 
colleagues (1986) conjugated a larger number of chlorin e6 molecules to a carrier (dextran) and 
subsequently conjugated the carrier to the carbohydrate residues on the Fc portion of antibody. 
Conjugation ratios of up to 24 - 36 chlorin e^mab were achieved using this method. Similarly, 
Rakestaw el al., (1990) reported conjugating up to 18.9 SnCe6 molecules per mab using a dextran 
carrier. Jiang et al. (1990) used the spacer polyvinyl alcohol to conjugate benzoporphyrin to an anti-T- 
cell mab. This resulted in a conjugation ratio of 3/4 residues per mab molecule. Therefore, the carrier 
systems used to date do not appear to increase the number of photosensitisers delivered to each antigen 
when compared to HMFG-l-Hp.
Figure 5.4.1.(a), shows that at a concentration of 2.7 x 10'2 mg/ml, HMFG-l-Hp killed 50% of the 
MCF-7 cells (IC50). This concentration of HMFG-l-Hp contains a total of 7.4 x 10'3 mg Hp/ml. This 
dose is significantly lower than the dose (2.3 x 102 mg/ml) used in toxicity studies by Bellinier and 
Dougherty (1982). Determination of the exact concentration of intracellular and membrane-associated 
HMFG-l-Hp and Hp was not possible and may be investigated at a later stage.
Both Mew et al. (1983; 1985) and Oseroff et al. (1987) have commented on the increased toxicity of 
photosensitisers when they are conjugated to monoclonal antibodies. Oseroff et al. reported that 200 
to 1,000 times more unconjugated photosensitiser was required to kill antigen-bearing cells under similar 
conditions. They went on to argue that this affects results from the localisation of porphyrin conjugates 
at the cell membrane. Singlet oxygen produced by Hp reacts with local membrane lipoproteins to cause 
oxidation and cell death. This theory has been supported by recent studies by Maziere et al. (1990) and 
Ricchelli el al. (1990). Using liposomes as a cell model, they showed that photosensitisers directly 
associated with the lipid layer gave higher levels of lipid oxidation than photosensitiser which was 
encapsulated within the liposome or in solution around the liposomes.
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Table 5.5.1: Summary of the methods used to prepare immunophotosensitisers.
A. Direct Labelling References
Hp - anti-myosarcoma Mew et al., 1983; 1985
Hp dihydrazine - anti-Leul Oseroff el al., 1985
anti-Leu2a
anti-Leu3
Chlorin e6 - anti-Leul Oseroff et al., 1986
anti-Leu2a
anti-Leu3
Hp - anti-T cell Steele el al., 1988
Chlorin e6 (CMA) - anti-leukaemia Hasan, 1988
bladder
anti-ovarian carcinoma
Chlorin e6 - anti-ovarian carcinoma Goff et al., 1991
Plhalocyanine - anti-EMA Dawson et al., 1991
Iodofluorescine - anti-E. coli Devanatan et al., 1991
TCPP - anti-lym-1 Biddle et at., 1991
B. Carrier Systems References
Alspc - liposome-anti-CEA Rakestraw et al., 1990
Benzoporphyrin - polyvinyl alcohol-anti-T cell Oseroff et al., 1990
chlorin e6 - Dextran anti-Leul Jiang et al., 1990
Sn Ce6 - Dextran anti-melanoma Yemul et al., 1990
Pyrene - liposome-anti-OKT4 Morgan et al., 1989
C. Non-Antibody Carriers References
Photosensitiser - low density lipoproteins Reviewed by Richelli et al., 1990
Cuomo et al., 1990
Photosensitiser - liposome Mosley et al., 1984
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The proximity of HMFG-l-Hp to the cell membrane when bound to the HMFG-l-Hp antigen allows 
singlet oxygen to diffuse more rapidly to membrane lipid components. Extracellular and intracellular 
Hp are diffusion-limited and this results in lower levels of membrane oxidation and therefore, less cell 
killing. Other drug delivery systems such as liposomes (Cuomo el al., 1990) and microspheres (Bachor 
el al., 1991) have also shown increased levels of cell kill in vitro. These carrier systems are thought 
to enter the cell by phagocytosis and Bachor and his colleagues have surmised that the high level of 
cell kill results from damage to lysosomal membranes and subsequent proteolytic breakdown, rather 
than through cell membrane damage. A more detailed study of both the chemistry and pharmacology 
of HMFG-l-Hp is required before the mechanism of action is fully understood.
5.5.4. Two-Stage Immunotherapy and Drug Delivery Systems.
IPDT with Hp-mab immunophotosensitisers appears to be an effective treatment in vitro and it has 
shown some promising results in animal studies (Mew et al., 1986; Steele el al., 1988). However, 
immunophotosensitisers have not been used in clinical studies to date.
Unconjugated photosensitisers such as HpD and phthalocyanines have been used to treat patients with 
several types of tumour. In recent reviews by Ash and Brown (1989), Dougherty (1989) and Brown
(1990), PDT was found to be particularly useful in treating smaller tumours of the colon, trachea and 
bladder. All of these tumours can be irradiated by the use of endoscopes fitted with fibre optic cables 
carrying laser light The main side-effect associated with PDT is the patient’s sensitivity to sunlight 
after treatment Patients treated with photosensitisers have to remain in a darkened room for 6 - 8 
weeks to avoid skin ulceration and discomfort. By using immunophotosensitisers, the selectivity of the 
photosensitiser for tumour cells should increase. A more selectively delivered drug requires a lower 
dose to achieve the same result and this would reduce the time the patient would need to spend in the 
absence of sunlight
Immunophotosensitisers would also bind to the liver and bone marrow cells. As these tissues would 
not be irradiated (either by laser or sunlight) IPDT also minimises the side-effects of immunotherapy 
on non-tumour cells. IPDT will not be useful in treating all stages and grade of tumour. The main 
challenge is to identify which tumour types can be treated by IPDT and to concentrate on developing 
effective treatment schedules which minimise the side-effects of both the photosensitiser (i.e. skin 
ulceration) and the mab (i.e. HAMA). Some of the more novel strategies which have been proposed 
include Suppressor Deletion Therapy, intravessicle treatment of bladder carcinoma and the intrathecal 
administration of immunoconjugates to treat parenchymal brain tumours. Each of these strategies will 
be looked at in more detail.
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Steele and his co-workers (1988), argued that elevated levels of T-suppressor cells (Ts) stops a patient 
producing large numbers of anti-Taa antibodies. Suppressor Deletion Therapy is based on the principle 
of removing Ts cells, and as a result, the patient should increase their production of anti-Taa antibodies. 
They proposed that Hp-anti-Ts immunoconjugates could be used to purge Ts cells from a patient’s bone 
marrow. The bone marrow cells (without Ts cells) could then be returned to the body. Similarly, 
Gulliay and Mathews (1988), proposed the use of ex-vivo PDT to kill leukaemia cells in bone marrow. 
Administration of the immunophotosensitiser a number of days before irradiation allows the conjugates 
to bind to the target cells and allows clearance of the conjugate from non-target cells. The volume of 
bone marrow which could be safely removed from a patient would limit the success of this technique. 
However, Lohde and his colleagues (1991) showed that patients could be treated with 
immunoconjugates after ex-vivo perfusion using an ex-vivo blood oxygenation system. This technique 
would require surgery to insert the external blood oxygenation system.
IPDT may also be used to treat superficial bladder cancers. Fitzpatrick (1989), has proposed that 
immunophotosensitisers which bind to superficial bladder cancers, may be irradiated by laser light 
delivered through an adapted endoscope and may be particularly useful in treating minimal residual 
disease of drug resistant tumours.
Bamias et al. (1991) have also shown that immunophotosensitisers can be administered intravesically 
(directly to the bladder). With intravesical mab administration the antibody does not enter the blood 
stream directly. This allows the repeated use of IPDT without adverse HAMA reactions.
Work by Colombatti and his colleagues (1988), indicates that immunotherapy is of use in treating 
parenchymal brain tumours. The tumours of the central nervous system are "immunologically 
privileged" which means that immune reactions (such as HAMA reactions) rarely take place under 
normal conditions. They proposed that imunoconjugates could be administered intrathecally or by other 
regional administration systems. The tumours could then be irradiated after a number of days by light 
delivered through a fibre optic cable which could be inserted through a biopsy needle. All of these 
novel treatment strategies try to work around the problems of non-specific localisation and killing of 
non-tumour cells. A number of other two-stage immunotherapy strategies were outlined in Section
1.10., but many of these strategies have only been used in vitro.
(a) ADEPT:
Antibody-directed enzyme prodrug therapy, ADEPT, has not been used in clinical studies but 
had reasonable success in animal models. These results were discussed at a recent conference 
held in Halkidiki, Greece. Haisma and his colleagues (1991), showed that anti-CEA 
conjugated to alkaline phosphatase successfully cleaved the prodrug phosphorylated etoposide
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(EP) into its active form in mice. Pre-treatment of the mice with unconjugated anti-CEA 
reduced the absorption of anti-CEA-AP by the liver and an overall 10-fold increase in 
cytotoxicity was reported. Similarly, Rowlinson-Busza and his colleagues (1991), showed that 
HMFG-1 and H17E2 antibodies linked to beta-glucosidase successfully cleaved glycoside 
amygdalin into free cyanide in vitro. They have called this type of prodrug therapy antibody - 
-guided enzyme nitrite therapy or AGENT. Senter (1991), remarked that a cocktail of mab- 
enzyme-fusion proteins directed against a range of Taas will increase the effectiveness of 
ADEPT in tumours which express a variety of Taas.
(b) Avidin-Biotin Therapy:
The specificity of avidin and streptavidin for biotin has led to the use of biotin-avidin 
immunoconjugates to localise and treat cancers (Sections 1.10. and 4.4.5.). Several researchers 
have used avidin-biotin techniques to localise tumours (reviewed by Paganelli et at., 1991) and 
to treat cancer (reviewed by Britton et al., 1991). Britton and his colleagues also proposed 
using a three-stage radioimmunotherapy strategy:
Stage 1: Administration of mab-biotin on Day 0.
Stage 2: Administration of free avidin to clear unbound mab-avidin from the blood
stream on Day 1.
Stflpe 3: Administration of radiolabelled (or photosensitiser drug, toxin or cytokine)-
labelled avidin on Day 3.
They also proposed the use of two and three stage therapy systems which would 
simultaneously image and treat tumour cells.
Stage 1: Inject a ” MTc-bifunctional antibody which reacts with tumour and a hapten
(i.e. biotin or IBH).
Stage 2: Image the tumour by 99MTc-scanning to record when the conjugate is in the
correct location in the tumour.
Stage 3: A P-32 linked ligand (i.e. avidin) which is a {J-emitter binds to the BFA and
is released and incorporated into tumour DNA after internalisation of the 
immunoconjugate.
Clinical studies using these two and three stage immunotherapy systems are currently 
underway in St. Bartholomew’s Hospital, London (Britton, 1991b).
5.5.5. Mabs and Other Drug Delivery Systems.
Mab-conjugates are one of a range of strategies to deliver drugs to target areas. Liposomes, 
reconstituted viral envelopes, microsponges, microspheres and "signalling targets" are just some of these 
strategies.
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Liposomes are phospholipid vesicles which can be used to carry drugs and other substances within the 
blood stream (reviewed by Alving, 1991). Liposomes have been quite successful as artificial surfactants 
in the treatment of respiratory distress syndrome when administered as a nasal aerosols. However, they 
have had very limited success in clinical studies. Mab-liposomes or immunoliposomes have also been 
prepared (reviewed by Peeters et al., 1988). However, like liposomes, most immunoliposomes are taken 
up by the liver after administration. The use of immunoliposomes incorporating photosensitisers such 
as Si(IV)-naphthalocyanine to successfully treat mice bearing MS-2 fibrosarcomas (Cuomo et al., 1990), 
has overcome this problem. Immunoliposomes have also been used to carry pyrene and AlsPC as 
shown in Table 5.5.1. Immunoliposomes delivered to the liver are not irradiated and therefore, were 
not toxic to the mice. A further injection of immunophotosensitiser at the tumour site increase the 
amount of immunoliposome at the tumour site. Following irradiation, the tumour micro-vasculature was 
destroyed. This led to a reduction in the oxygen delivered to the tumour and resulted in tumour anoxia.
Reconsistuted viral envelopes (RVEs) are similar to liposomes. REVs are formed by solubilising intact 
virus in detergent and reassembling the envelope on removal of detergent (reviewed by Blumenthal and 
Loyster, 1991; Kingsman et al., 1991). Like liposomes, RVEs have been used to deliver biological 
therapeutics, and they have been of particular use in delivering genes, antisense nucleic acids, ribosomes 
and proteins. However, the presence of viral proteins on the surface of REVs means that a patient may 
raise an immune-response to REVs which were injected. REVs may be used as "Trojan Horses" to 
deliver drugs and genes. This may be particularly useful in delivering chemoimmunoconjugates and 
immunotoxins which need to be internalised in order to kill cells. However, the amount of drug, DNA 
or protein which can be encapsulated in a REV is quite low and this has slowed clinical studies on REV 
targeting.
Microspheres and microsponges are both made of synthetic polymers and are not immunogenic 
(reviewed by Van Brunt, 1989). Morgan et al., 1986, have used Chlorin e6-conjugated to microspheres 
to deliver photosensitiser in mice. Unlike immunophotosensitisers, the Chlorin e6-conjugates were 
delivered to tumours which had increased blood supply.
"Smart drugs", or drugs that act on particular cell functions, are also used to target specific cell types. 
Several drugs are already available which can act on protein serine/threonine kinases, protein tyrosine 
kinases and phospholipase C as well as inhibitors of wyo-inositol signalling. These enzymes are 
involved in growth control and are particularly important in the search for more selective drugs for 
treating cancer (reviewed by Powis, 1991). To combine this technology (i.e. identify drugs which 
selectively interact with cancer cell-specific signalling targets) with ADEPT and other two-stage 
monoclonal antibody therapies may help to selectively kill cancer cells.
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Finally, conventional mabs, mab-conjugates and the new genetically engineered mabs will not provide 
the cure to all cancers. The challenge is to involve chemists, biochemists, geneticists, physicists and 
oncologists in the design of more effective conjugates. These conjugates should then be used to treat 
specific types of tumours or minimal residual disease which are amenable to immunotherapy. It is 
highly unlikely that all cancers will be suitable candidates for immunotherapy.
1 5 7
SECTION 6 : CONCLUSION
6.1. CONCLUSION
In conclusion, three separate aspects of monoclonal antibody technology were investigated in this thesis.
In Section 3, the use of myeloma-derived cell lines to produce human mabs was explored. Two new 
cell lines were established, C23/11 was shown to have many of the characteristics of a lymhphoblastoid 
cell line, including the expression of the CD23 antigen, the presence of EBVNA and a clump-like 
growth pattern in vivo. The C23/11 cell line was used as a fusion partner with the NSO mouse 
myeloma cell line to produce the heteromyeloma cell line, HET-37. HET-37 grows as a single cell 
suspension. Both C23/11 and HET-37 have ulstrastructural characteristics such as endoplasmic 
reticulum and golgi apparatus which are associated with the secretion of antibodies. The advances in 
recombinant mab technology allows the production of human mabs by transfection of human B-cell 
DNA into human, murine and microbial hosts provides the addition strategy for producing human mabs 
for use in the diagnosis and treatment of cancers.
inIn-labelled and 99MTc-labelled fragments were used to detect the distribution of tumour in patients with 
ovarian carcinoma. mIn-HMFG-l conjugates were found to have the highest tumour to background ratio 
and were therefore used on the majority of patients in the study. Tumours were also localised using 
,nIn-AUA-l and m-H17E2 conjugates. mIn-mab immunoscintigraphy was found to be more sensitive 
than techniques such as CAT scanning, ultrasound and X-ray for detecting tumours in patients with 
suspected ovarian carcinoma. The presence of the tumour associated antigen serum CA-125 in elevated 
levels was found to be more sensitive than immunoscintigraphy for indicating the presence of tumour. 
However, this marker gives no information on the location of the tumour or the distribution of the 
tumour in vivo. Preliminary results using 99MTc-F(ab’)2 fragments on one patient with residual 
carcinoma suggests that this technique is a more cost-efficient and convenient alternative to mIn-rnab 
immunoscintigraphy.
In Section 5, a two-step strategy for killing tumour cells in vitro was investigated. Hematoporphyrin 
(Hp), and its more toxic derivative HpD, were shown to be potent photosensitizers which killed 
Landschiitz ascites tumours (LAT) cells when activated by light While acridine orange was shown to 
be an effective photosensitizer in vitro, coumarin, 7-hydroxycoumarin, 4-hydroxycoumarin and AMCA 
did not show any phototoxic effects on LAT cells in vitro. Tumouristatic effects were detected with 
some of these coumarin compounds. The mab HMFG-1 was chemically linked to Hp and this 
conjugate killed MCF-7 cells which expressed the HMFG antigen, following irradiation with light from 
a Xenon Arc Lamp. HMFG-l-Hp did not kill EJ-138 cells which do not express the HMFG antigen.
159
Thus, the work described clearly indicates that radiolabelled mabs can successfully be applied to image 
tumours and that they may be used as a non-surgical technique to localise tumours, particularly when 
used in combination with serum markers. It is also evident that antibody targeted drugs can specifically 
kill tumours in vitro. However, for this system to be applied in vivo problems associated with non­
specific uptake and immunogenicity associated with the administration of repeated doses of murine mab 
must be overcome. It may be possible to use C23/11 and HET-37 fusion partners and/or genetic 
approaches to make less immunogenic human mab with the required specificity for clinical use. 
Realistic antibody therapies must be devised and used in combination with conventional drugs and 
radiotherapy to improve the scope of treatment available to cancer patients.
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